

10/803,277

=> d his

(FILE 'HOME' ENTERED AT 14:21:51 ON 01 MAR 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 14:24:19 ON 01 MAR 2005

L1 1289986 S KINASE?
L2 1289986 S KINASE?
L3 479392 S HUMAN AND L1
L4 6944918 S CLON? OR EXPRESS? OR RECOMBINANT
L5 238969 S L3 AND L4
L6 3408473 S BRAIN OR PITUITARY OR CEREBELUM OR UTERUS
L7 19300 S L5 AND L6
L8 1674498 S MAMMARY (A) GLAND? OR CARCINOMA OR OSTEOSARCOMA
L9 1859 S L7 AND L8
L10 970047 S HYPOTHALAMUS OR TESTIS OR FETUS
L11 242 S L9 AND L10
L12 77760 S SPLICE
L13 6 S L11 AND L12
L14 6 DUP REM L13 (0 DUPLICATES REMOVED)
L15 21453 S HUMAN (3W) L1
L16 63 S L11 AND L15
L17 45 DUP REM L16 (18 DUPLICATES REMOVED)
E TURNER C A/AU
L18 136 S E8-E9
E MATHUR B/AU
L19 69 S E3
E FRIDDLE C J/AU
L20 45 S E6
L21 233 S L18 OR L19 OR L20
L22 29 S L5 AND L21
L23 22 DUP REM L22 (7 DUPLICATES REMOVED)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1652MXM

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	4	OCT 28	KOREAPAT now available on STN
NEWS	5	NOV 30	PHAR reloaded with additional data
NEWS	6	DEC 01	LISA now available on STN
NEWS	7	DEC 09	12 databases to be removed from STN on December 31, 2004
NEWS	8	DEC 15	MEDLINE update schedule for December 2004
NEWS	9	DEC 17	ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	10	DEC 17	COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	11	DEC 17	SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	12	DEC 17	CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected
NEWS	13	DEC 17	THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB
NEWS	14	DEC 30	EPFULL: New patent full text database to be available on STN
NEWS	15	DEC 30	CAPLUS - PATENT COVERAGE EXPANDED
NEWS	16	JAN 03	No connect-hour charges in EPFULL during January and February 2005
NEWS	17	FEB 25	CA/CAPLUS - Russian Agency for Patents and Trademarks (ROSPATENT) added to list of core patent offices covered
NEWS	18	FEB 10	STN Patent Forums to be held in March 2005
NEWS	19	FEB 16	STN User Update to be held in conjunction with the 229th ACS National Meeting on March 13, 2005
NEWS	20	FEB 28	PATDPAFULL - New display fields provide for legal status data from INPADOC
NEWS	21	FEB 28	BABS - Current-awareness alerts (SDIs) available
NEWS	22	FEB 28	MEDLINE/LMEDLINE reloaded
NEWS EXPRESS			JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:21:51 ON 01 MAR 2005

=> file medline embase biosis biotechds scisearch hcaplus ntis lifesci		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.84	0.84

FILE 'MEDLINE' ENTERED AT 14:24:19 ON 01 MAR 2005

FILE 'EMBASE' ENTERED AT 14:24:19 ON 01 MAR 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'BIOSIS' ENTERED AT 14:24:19 ON 01 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 14:24:19 ON 01 MAR 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'SCISEARCH' ENTERED AT 14:24:19 ON 01 MAR 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'HCAPLUS' ENTERED AT 14:24:19 ON 01 MAR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 14:24:19 ON 01 MAR 2005
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2005)

FILE 'LIFESCI' ENTERED AT 14:24:19 ON 01 MAR 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

=> s kinase?
L1 1289986 KINASE?

=> s kinase?
L2 1289986 KINASE?

=> s human and l1
L3 479392 HUMAN AND L1

=> s clon? or express? or recombinant
4 FILES SEARCHED...
L4 6944918 CLON? OR EXPRESS? OR RECOMBINANT

=> s l3 and l4
L5 238969 L3 AND L4

=> s brain or pituitary or cerebelum or uterus
L6 3408473 BRAIN OR PITUITARY OR CEREBELUM OR UTERUS

=> s l5 and l6
L7 19300 L5 AND L6

=> s mammary (a) gland? or carcinoma or osteosarcoma
L8 1674498 MAMMARY (A) GLAND? OR CARCINOMA OR OSTEOSARCOMA

=> s l7 and l8
L9 1859 L7 AND L8

=> s hypothalamus or testis or fetus or testis
<-----User Break----->

SEARCH ENDED BY USER

=> s hypothalamus or testis or fetus
L10 970047 HYPOTHALAMUS OR TESTIS OR FETUS

=> s l9 and l10
L11 242 L9 AND L10

=> dup rem l11
COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> s splice
L12 77760 SPLICE

=> s l11 and l12
L13 6 L11 AND L12

=> dup rem l13
PROCESSING COMPLETED FOR L13
L14 6 DUP REM L13 (0 DUPLICATES REMOVED)

=> d 1-6 ibib ab

L14 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:449884 HCAPLUS
DOCUMENT NUMBER: 140:420388
TITLE: Binary prediction tree modeling with many predictors
and its uses in clinical and genomic applications
INVENTOR(S): Nevins, Joseph R.; West, Mike; Huang, Andrew T.
PATENT ASSIGNEE(S): Duke University, USA
SOURCE: PCT Int. Appl., 886 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038376	A2	20040506	WO 2003-XB33946	20031024
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004038376	A2	20040506	WO 2003-US33946	20031024
WO 2004038376	A3	20040826		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
 US 2002-420729P P 20021024
 US 2002-421062P P 20021025
 US 2002-421102P P 20021025
 US 2002-424701P P 20021108
 US 2002-424715P P 20021108
 US 2002-424718P P 20021108
 US 2002-425256P P 20021112
 US 2003-448461P P 20030221
 US 2003-448462P P 20030221
 US 2003-457877P P 20030327
 US 2003-458373P P 20030331
 WO 2003-US33946 A 20031024

AB The statistical anal. described and claimed is a predictive statistical tree model that overcomes several problems observed in prior statistical models and regression analyses, while ensuring greater accuracy and predictive capabilities. Although the claimed use of the predictive statistical tree model described herein is directed to the prediction of a disease in individuals, the claimed model can be used for a variety of applications including the prediction of disease states, susceptibility of disease states or any other biol. state of interest, as well as other applicable non-biol. states of interest. This model first screens genes to reduce noise, applies kmeans correlation-based clustering targeting a large number of clusters, and then uses singular value decompns. (SVD) to extract the single dominant factor (principal component) from each cluster. This generates a statistically significant number of cluster-derived singular factors, that are referred to as metagenes, that characterize multiple patterns of **expression** of the genes across samples. The strategy aims to extract multiple such patterns while reducing dimension and smoothing out gene-specific noise through the aggregation within clusters. Formal predictive anal. then uses these metagenes in a Bayesian classification tree anal. This generates multiple recursive partitions of the sample into subgroups (the 'leaves' of the classification tree), and assocs. Bayesian predictive probabilities of outcomes with each subgroup. Overall predictions for an individual sample are then generated by averaging predictions, with appropriate wts., across many such tree models. The model includes the use of iterative out-of-sample, cross-validation predictions leaving each sample out of the data set one at a time, refitting the model from the remaining samples and using it to predict the hold-out case. This rigorously tests the predictive value of a model and mirrors the real-world prognostic context where prediction of new cases as they arise is the major goal.

L14 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:912743 HCAPLUS

DOCUMENT NUMBER: 139:392150

TITLE: Novel **human** imidazoline receptor homologs
 IMRRP1 and IMRRP1b, cDNAs and therapeutic use
 imidazoline receptor homologs

INVENTOR(S): Feder, John N.; Kinney, Gene G.; Mintier, Gabriel;
 Ramanathan, Chandra S.; Bol, David K.; Ryseck,
 Rolf-peter

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 79 pp., Cont.-in-part of U.S.
 Ser. No. 932,145.
 CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003215916	A1	20031120	US 2003-395812	20030321
US 2002161191	A1	20021031	US 2001-932145	20010817
WO 2004084810	A2	20041007	WO 2004-US8207	20040316

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2000-226411P P 20000818
US 2001-261779P P 20010116
US 2001-932145 A2 20010817
US 2003-395812 A 20030321

AB Novel imidazoline receptor homologs, designated imidazoline receptor related protein 1 (IMRRP1), imidazoline receptor related protein 1b (IMRRP1b), and derivs. thereof are described. Specifically disclosed are cDNA and protein sequences of human IMRRP1 and its splice variant IMRRP1b. The IMRRP1 expression profiles in normal tissues and tumor tissues or cell lines are also provided. Pharmaceutical compns. comprising at least one IMRRP1, IMRRP1b, or a functional portion thereof, are provided as are methods for producing IMRRP1, IMRRP1b or a functional portion thereof. In addition, nucleic acid sequences encoding polypeptides, oligonucleotides, fragments, portions or antisense mols. thereof, and expression vectors and host cells comprising polynucleotides that encode IMRRP1 or IMRRP1b are provided. The novel association of IMRRP1 and/or IMRRP1b to modulating the NFkB pathway and the p21 cell cycle checkpoint, and uses thereof are also provided.

L14 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:836585 HCAPLUS

DOCUMENT NUMBER: 136:353325

TITLE: PIP92 and NVM-1: Two genes associated with motility and metastasis

AUTHOR(S): Novac, Natalia

CORPORATE SOURCE: Inst. Toxikologie Genetik, Univ. Karlsruhe, Germany

SOURCE: Wissenschaftliche Berichte - Forschungszentrum Karlsruhe (2001), FZKA 6655, A, B, i-iii, iv-xvii, 1-165

CODEN: WBFKF5; ISSN: 0947-8620

DOCUMENT TYPE: Report

LANGUAGE: English

AB The differential screening method of Suppression Subtractive Hybridization (SSH) has previously been used to compare/identify genes associated with tumor progression and metastasis. More than a hundred genes were up-regulated in the highly metastatic cell line ASML in comparison to its non-metastatic counterpart IAS cells. In her thesis work the author has further differentially screened this group of genes to identify those that might play a role in the migration of metastasizing cells. This was achieved by analyzing the expression of these genes in mobilized and resident macrophages and in activated and non-activated lymphocytes. Those genes identified by these screens were then further screened for metastasis-related expression in multiple tumor models.

Following this screening, two genes were selected for further characterization, Pip92 and NVM-1. Pip92 belongs to the "immediate early" gene family and has not previously been associated with tumor progression and metastasis. Its function is still obscure. To permit the functional anal. of the Pip92 protein polyclonal antibodies were generated. Pip92 has previously been shown by others to be cytoplasmic. However, the results obtained in the authors' work suggest that the Pip92 protein translocates to the nuclei for example upon serum stimulation. To get an insight into the functional role of Pip92, the phenotype of IAS-Bsp73 cells stably overexpressing Pip92 protein was studied. IAS cells ectopically **expressing** the Pip92 protein exhibit enhanced motility in in vitro migration assays as compared to empty vector-transfected cells, suggesting that Pip92 might belong to the set of genes responsible for regulating cell migration. Properties of the Pip92 protein suggest it might act as a transcription regulatory protein and a search for genes whose **expression** is altered in Pip92-overexpressing cells was therefore performed. The **expression** of three genes was clearly up-regulated in cells overexpressing Pip92. The strongest induction was observed for osteopontin, a gene whose **expression** has previously been associated with migration and metastasis. Sections of **human** tumors dissected from patients with invasive ductal **carcinoma** were immunostained with the Pip92 antiserum. Pos. staining was observed only in tumor cells but not in non-neoplastic healthy tissues. NVM-1 (novel gene associated with metastasis) is a previously undescribed gene. Its full-length coding sequence was isolated and the predicted open reading frame was confirmed by an in vitro transcription/translation. The correlation of **expression** of NVM-1 with metastasis was confirmed in three tumor progression models in addition to one used for SSH. Upon completion of the **human** genome sequencing project it became apparent that the **human** homolog of NVM-1 (hNVM-1) gene is located on chromosome 14. The predicted amino acid sequence of hNVM-1 shows high homol. to the rat sequence. The genome sequence allowed the author to characterize the hNVM-1 promoter and the gene structure. Anal. of the hNVM-1 promoter revealed a number of potential transcription factor-binding sites within the putative hNVM-1 promoter sequence. The hNVM-1 gene consists of 6 exons and 5 introns. A thorough computer anal. of the hNVM-1 gene structure and ESTs revealed the presence of two **splice** donor sites at the exon 2-intron 2 junction which are alternatively used in different tissues of **human** and rodent origin. Monoclonal antibodies against rNVM-1 protein were generated and proved to be useful for Western Blot and immunohistochem. analyses, demonstrating a cytoplasmic location for the rNVM-1 protein and **expression** of the protein in tumors. Further study of these genes may lead to the discovery of the new targets for antitumor drugs and may significantly help us to understand the process of transformation of nonmetastatic tumor cells into metastatic ones.

REFERENCE COUNT: 296 THERE ARE 296 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:244519 HCAPLUS

DOCUMENT NUMBER: 135:17774

TITLE: **Human** glial cell line-derived neurotrophic factor receptor $\alpha 4$ is the receptor for persephin and is predominantly **expressed** in normal and malignant thyroid medullary cells

AUTHOR(S): Lindahl, Maria; Poteryaev, Dmitry; Yu, Liying; Arumae, Urmas; Timmusk, Tonis; Bongarzone, Italia; Aiello, Antonella; Pierotti, Marco A.; Airaksinen, Matti S.; Saarma, Mart

CORPORATE SOURCE: Program in Molecular Neurobiology, Institute of Biotechnology, Viikki Biocenter, University of Helsinki, Helsinki, FIN-00014, Finland

SOURCE: Journal of Biological Chemistry (2001), 276(12), 9344-9351
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Glial cell line-derived neurotrophic factor (GDNF) family ligands signal through receptor complex consisting of a glycosylphosphatidylinositol-linked GDNF family receptor (GFR) α subunit and the transmembrane receptor tyrosine **kinase** RET. The inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN2), associated with different mutations in RET, is characterized by medullary thyroid **carcinoma**. GDNF signals via GFR α 1, neurturin via GFR α 2, artemin via GFR α 3, whereas the mammalian GFR α receptor for persephin (PSPN) is unknown. Here the authors characterize the **human** GFR α 4 as the ligand-binding subunit required together with RET for PSPN signaling. **Human** and mouse GFR α 4 lack the first Cys-rich domain characteristic of other GFR α receptors. Unlabeled PSPN displaces 125I-PSPN from GFRA4-transfected cells, which **express** endogenous Ret. PSPN can be specifically cross-linked to mammalian GFR α 4 and Ret, and is able to promote autophosphorylation of Ret in GFRA4-transfected cells. PSPN, but not other GDNF family ligands, promotes the survival of cultured sympathetic neurons microinjected with GFRA4. The authors identified different **splice** forms of **human** GFRA4 mRNA encoding for two glycosylphosphatidylinositol-linked and one putative soluble isoform that were predominantly **expressed** in the thyroid gland. Overlapping **expression** of RET and GFRA4 but not other GFRA mRNAs in normal and malignant thyroid medullary cells suggests that GFR α 4 may restrict the MEN2 syndrome to these cells.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:775265 HCAPLUS
DOCUMENT NUMBER: 136:132090
TITLE: Investigation of differentially **expressed** genes during the development of mouse cerebellum
AUTHOR(S): Kagami, Yoshihiro; Furuichi, Teiichi
CORPORATE SOURCE: Laboratory for Molecular Neurogenesis, Brain Science Institute, RIKEN, Wako, 351-0198, Japan
SOURCE: Gene Expression Patterns (2001), 1(1), 39-59
CODEN: GEPEAD; ISSN: 1567-133X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Before the discovery of DNA microarray and DNA chip technol., the **expression** of only a small number of genes could be analyzed at a time. Currently, such technol. allows us the simultaneous anal. of a large number of genes to systematically monitor their **expression** patterns that may be associated with various biol. phenomena. We utilized the Affymetrix GeneChip MullK to analyze the gene **expression** profile in developing mouse cerebellum to assist in the understanding of the genetic basis of cerebellar development in mice. Our anal. showed 81.6% (10.321/12.654) of the genes represented on the GeneChip were **expressed** in the postnatal cerebellum, and among those, 8.7% (897/10.321) were differentially **expressed** with more than a two-fold change in their maximum and min. **expression** levels during the developmental time course. Further anal. of the differentially **expressed** genes that were clustered in terms of their **expression** patterns and the function of their encoded products revealed an aspect of the genetic foundation that lies beneath the cellular events and neural network formation that takes place during the

development of the mouse cerebellum.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:457223 HCAPLUS

DOCUMENT NUMBER: 133:85129

TITLE: Method for improving transduction efficiency of
adeno-associated virus 2 (AAV) by using human
fibroblast growth factor receptor 1(FGFR1) as a
co-receptor

INVENTOR(S): Srivastava, Arun; Qing, Keyun; Mah, Cathryn; Hansen,
Jonathan; Zhou, Shangzhen; Dwarki, Varavani

PATENT ASSIGNEE(S): Advanced Research and Technology Institute, USA

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039311	A1	20000706	WO 1999-US31220	19991229
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2358094	AA	20000706	CA 1999-2358094	19991229
EP 1141339	A1	20011010	EP 1999-968572	19991229
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002533128	T2	20021008	JP 2000-591202	19991229
PRIORITY APPLN. INFO.:			US 1998-114596P	P 19981231
			WO 1999-US31220	W 19991229

AB The present invention provides a method for improving transduction efficiency of adeno-associated virus (AAV) by increasing gene **expression** of human fibroblast growth factor receptor (FGFR) and heparan sulfate proteoglycan (HSPG), and inhibiting single strand D-sequence-binding protein (ssD-BP) functions. The present invention relates to constructing a transgene **expression** cassette encoding FGFR or HSPG or both, wherein **expression** of FGFR and HSPG results in increased AAV infection. The invention also relates to inhibiting ssD-BP functions by manipulating phosphorylation states or reducing gene **expression** of ssD-BP. Also disclosed are methods for decreasing phosphorylated ssD-BP by reducing activities or gene **expression** of epidermal growth factor receptor (EGFR) tyrosine **kinase**. The invention further relates to the uses of methods of this invention in gene therapy.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:21:51 ON 01 MAR 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 14:24:19 ON 01 MAR 2005

L1 1289986 S KINASE?

L2 1289986 S KINASE?
 L3 479392 S HUMAN AND L1
 L4 6944918 S CLON? OR EXPRESS? OR RECOMBINANT
 L5 238969 S L3 AND L4
 L6 3408473 S BRAIN OR PITUITARY OR CEREBELUM OR UTERUS
 L7 19300 S L5 AND L6
 L8 1674498 S MAMMARY (A) GLAND? OR CARCINOMA OR OSTEOSARCOMA
 L9 1859 S L7 AND L8
 L10 970047 S HYPOTHALAMUS OR TESTIS OR FETUS
 L11 242 S L9 AND L10
 L12 77760 S SPLICE
 L13 6 S L11 AND L12
 L14 6 DUP REM L13 (0 DUPLICATES REMOVED)

=> s human (3w) l1
 7 FILES SEARCHED...

L15 21453 HUMAN (3W) L1

=> s l11 and l15

L16 63 L11 AND L15

=> dup rem l16

PROCESSING COMPLETED FOR L16

L17 45 DUP REM L16 (18 DUPLICATES REMOVED)

=> d 1-45 ibib ab

L17 ANSWER 1 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:99595 HCAPLUS

DOCUMENT NUMBER: 142:170059

TITLE: Microtubule affinity regulating **kinases**
 (MARKs) as modifiers of the PTEN pathway and methods
 for antitumor use

INVENTOR(S): Costa, Michael R.; McGrath, Garth Joseph; Lickteig,
 Kim; Heuer, Timothy S.

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005010148	A2	20050203	WO 2004-US19533	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2003-479768P P 20030619

AB The present invention provides methods for utilizing phosphatase PTEN
 modifiers and polypeptides to identify microtubule affinity regulating
kinase (MARK)-modulating agents that are candidate therapeutic
 agents that can be used in the treatment of disorders associated with
 defective or impaired PTEN function and/or MARK function. Specifically,
human MARK genes are identified as modulators of the PTEN pathway,

and thus are therapeutic targets for disorders associated with defective PTEN function. The invention also relates to preferred MARK-modulating agents specifically bind to MARK polypeptides and restore PTEN function. Other preferred MARK-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress MARK gene **expression** or product activity by, for example, binding to and inhibiting the resp. nucleic acid. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MARK are provided.

L17 ANSWER 2 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:16967 HCAPLUS
DOCUMENT NUMBER: 142:108390
TITLE: Quantitative RT-PCR method for the detection in blood of microarray-identified rheumatoid arthritis-related gene transcripts for diagnosing and monitoring disease state
INVENTOR(S): Liew, Choong-Chin
PATENT ASSIGNEE(S): Chondrogene Limited, Can.
SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 802,875.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	----	-----	-----
US 2005003394 A1		20050106	US 2004-812782	20040330
PRIORITY APPLN. INFO.:			US 1999-PV115125	19990106
			US 2000-477148	20000104
			US 2002-268730	20021009
			US 2003-601518	20030620
			US 2004-802875	20040312

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood for diagnosing and monitoring diseases. The present invention demonstrates that a simple drop of blood may be used to determine the quant. **expression** of various mRNAs that reflect the health/disease state of the subject through the use of quant. reverse transcription-polymerase chain reaction (QRT-PCR) anal. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing and monitoring rheumatoid arthritis using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L17 ANSWER 3 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:33225 HCAPLUS
DOCUMENT NUMBER: 142:112460
TITLE: Monoclonal antibodies to fragment of **human** mitotic **kinase** Aurora-A phosphorylated at threonine 288, preparation, and use in cancer therapy
INVENTOR(S): Urano, Takeshi; Furukawa, Koichi
PATENT ASSIGNEE(S): Farma Design Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	----	-----	-----

JP 2005006532 A2 20050113 JP 2003-172730 20030618
PRIORITY APPLN. INFO.: JP 2003-172730 20030618

AB This invention relates to antibodies, particularly, monoclonal antibodies, against human mitotic kinase Aurora-A (Aur-A) phosphorylated at threonine 288 (Thr-288), production in hybridoma, and use in treatment of diseases associated with Aur-A (over)expression, notably cancer. Monoclonal antibodies (mAbs) were raised against human Thr-288 phosphorylated Aur-A fragment. The mAbs were able to inhibit activation of Aur-A via phosphorylation of Thr-288.

L17 ANSWER 4 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2004:449884 HCAPLUS

DOCUMENT NUMBER: 140:420388

TITLE: Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications

INVENTOR(S): Nevins, Joseph R.; West, Mike; Huang, Andrew T.

PATENT ASSIGNEE(S): Duke University, USA

SOURCE: PCT Int. Appl., 886 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004038376	A2	20040506	WO 2003-XB33946	20031024
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2004038376	A2	20040506	WO 2003-US33946	20031024
WO 2004038376	A3	20040826		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.:
US 2002-420729P P 20021024
US 2002-421062P P 20021025
US 2002-421102P P 20021025
US 2002-424701P P 20021108
US 2002-424715P P 20021108
US 2002-424718P P 20021108
US 2002-425256P P 20021112
US 2003-448461P P 20030221
US 2003-448462P P 20030221
US 2003-457877P P 20030327
US 2003-458373P P 20030331
WO 2003-US33946 A 20031024

AB The statistical anal. described and claimed is a predictive statistical tree model that overcomes several problems observed in prior statistical

models and regression analyses, while ensuring greater accuracy and predictive capabilities. Although the claimed use of the predictive statistical tree model described herein is directed to the prediction of a disease in individuals, the claimed model can be used for a variety of applications including the prediction of disease states, susceptibility of disease states or any other biol. state of interest, as well as other applicable non-biol. states of interest. This model first screens genes to reduce noise, applies kmeans correlation-based clustering targeting a large number of clusters, and then uses singular value decompns. (SVD) to extract the single dominant factor (principal component) from each cluster. This generates a statistically significant number of cluster-derived singular factors, that are referred to as metagenes, that characterize multiple patterns of **expression** of the genes across samples. The strategy aims to extract multiple such patterns while reducing dimension and smoothing out gene-specific noise through the aggregation within clusters. Formal predictive anal. then uses these metagenes in a Bayesian classification tree anal. This generates multiple recursive partitions of the sample into subgroups (the 'leaves' of the classification tree), and assocs. Bayesian predictive probabilities of outcomes with each subgroup. Overall predictions for an individual sample are then generated by averaging predictions, with appropriate wts., across many such tree models. The model includes the use of iterative out-of-sample, cross-validation predictions leaving each sample out of the data set one at a time, refitting the model from the remaining samples and using it to predict the hold-out case. This rigorously tests the predictive value of a model and mirrors the real-world prognostic context where prediction of new cases as they arise is the major goal.

L17 ANSWER 5 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2005:139369 HCAPLUS

DOCUMENT NUMBER: 142:175392

TITLE: Analysis of genetic information contained in peripheral blood for diagnosis, prognosis and monitoring treatment of allergy, infection and genetic disease in **human**

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 37

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004014059	A1	20040122	US 2002-268730	20021009
US 2004241726	A1	20041202	US 2004-812707	20040330
US 2004248169	A1	20041209	US 2004-812737	20040330
WO 2004112589	A2	20041229	WO 2004-US20836	20040621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-115125P P 19990106

US 2000-477148	B1 20000104
US 2002-268730	A2 20021009
US 2003-601518	A2 20030620
US 2004-802875	A2 20040312
US 2004-812707	A 20040330
US 2001-271955P	P 20010228
US 2001-275017P	P 20010312
US 2001-305340P	P 20010713
US 2002-85783	A2 20020228
US 2004-809675	A 20040325

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular allergy, using gene-specific and/or tissue-specific primers. Affymetrix Human Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publications system constraints.]

L17 ANSWER 6 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:355085 HCAPLUS
DOCUMENT NUMBER: 140:369944
TITLE: Human tissue-specific housekeeping genes identified by **expression** profiling
INVENTOR(S): Aburatani, Hiroyuki; Yamamoto, Shogo
PATENT ASSIGNEE(S): NGK Insulators, Ltd., Japan
SOURCE: PCT Int. Appl., 372 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035785	A1	20040429	WO 2002-JP10753	20021016
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004229233	A1	20041118	US 2003-684422	20031015
PRIORITY APPLN. INFO.:			US 2002-418614P	P 20021016
			WO 2002-JP10753	W 20021016

AB Housekeeping genes commonly **expressed** in 35 different human tissues, oligonucleotide probes and DNA microarrays containing them, are disclosed.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 7 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:60757 HCAPLUS

Correction of: 2004:1060658

DOCUMENT NUMBER: 142:132329

Correction of: 142:33757

TITLE: Gene **expression** profiles and biomarkers for the detection of hyperlipidemia and other disease-related gene transcripts in blood

INVENTOR(S): Liew, Choong-Chin

PATENT ASSIGNEE(S): Chondrogene Limited, Can.

SOURCE: U.S. Pat. Appl. Publ., 155 pp., Cont.-in-part of U.S. Ser. No. 802,875.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004248170 A1		20041209	US 2004-812777	20040330
PRIORITY APPLN. INFO.:			US 1999-PV115125	19990106
			US 2000-477148	20000104
			US 2002-268730	20021009
			US 2003-601518	20030620
			US 2004-802875	20040312

AB The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is anal. performed on a drop of blood for detecting, diagnosing, and monitoring diseases, and in particular hyperlipidemia, using gene-specific and/or tissue-specific primers. Affymetrix **Human** Genome U133 and ChondroChip microarrays were used to detect differentially **expressed** gene transcripts in hypertension, obesity, allergy, systemic steroids, coronary artery disease, diabetes type 2, hyperlipidemia, lung disease, bladder cancer, rheumatoid arthritis, osteoarthritis, liver cancer, schizophrenia, Chagas disease, asthma, and manic depression syndrome. The present invention describes methods by which delineation of the sequence and/or quantitation of the **expression** levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

L17 ANSWER 8 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:825035 HCAPLUS

DOCUMENT NUMBER: 141:308582

TITLE: Proteomic analysis of biological fluids, particularly amniotic fluid and maternal serum, for diagnosing maternal/fetal conditions

INVENTOR(S): Rosenfeld, Ron; Nagalla, Sri; Gravett, Mike

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 39 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004197930	A1	20041007	US 2003-400005	20030325
WO 2004088324	A2	20041014	WO 2004-US8954	20040323
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,			

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
 SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
 TD, TG

PRIORITY APPLN. INFO.: US 2003-400005 A 20030325

AB The present invention provides non-invasive and sensitive methods for the early diagnosis, prognosis, and monitoring of pathol. fetal/maternal conditions, by proteomic anal. of biol. fluids. The invention concerns the identification of proteomes of biol. fluids and their use in determining the

state of maternal/fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns the identification of the proteome of amniotic fluid (multiple proteins representing the composition of amniotic fluid) and the correlation of characteristic changes in the normal proteome with various pathol. maternal/fetal conditions, such as intra-amniotic infection, or chromosomal defects.

L17 ANSWER 9 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:802537 HCAPLUS

DOCUMENT NUMBER: 141:289087

TITLE: **Expression** and screening for compounds regulating activity of ceramide **kinase** in tissues, for use in treatment of **human** diseases

INVENTOR(S): Kossida, Sophia; Encinas, Jeffrey; Takao, Eiko

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany

SOURCE: U.S. Pat. Appl. Publ., 50 pp., Cont.-in-part of U.S. Ser. No. 969,896, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004192580	A1	20040930	US 2003-631958	20031219
US 2003125533	A1	20030703	US 2001-969896	20011004
PRIORITY APPLN. INFO.:			US 2000-238005P	P 20001006
			US 2001-314113P	P 20010823
			US 2001-969896	B2 20011004

AB This invention relates to **expression** and screening for compds. regulating activity of ceramide **kinase** in tissues, for use in treatment of **human** diseases. Ceramide **kinase** cDNA and protein sequences, as well as **expression** profiles in various **human** tissues and cell lines, are provided. Reagents that regulate **human** ceramide **kinase** protein activity and reagents that bind to **human** ceramide **kinase** gene products can be used to regulate intracellular signaling and consequently cell proliferation and apoptosis. Methods of drug screening for reagents influencing ceramide **kinase** activity in HEK293 cells was exemplified by use of sphingosine derivs., in conjunction with anal. of cellular apoptotic response. Such regulation is particularly useful for treating allergies including but not limited to asthma, autoimmune diseases such as rheumatoid arthritis, inflammatory disease, transplant rejection, and cancer, particularly lymphocytic leukemias, and could be a useful target of vaccination enhancing adjuvants. Central and peripheral nervous system disorders, such as Parkinson's disease, also can be

treated.

L17 ANSWER 10 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:513311 HCAPLUS

DOCUMENT NUMBER: 141:65073

TITLE: Lyn **kinase**-derived peptides for the treatment of cancer

INVENTOR(S): Ben-Sasson, Shmuel; Reuveni, Hadas

PATENT ASSIGNEE(S): Children's Medical Center Corporation, USA; Yissum Research and Development

SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 12,030.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004121952	A1	20040624	US 2003-455787	20030606
US 6723694	B1	20040420	US 1997-861153	19970521
US 2002019346	A1	20020214	US 2000-735279	20001211
US 2002151497	A1	20021017	US 2001-12030	20011211
PRIORITY APPLN. INFO.:			US 1997-861153	A2 19970521
			US 2000-735279	A2 20001211
			US 2001-12030	A2 20011211
			US 2002-385900P	P 20020606
			WO 1998-US10321	A2 19980520

AB The invention provides methods for the treatment of solid tumors by the inhibition of Lyn-associated signal transduction. Preferred inhibitors comprise sequences derived from specific regions of Lyn. The invention also provides a method for the treatment of cancer by the administration of compds. comprising Lyn-derived peptides.

L17 ANSWER 11 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:250713 HCAPLUS

DOCUMENT NUMBER: 140:265666

TITLE: cDNA and protein sequences of **human** 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, 38555, 593, and mouse m1983 proteins, and their uses

INVENTOR(S): Kapeller-Libermann, Rosana; Hunter, John Joseph; Meyers, Rachel E.; Rudolph-Owen, Laura A.; Curtis, Rory A. J.; Olandt, Peter J.; Tsai, Fong Ying; Galvin, Katherine M.; Chun, Miyoung; Williamson, Mark J.; Silos-Santiago, Inmaculada; Bandaru, Rajasekhar

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 139 pp., Cont.-in-part of U.S. Ser. No. 336,153.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 57

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004058355	A1	20040325	US 2003-423543	20030425
US 6140056	A	20001031	US 1999-276400	19990325
US 6403358	B1	20020611	US 1999-412210	19991005
US 6300092	B1	20011009	US 1999-448076	19991123
US 2002042099	A1	20020411	US 2001-797039	20010228

US 6730491	B2	20040504		
US 2002151007	A1	20021017	US 2001-909743	20010720
US 2002081658	A1	20020627	US 2001-920346	20010731
US 2002086405	A1	20020704	US 2001-928531	20010813
US 2003096391	A1	20030522	US 2001-929218	20010814
US 2003017572	A1	20030123	US 2001-961656	20010924
US 2002077312	A1	20020620	US 2001-963159	20010925
US 2002173630	A1	20021121	US 2001-8016	20011108
US 2002164750	A1	20021107	US 2001-12055	20011113
US 6787345	B1	20040907	US 2001-3690	20011115
US 2003022286	A1	20030130	US 2002-60763	20020130
US 2003003477	A1	20030102	US 2002-105989	20020325
US 2002164632	A1	20021107	US 2002-121911	20020412
US 6607892	B2	20030819		
US 2003087382	A1	20030508	US 2002-217168	20020812
WO 2003027308	A2	20030403	WO 2002-US30054	20020923

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003108934	A1	20030612	US 2002-278036	20021022
US 2003119147	A1	20030626	US 2003-336489	20030102
US 2003113790	A1	20030619	US 2003-336153	20030103

PRIORITY APPLN. INFO.:

US 1998-163821	B2	19980930
US 1999-117580P	P	19990127
US 1999-276400	A2	19990325
US 1999-365162	B1	19990730
US 1999-392189	B1	19990909
US 1999-412210	A3	19991005
US 1999-448076	A3	19991123
US 2000-186061P	P	20000229
US 2000-200688P	P	20000428
US 2000-205447P	P	20000519
US 2000-608921	B1	20000630
US 2000-221925P	P	20000731
US 2000-234922P	P	20000925
US 2000-235035P	P	20000925
US 2000-246669P	P	20001108
US 2000-711216	B1	20001109
US 2000-248325P	P	20001114
US 2000-248893P	P	20001115
US 2000-257511P	P	20001222
US 2001-260166P	P	20010105
US 2001-797039	A2	20010228
US 2001-845044	B1	20010427
US 2001-909743	A2	20010720
US 2001-920346	A2	20010731
US 2001-928531	B2	20010813
US 2001-929218	B2	20010814
US 2001-312539P	P	20010815
US 2001-963159	B2	20010925
US 2001-8016	A2	20011108
US 2001-12055	A2	20011113
US 2001-3690	A2	20011115
US 2002-60763	B2	20020130
US 2002-105989	A2	20020325
US 2002-121911	A2	20020412
US 2002-217168	A2	20020812

US 2002-278036	A2 20021022
US 2003-336489	A2 20030102
US 2003-336153	A2 20030103
WO 1999-US22923	A2 19990930
US 2001-961656	A 20010924

AB The invention provides isolated nucleic acids mols., designated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid mols. The invention also provides antisense nucleic acid mols., **recombinant expression** vectors containing the same, host cells into which the **expression** vectors have been introduced, and nonhuman transgenic animals in which above genes has been introduced or disrupted. The invention still further provides isolated their encoded proteins, fusion proteins containing the same, and antigenic peptides and antibodies. 21910 Protein is a sequence homolog of membrane-associated guanylate **kinase** (MAGK). 56634 Protein is a sequence homolog of phosphatidylinositol 4-phosphate 5-**kinase**. 55053, 2504, 15977, 14760 And 3700 proteins are sequence homologs of protein **kinases**. 25501 Protein is a sequence homolog of transferases. 17903 Protein is a sequence homolog of aminopeptidases. 21529 Protein is a sequence homolog of adenylate cyclases. 26176 Protein is a sequence homolog of calpain proteases. 26343 Protein is a sequence homolog of oxidoreductases. 56638 Protein is a sequence homolog of neprilysin proteases. 18610 Protein is a sequence homolog of transient receptor potential ion channel family. 33217 Protein is a sequence homolog of AMP-binding enzymes. 21967 Protein is a sequence homolog of lysyl oxidases. **Human** and mouse 1983 (SLGP) proteins are sequence homologs of G protein-coupled receptors. 38555 And 593 proteins are sequence homologs of transport proteins. Diagnostic and therapeutic methods utilizing compns. of the invention are also provided.

L17 ANSWER 12 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:839566 HCAPLUS

DOCUMENT NUMBER: 142:18323

TITLE: The cyclin A1-CDK2 complex regulates DNA double-strand break repair

AUTHOR(S): Mueller-Tidow, Carsten; Ji, Ping; Diederichs, Sven; Potratz, Jenny; Baeumer, Nicole; Koehler, Gabriele; Cauvet, Thomas; Choudary, Chunaram; van der Meer, Tiffany; Chan, Wan-Yu Iris; Nieduszynski, Conrad; Colledge, William H.; Carrington, Mark; Koeffler, H. Phillip; Restle, Anja; Wiesmueller, Lisa; Sobczak-Thepot, Joelle; Berdel, Wolfgang E.; Serve, Hubert

CORPORATE SOURCE: Hematology/Oncology, Department of Medicine, University of Muenster, Muenster, Germany

SOURCE: Molecular and Cellular Biology (2004), 24(20), 8917-8928

CODEN: MCEBD4; ISSN: 0270-7306

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Vertebrates **express** two A-type cyclins; both associate with and activate the CDK2 protein **kinase**. Cyclin A1 is required in the male germ line, but its mol. functions are incompletely understood. We observed specific induction of cyclin A1 **expression** and promoter activity after UV and γ -irradiation which was mediated by p53. Cyclin A1-/- cells showed increased radiosensitivity. To unravel a potential role of cyclin A1 in DNA repair, we performed a yeast triple hybrid screen and identified the Ku70 DNA repair protein as a binding partner and substrate of the cyclin A1-CDK2 complex. DNA double-strand break (DSB) repair was deficient in cyclin A1-/- cells. Further expts. indicated that A-type cyclins activate DNA DSB repair by mechanisms that depend on CDK2 activity and Ku proteins. Both cyclin A1 and cyclin A2 enhanced DSB

repair by homologous recombination, but only cyclin A1 significantly activated nonhomologous end joining. DNA DSB repair was specific for A-type cyclins because cyclin E was ineffective. These findings establish a novel function for cyclin A1 and CDK2 in DNA DSB repair following radiation damage.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 45 MEDLINE on STN

ACCESSION NUMBER: 2004269352 MEDLINE

DOCUMENT NUMBER: PubMed ID: 15168726

TITLE: **Cloning** and characterization of a novel **human** TGF-beta activated **kinase**-like gene.

AUTHOR: Li Jixi; Ji Chaoneng; Yang Qisheng; Chen Jinzhong; Gu Shaohua; Ying Kang; Xie Yi; Mao Yumin

CORPORATE SOURCE: State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200433, People's Republic of China.

SOURCE: Biochemical genetics, (2004 Apr) 42 (3-4) 129-37. Journal code: 0126611. ISSN: 0006-2928.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

OTHER SOURCE: GENBANK-AY171599

ENTRY MONTH: 200412

ENTRY DATE: Entered STN: 20040601

Last Updated on STN: 20041220

Entered Medline: 20041214

AB TGF-beta activated **kinase** (TAK1) plays a critical role in the TGF-beta signaling transduction pathway. By screening a **human** 18-week fetal **brain** library, we isolated a novel **human** TAK1-like (TAKL) gene. The gene encoded a putative protein of 242 amino acids, which shared a homology with **human**, mouse, and Xenopus TAK1. The TAKL gene was located in chromosome 21q21. Northern blot analysis revealed that the TAKL mRNA was **expressed** predominantly in peripheral blood leukocytes and ubiquitously in **human** adult and fetal tissues. TAKL was also **expressed** strongly in breast **carcinoma** GI-101, colon adenocarcinoma GI-112, and prostatic adenocarcinoma PC3.

L17 ANSWER 14 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2003:442068 HCAPLUS

DOCUMENT NUMBER: 139:2022

TITLE: Gene expression profiles useful for methods of diagnosis of cancer and screening for modulators of cancer

INVENTOR(S): Afar, Daniel; Aziz, Natasha; Ginsburg, Wendy M.; Gish, Kurt C.; Glynne, Richard; Hevezi, Peter A.; Mack, David H.; Murray, Richard; Watson, Susan R.; Wilson, Keith E.; Zlotnik, Albert

PATENT ASSIGNEE(S): Eos Biotechnology, Inc., USA

SOURCE: PCT Int. Appl., 1385 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 38

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042661	A2	20030522	WO 2002-XJ36810	20021113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG
WO 2003042661 A2 20030522 WO 2002-US36810 20021113
WO 2003042661 C1 20031016
WO 2003042661 A3 20041028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
US 2004197325 A1 20041007 US 2003-741657 20031219
PRIORITY APPLN. INFO.: US 2001-350666P P 20011113
US 2001-332464P P 20011121
US 2001-334393P P 20011129
US 2001-335394P P 20011203
US 2001-340376P P 20011214
US 2002-347211P P 20020108
US 2002-347349P P 20020110
US 2002-356714P P 20020213
US 2002-359077P P 20020220
US 2002-368809P P 20020329
US 2002-370110P P 20020404
US 2002-372246P P 20020412
US 2002-386614P P 20020605
US 2002-396839P P 20020716
US 2002-397775P P 20020722
US 2002-397845P P 20020722
US 2002-409450P P 20020909
WO 2002-US36810 W 20021113
US 2002-173999 A 20020617
US 2002-435618P P 20021220

AB Described herein are genes whose **expression** are up-regulated or down-regulated in specific cancers or other diseases, or are otherwise regulated in disease. Mol. profiles of various normal and cancerous tissues were determined and analyzed using the Affymetrix/Eos Hu3 GeneChip array comprising .apprx.58,680 probesets. Related methods and compns. that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of these selected conditions. [This abstract record is one of twelve records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L17 ANSWER 15 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 4

ACCESSION NUMBER: 2003:270223 HCAPLUS

DOCUMENT NUMBER: 138:266964

TITLE: Gene **expression** profiles useful in methods of diagnosis of cancer compositions and methods of screening for modulators of cancer

INVENTOR(S): Afar, Daniel; Aziz, Natasha; Gish, Kurt C.; Hevezi, Peter A.; Mack, David H.; Wilson, Keith E.; Zlotnik,

PATENT ASSIGNEE(S): Albert
 SOURCE: EOS Biotechnology, Inc., USA
 PCT Int. Appl., 767 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 38
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025138	A2	20030327	WO 2002-XD29560	20020917
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2003025138	A2	20030327	WO 2002-US29560	20020917
WO 2003025138	A3	20030508		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004197325	A1	20041007	US 2003-741657	20031219
PRIORITY APPLN. INFO.:			US 2001-323469P	P 20010917
			US 2001-323887P	P 20010920
			US 2001-350666P	P 20011113
			US 2002-355145P	P 20020208
			US 2002-355257P	P 20020208
			US 2002-372246P	P 20020412
			WO 2002-US29560	A 20020917
			US 2002-173999	P 20020617
			US 2002-435618P	P 20021220

AB Described herein are genes whose **expression** are up-regulated or down-regulated in specific cancers, including acute lymphocytic leukemia, glioblastoma, glioblastoma multiforme, glioma, kidney cancer, stomach cancer, melanoma, and benign NEVI. Mol. profiles of various normal and cancerous tissues were determined and analyzed using the Affymetrix/Eos Hu01 and Hu03 GeneChip microarrays containing 35,403 and 59,680 probe sets, resp. Related methods and compns. that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers. [This abstract record is one of nine records for this documents necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L17 ANSWER 16 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:892894 HCAPLUS
 DOCUMENT NUMBER: 139:359962
 TITLE: Protein and cDNA and genomic sequences of a **human cyclin dependent protein kinase** sequence homolog, its tissue **expression**,

INVENTOR(S): SNPs, and therapeutic use
 Sun, Jingtiao; Neelam, Beena; Yan, Chunhua
 PATENT ASSIGNEE(S): Applera Corporation, USA
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093435	A2	20031113	WO 2003-US13718	20030502
WO 2003093435	A3	20041028		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004014659	A1	20040122	US 2003-428164	20030502
EP 1499718	A2	20050126	EP 2003-724395	20030502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-377288P	P 20020503
			US 2003-428164	A 20030502
			WO 2003-US13718	W 20030502

AB The invention provides protein and cDNA and genomic sequences for a new **human cyclin dependent protein kinase** sequence homolog. In addition, its functional domains and protein motifs are analyzed based on sequence homol. anal. Exptl. data indicates cyclin dependent protein **kinase** gene **expression** in prostate **carcinoma**, pooled colon/kidney/stomach samples, **brain** (including hippocampus, **hypothalamus**, and medulla), cervical **carcinoma**, stomach ascites, **uterus** leiomyosarcoma, T cells from T cell leukemia, eye (fetal), lung large cell **carcinoma**, leukocytes, **testis**, and pooled **brain/lung/testis** samples. The cyclin dependent protein **kinase** gene is located on chromosome 16. SNPs, including insertion and deletion variants are identified at 10 different nucleotide positions.

L17 ANSWER 17 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:837255 HCAPLUS
 DOCUMENT NUMBER: 139:319351
 TITLE: Protein and cDNA sequences of a **human citron kinase** and diagnostic, and therapeutic use
 INVENTOR(S): Davison, Daniel B.; Feder, John N.; Lee, Liana M.; Ott, Karl-heinze
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 203 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087332	A2	20031023	WO 2003-US11189	20030411
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003220224 A1 20031127 US 2003-412897 20030411

PRIORITY APPLN. INFO.: US 2002-372745P P 20020412

AB The present invention provides protein and cDNA sequences of a
human citron kinase. Also described are
expression vectors, host cells, antisense mols., and antibodies
 associated with the protein **kinase** polynucleotide and/ or
 polypeptide of this invention. In addition, methods for treating,
 diagnosing, preventing, and screening for disorders or diseases associated
 with abnormal biol. activity of the protein **kinase** are
 described, as are methods for screening for modulators, e.g., agonists or
 antagonists, of the protein **kinase** activity and/or function.

L17 ANSWER 18 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:777976 HCAPLUS

DOCUMENT NUMBER: 139:291108

TITLE: Complete polypeptides or fragments (extracellular
 domains) of **human ErbB-3 kinase**,
 their sequences, **recombinant** production, and
 use in vaccines and/or pharmaceutical composition for
 preventing or treating neoplasms

INVENTOR(S): Zhou, Mingdong

PATENT ASSIGNEE(S): Zensun Sci-Tech. Ltd., Peop. Rep. China

SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080835	A1	20031002	WO 2003-CN217	20030326

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CN 1444992 A 20031001 CN 2002-116259 20020326

EP 1495123 A1 20050112 EP 2003-711804 20030326

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: CN 2002-107357 A 20020318

CN 2002-116259 A 20020326

WO 2003-CN217 W 20030326

AB The invention provides a method for preventing, treating or delaying
 neoplasm in individuals which involves administering an effective amount of
ErbB-3 kinase, nucleic acid mol. encoding **ErbB-3 kinase**
 , or functional fragments thereof, along with an immune response
 potentiator. The invention relates that said method also involves
 co-administering an anti-neoplasm agent, along with said **ErbB-3**

kinase, or nucleic acid mol. encoding ErbB-3 **kinase**.
The invention also relates that functional fragments of ErbB-3 include the extracellular domain, or functional fragments thereof. The invention also provides antibodies specific for said ErbB-3 **kinases**, and use of antibodies in pharmaceutical compns. The invention further provides for the **recombinant** production of ErbB-3 **kinases** and functional fragments thereof, and fusion proteins comprising said ErbB-3 **kinases**. Still further, the invention provides for: (a) pharmaceutical compns. comprising the extracellular domain of ErbB-3, or nucleic acid mols. encoding said ErbB-3 fragment plus an anti-neoplasm agent and immune response potentiator; and (b) vaccines comprising nucleic acid mols. encoding ErbB-3 **kinase** fragments, or ErbB-3 **kinase** fragments plus an immune response potentiator. Finally, the invention provides the amino acid sequences of the complete ErbB-3 **kinase**, the extracellular domain of ErbB-3 **kinase**, and fragments thereof. In the examples, the invention demonstrated the use of said ErbB-3 **kinases** fragments, designated B3, DE3-1, rhErbB3-f12 and rhErbB3-f78, as anti-tumor vaccines in treatment of cancer in mice. The results revealed that said ErbB-3 **kinase** fragments when administered along with CFA (complete Freud's adjuvant) or Al(OH)₃ caused tumor growth inhibition in mice.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 19 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:633903 HCAPLUS

DOCUMENT NUMBER: 139:174873

TITLE: Protein and cDNA and genomic sequences of a **human** serine/threonine protein **kinase** sequence homolog, its tissue **expression**, SNPs, and therapeutic use

INVENTOR(S): Yan, Chunhua; Ke, Zhaoxi

PATENT ASSIGNEE(S): Applera Corporation, USA

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066835	A2	20030814	WO 2003-US3967	20030210
WO 2003066835	A3	20040325		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003157679	A1	20030821	US 2002-67977	20020208
US 6830911	B2	20041214		
EP 1474525	A2	20041110	EP 2003-737720	20030210
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
US 2004203127	A1	20041014	US 2004-827272	20040420
PRIORITY APPLN. INFO.:			US 2002-67977	A 20020208
			WO 2003-US3967	W 20030210

AB The invention provides protein and cDNA and genomic sequences for a new **human** serine/threonine protein **kinase** sequence homolog.

In addition, its functional domains and protein motifs are analyzed based on sequence homol. anal. Exptl. data of tissue **expression** indicates its **expression** in the **brain** (**hypothalamus** and **hippocampus**), **placenta**, and **mammary gland**. The serine/threonine protein **kinase** gene is located on **human** chromosome 6. SNP is identified at one different nucleotide position.

L17 ANSWER 20 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:23112 HCAPLUS
DOCUMENT NUMBER: 138:69485
TITLE: LIM **kinase expression** diagnostic methods and agents
INVENTOR(S): Bernard, Ora; Foletta, Victoria Caitlin
PATENT ASSIGNEE(S): The Walter and Eliza Hall Institute of Medical Research, Australia
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003003016	A1	20030109	WO 2002-AU834	20020627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1412754	A1	20040428	EP 2002-748418	20020627
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004538452	T2	20041224	JP 2003-509148	20020627
US 2005008643	A1	20050113	US 2004-481849	20040913
PRIORITY APPLN. INFO.:			AU 2001-5965	A 20010627
			US 2001-330361P	P 20011018
			WO 2002-AU834	W 20020627

AB The present invention relates generally to a method for detecting an aberrant cell in a subject or in a biol. sample from said subject and agents useful for same. The presence of the aberrant cell or group of aberrant cells provides an indication of a particular disease or condition or a propensity for development of a disease or condition. More particularly, the present invention contemplates a method for detecting a cell associated with cancer or having a propensity to develop into a cancer cell in a subject or in a biol. sample from said subject by determining the relative increase in the presence of a LIM **kinase** protein or a related enzyme or a relative increase in LIM **kinase** activity or a relative increase in the presence of **expression** products from a gene encoding a LIM **kinase** or a related protein. The present invention further provides a method for diagnosing the presence of a cancer or cancerous-like growth or distinguishing between an invasive and non-invasive cancer in a subject or in a biol. sample from said subject by screening for up-regulation of a LIM **kinase** or a related protein in a cell or group of cells or an up-regulation in the presence of **expression** products of genetic sequences encoding a LIM **kinase** or a related protein. The present invention provides diagnostic agents useful for detecting LIM **kinase** or

expression products of genetic material encoding LIM **kinase**. Such diagnostic agents include immuno-interactive mols., such as antibodies, and genetic probes for detecting **expression** products of LIM **kinase** genes. The present invention further provides genetically modified animals exhibiting altered levels of LIM **kinase**. Such animals are useful models for screening for anti-cancer agents.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 21 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:874888 HCAPLUS

DOCUMENT NUMBER: 139:359923

TITLE: Protein and cDNA and genomic sequences of a **human** protein serine/threonine **kinase** (phosphorylating) sequence homolog, its tissue **expression**, SNPs, and therapeutic use

INVENTOR(S): Neelam, Beena; Yan, Xianghe; Yan, Chunhua

PATENT ASSIGNEE(S): Applera Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 128 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003207311	A1	20031106	US 2003-427923	20030502
CA 2483520	AA	20031127	CA 2003-2483520	20030505
WO 2003097793	A2	20031127	WO 2003-US13987	20030505
WO 2003097793	A3	20040311		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1499740 A2 20050126 EP 2003-752996 20030505

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

PRIORITY APPLN. INFO.: US 2002-377592P P 20020506
US 2003-427923 A 20030502
WO 2003-US13987 W 20030505

AB The invention provides protein and cDNA and genomic sequences for a new **human** protein serine/threonine **kinase** (phosphorylating) sequence homolog. Exptl. data indicates protein serine/threonine **kinase** (phosphorylating) sequence homolog gene **expression** in lung squamous cell **carcinoma** and large cell **carcinoma**, kidney, B-cell chronic lymphatic leukemia, kidney tumors, breast, ovary fibrotheoma, **brain** anaplastic oligodendroglioma, head, stomach, **testis** embryonal **carcinoma**, and lymphoma. In addition, its functional domains and protein motifs are analyzed based on sequence homol. anal. The protein serine/threonine **kinase** (phosphorylating) gene is located on chromosome X. SNPs, including insertion and deletion variants are identified at 57 different nucleotide positions.

L17 ANSWER 22 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:969412 HCAPLUS

DOCUMENT NUMBER: 140:730
 TITLE: **Human** genes deregulated in drug-resistant tumor cells in response to cytotoxic drugs and methods for diagnosis and treatment of cancer
 INVENTOR(S): Wittig, Rainer; Poustka, Annemarie; Mollenhauer, Jan; Schadendorf, Dirk
 PATENT ASSIGNEE(S): Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Germany
 SOURCE: Eur. Pat. Appl., 23 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1369482	A1	20031210	EP 2002-12705	20020607
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2004038020	A1	20040506	WO 2003-EP6061	20030610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 2002-12705 A 20020607

AB The present invention relates to the identification and use of target genes for the detection and treatment of drug-resistant tumor cells. The nucleic acids of the present invention exhibit a deregulated phenotype when the tumor cells are subjected to cytostatic drugs, i.e.. they are **expressed** in a higher or lower amount as compared to parental drug-sensitive cancer cells. Thus, they can be used as a diagnostic and pharmaceutical tool to render drug-resistant cells drug-sensitive. In addition, the present invention includes the polypeptides encoded by the resp. nucleic acids, **expression** vectors harboring the nucleic acids, host cells for **expression** and methods for the diagnosis and treatment of drug-resistant tumor cells.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 23 OF 45 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN DUPLICATE 5

ACCESSION NUMBER: 2003-06755 BIOTECHDS

TITLE: New peptides related to calcium/calmodulin-dependent protein **kinase** subfamily useful for treating disorders associated with abnormal **expression** of **kinase** in fetal **brain, testis, lung small cell carcinoma, uterus** adenocarcinoma;

vector-mediated **recombinant** protein gene transfer and **expression** in host cell for use in drug screening, gene therapy and pharmacogenetics

AUTHOR: SHAO W; MERKULOV G V; DI FRANCESCO V

PATENT ASSIGNEE: PE CORP NY; BEASLEY E M

PATENT INFO: WO 2002079431 10 Oct 2002

APPLICATION INFO: WO 2002-US9744 1 Apr 2002

PRIORITY INFO: US 2001-820790 30 Mar 2001; US 2001-820790 30 Mar 2001

DOCUMENT TYPE: Patent

LANGUAGE: English
OTHER SOURCE: WPI: 2003-046806 [04]
AB DERWENT ABSTRACT:

NOVELTY - An isolated peptide (I) comprising a 516 residue amino acid sequence (P1), given in the specification, an allelic variant or ortholog of (P1), which is encoded by a nucleic acid molecule that hybridizes under stringent conditions to a 2218 (S1) or 28438 (S2) base pair sequence, given in the specification, or a fragment of (P1) comprising at least 10 contiguous amino acids, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following: (1) an isolated antibody that selectively binds to (I); (2) an isolated nucleic acid molecule (II) comprising a sequence encoding (I), or its complement; (3) a gene chip comprising (II); (4) a transgenic non-human animal comprising (II); (5) a nucleic acid vector comprising (II); (6) a host cell containing the vector in (5); (7) producing (I), comprising: (a) introducing a nucleotide sequence encoding the amino acid sequence of (I) into a host cell; and (b) culturing the host cell under conditions suitable for the **expression** of the peptide from the nucleotide sequence; (8) detecting the presence of (I) in a sample, comprising contacting the sample with a detection agent that specifically allows detection of the presence of the peptide in the sample then detecting the presence of the peptide; (9) detecting the presence of (II) in a sample, comprising: (a) contacting the sample with an oligonucleotide that hybridizes to (II) under stringent conditions; and (b) determining if the oligonucleotide binds to (II) in the sample; (10) identifying a modulator of (I) or its **expression**, comprising: (a) contacting (I) or a cell **expressing** (I) with an agent; and (b) determining if the agent modulated the function or activity, or **expression** of the peptide; (11) identifying an agent that binds to (I), comprising: (a) contacting the peptide with an agent; and (b) assaying the contacted mixture to determine if a complex is formed with the agent bound to the peptide; (12) a pharmaceutical composition comprising the agent identified in (11) and a carrier; (13) treating a disease or condition mediated by **human kinase** protein, comprising administering to a patient the agent identified in (11); (14) an isolated **human kinase** peptide comprising a sequence that is at least 70 % identical to a (P1); and (15) an isolated nucleic acid molecule encoding a **human kinase** peptide, which is at least 80 % identical to (S1) or (S2).

BIOTECHNOLOGY - Preferred Method: Identifying a modulator of (I) comprises administration of the agent to a host cell containing the vector that **expresses** (I). Preferred Peptide: The **human kinase** peptide is preferably 90 % identical to (P1). Preferred Nucleic Acid: The nucleic acid molecule in (15) is preferably 90 % identical to (S1) or (S2).

ACTIVITY - Cytostatic; Antiinflammatory; Immunomodulator. No biological data is given.

MECHANISM OF ACTION - Gene therapy; Protein **kinase**.

USE - The peptides are useful in substantial and specific assays related to functional information of the peptide sequences, to raise antibodies or to elicit immune response, as reagents in assays to determine the levels of protein in biological fluids, and as markers for tissues where the corresponding protein is **expressed**. The peptides and antibodies are useful in drug screening assays, tissue typing and pharmacogenomic analysis. They are also useful in treating disorders associated with the absence of, inappropriate, or unwanted **expression** of **kinase** protein in fetal **brain**, **testis**, lung small cell **carcinoma**, or **uterus** endometrium adenocarcinoma, such as cancer, inflammation, immune disorders, or disorders affecting growth and development. The nucleic acid molecules are useful for probes, primers and chemical intermediates in biological assays, for constructing **recombinant** vectors, **expressing** antigenic portions of the protein. The peptide and nucleic acid sequences are useful as models for the development of

human therapeutic targets, aid in the identification of therapeutic proteins and serve as targets for the development of human therapeutic agents that modulate kinase activity in cells and tissues that express the transporter. The host cells are useful in producing a kinase protein or peptide, and non-human transgenic animals.

EXAMPLE - No example given. (86 pages)

L17 ANSWER 24 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:594985 HCAPLUS

DOCUMENT NUMBER: 137:151128

TITLE: Protein, gene and cDNA sequences of a novel human protein kinase related to Pftaire kinase subfamily and their uses in drug screening

INVENTOR(S): Yan, Chunhua; Ketchum, Karen; Di Francesco, Valentina; Beasley, Ellen M.

PATENT ASSIGNEE(S): PE Corporation (NY), USA

SOURCE: PCT Int. Appl., 131 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002061060	A2	20020808	WO 2002-US1106	20020117
WO 2002061060	A3	20021212		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002119544	A1	20020829	US 2001-801861	20010309
US 6492154	B2	20021210		
CA 2436088	AA	20020808	CA 2002-2436088	20020117
EP 1368461	A2	20031210	EP 2002-704134	20020117
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2003022229	A1	20030130	US 2002-224562	20020821
US 6730506	B2	20040504		
US 2004146924	A1	20040729	US 2004-786065	20040226
PRIORITY APPLN. INFO.:			US 2001-265151P	P 20010131
			US 2001-801861	A 20010309
			WO 2002-US1106	W 20020117
			US 2002-224562	A3 20020821

AB The invention provides protein, cDNA and genomic sequences for a novel human protein kinase related to Pftaire kinase subfamily. The protein kinase gene is expressed in human uterus endometrium adenocarcinoma, testis, lung fibroblasts, kidney renal cell adenocarcinoma, and brain. The protein kinase gene has been mapped to chromosome 2. The invention also relates to screening modulator of said protein kinase and use them in therapy. The invention further relates to methods, vector and hosts for expression of said protein kinase.

L17 ANSWER 25 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:408781 HCAPLUS

DOCUMENT NUMBER: 137:2411
 TITLE: Protein and cDNA sequences of **human kinase** sequence homologs
 INVENTOR(S): Friddle, Carl Johan; Hilbun, Erin; Mathur, Brian; Turner, C. Alexander, Jr.
 PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002042438	A2	20020530	WO 2001-US43825	20011119
WO 2002042438	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002028633	A5	20020603	AU 2002-28633	20011119
US 2002110908	A1	20020815	US 2001-992481	20011119
US 6593125	B2	20030715		
US 2003181705	A1	20030925	US 2003-434034	20030508
US 6815188	B2	20041109		

PRIORITY APPLN. INFO.:
 US 2000-252011P P 20001120
 US 2001-992481 A1 20011119
 WO 2001-US43825 W 20011119

AB This invention provides protein and cDNA sequences for newly identified **human** proteins, designated NHPs, which shares substantial sequence homol. with animal **kinases**, especially NEK family **kinases** and calcium/calmodulin-dependent protein **kinase**. NEK family **kinase** homolog gene, which has been mapped on **human** chromosome 17, is **expressed** in, inter alia, **human** cell lines and **pituitary**, thymus, spleen, lymph node, bone marrow, trachea, kidney, prostate, **testis**, thyroid, adrenal gland, pancreas, salivary gland, stomach, small intestine, skeletal muscle, heart, **uterus**, placenta, adipose, skin, bladder, rectum, pericardium, ovary, fetal kidney, fetal lung, gallbladder, tongue, aorta, 6-, 9-, and 12-wk embryos, adenocarcinoma, **osteosarcoma**, and embryonic **carcinoma** cells. Calcium/calmodulin-dependent protein **kinase** homolog gene, which has been mapped on **human** chromosome 3, is predominantly **expressed** in fetal **brain**, **brain**, spinal cord, thymus, lymph node, trachea, lung, prostate, **testis**, thyroid, adrenal gland, stomach, small intestine, skeletal muscle, **uterus**, placenta, **mammary gland**, skin, bladder, pericardium, **hypothalamus**, fetal kidney, fetal lung, tongue, aorta, 6-, 9-, and 12-wk embryos, and embryonic **carcinoma** cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases associated with inappropriate NHP activity or levels.

L17 ANSWER 26 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:391912 HCAPLUS

DOCUMENT NUMBER: 137:1836

TITLE: Measurement of DNA methylation for analysis of the

toxicology of substances
 INVENTOR(S): Olek, Alexander; Piepenbrock, Christian; Berlin, Kurt
 PATENT ASSIGNEE(S): Epigenomics Ag, Germany
 SOURCE: PCT Int. Appl., 113 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040710	A2	20020523	WO 2001-EP12951	20011108
WO 2002040710	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056802	A1	20020529	DE 2000-10056802	20001114
AU 2002023672	A5	20020527	AU 2002-23672	20011108
EP 1337668	A2	20030827	EP 2001-996625	20011108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004513650	T2	20040513	JP 2002-543021	20011108
US 2004048279	A1	20040311	US 2003-416905	20030514
PRIORITY APPLN. INFO.: DE 2000-10056802 A 20001114				
WO 2001-EP12951 W 20011108				

AB The invention relates to a method for anal. of the toxicol. of a substance by measuring its effects using changes in DNA methylation as an indicator of toxicol. According to the invention, a DNA sample is taken from an organism or a cell culture which has been exposed to a specific substance which is to be examined on account of its toxicol. effect. The DNA contained in said sample is chemical pre-treated and the base sequence of a section of the modified DNA is determined. The preferred method is to convert cytosine in CpG dinucleotides to uracil using bisulfite. Probes specific for cytosine- or uracil-containing DNA can be used to detect changes in methylation. From there, a characteristic methylation state or a characteristic methylation model is determined for the sample. By comparison with data from methylation states of other samples, the effect of a substance on the organism or the cell culture is determined and/or compared to other substances in toxicol. terms. A panel of sequences that can be used to analyze the effects of poisons is described.

L17 ANSWER 27 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:276032 HCAPLUS

DOCUMENT NUMBER: 136:304111

TITLE: Regulation of **human** sphingosine **kinase**-like protein and uses in diagnosis, therapy and drug screening

INVENTOR(S): Kossida, Sophia; Encinas, Jeffrey

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002028906	A2	20020411	WO 2001-EP11516	20011005
WO 2002028906	A3	20021114		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002023593	A5	20020415	AU 2002-23593	20011005
EP 1326986	A2	20030716	EP 2001-986303	20011005
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004510429	T2	20040408	JP 2002-532488	20011005
PRIORITY APPLN. INFO.:				
			US 2000-238005P	P 20001006
			US 2001-314113P	P 20010823
			WO 2001-EP11516	W 20011005

AB Reagents which regulate **human** sphingosine **kinase**-like protein activity and reagents which bind to **human** sphingosine **kinase**-like protein gene products can be used to regulate intracellular signaling intracellular signaling and consequently cell proliferation and apoptosis. Such regulation is particularly useful for treating cancer, allergies including but not limited to asthma, autoimmune diseases such as rheumatoid arthritis, and central and peripheral nervous system disorders, such as Parkinson's disease.

L17 ANSWER 28 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:172058 HCAPLUS

DOCUMENT NUMBER: 136:227966

TITLE: Protein and cDNA sequences of **human** protein **kinase** sequence homologs and uses thereof in diagnosis, therapy and drug screening

INVENTOR(S): Friddle, Carl Johan; Hilbun, Erin; Nepomnichy, Boris; Hu, Yi

PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018555	A2	20020307	WO 2001-US26776	20010828
WO 2002018555	A3	20030227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001085326	A5	20020313	AU 2001-85326	20010828
US 2002147320	A1	20021010	US 2001-940921	20010828
PRIORITY APPLN. INFO.:				
			US 2000-229280P	P 20000831
			WO 2001-US26776	W 20010828

AB This invention provides protein and cDNA sequences for newly identified

human proteins, designated NHPs, which shares substantial sequence homol. with animal **kinases**, and particularly NIMA (never in mitosis A) related **kinases**, serine/threonine **kinases**, calcium/calmodulin-dependent **kinases**, and myosin light chain **kinases**. While NHP shares sequence homol. with other protein **kinases**, its primary sequence is unique. **Expression** of NHPs can be detected in, inter alia, human cell lines, and human fetal and adult **brain, pituitary, cerebellum, spinal cord, thymus, spleen, lymph node, bone marrow, trachea, lung, kidney, fetal and adult liver, prostate, testis, thyroid, small intestine, heart, uterus, placenta, mammary gland, adipose, esophagus, cervix, rectum, fetal kidney, and fetal lung (SEQID NOS:2 and 4), or human pituitary, kidney, thyroid, skeletal muscle, and heart cells (SEQ ID NOS: 7 and 9)**. The described sequences were compiled from sequences available in GENBANK, and cDNAs generated from kidney, **testis, trachea, esophagus, pituitary, human gene trapped products (SEQ ID NOS: 2 and 4), or bone marrow and skeletal muscle mRNAs**. In one embodiment, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases associated with inappropriate NHP activity or levels.

L17 ANSWER 29 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:107557 HCAPLUS

DOCUMENT NUMBER: 136:162371

TITLE: **Cloning and characterization of novel human protein kinase family members**

INVENTOR(S): 32374 and 18431 and their therapeutic uses
Meyers, Rachel; Kapeller-Libermann, Rosana;
Silos-Santiago, Immaculada

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 141 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010401	A2	20020207	WO 2001-US23653	20010727
WO 2002010401	A3	20030306		
WO 2002010401	C2	20030912		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002061573	A1	20020523	US 2001-916790	20010727
EP 1315817	A2	20030604	EP 2001-957286	20010727
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 2004083496	A1	20040429	US 2003-678786	20031003
PRIORITY APPLN. INFO.:			US 2000-221543P	P 20000728
			US 2001-916790	B1 20010727
			WO 2001-US23653	W 20010727

AB The invention provides isolated nucleic acids mols., designated 32374 or 18431 nucleic acid mols., which encode novel protein **kinase**

family members. The invention also provides antisense nucleic acid mols., **recombinant expression** vectors containing 32374 or 18431 nucleic acid mols., host cells into which the **expression** vectors have been introduced, and nonhuman transgenic animals in which a 32374 or 18431 gene has been introduced or disrupted. Their putative function domains are analyzed and their gene **expression** profiles are provided. The invention still further provides isolated 32374 or 18431 proteins, fusion proteins, antigenic peptides and anti-32374 or -18431 antibodies. Diagnostic methods utilizing compns. of the invention are also provided.

L17 ANSWER 30 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:66831 HCAPLUS
DOCUMENT NUMBER: 136:113833
TITLE: Protein, gene and cDNA sequences of **human** protein **kinase** sequence homolog
INVENTOR(S): Yan, Chunhua; Ketchum, Karen A.; Di Francesco, Valentina; Beasley, Ellen M.
PATENT ASSIGNEE(S): PE Corporation (NY), USA
SOURCE: U.S., 88 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6340583	B1	20020122	US 2001-813817	20010322
US 6403353	B1	20020611	US 2001-978197	20011017
CA 2442052	AA	20021003	CA 2002-2442052	20020322
WO 2002077171	A2	20021003	WO 2002-US8657	20020322
WO 2002077171	A3	20030227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1379631	A2	20040114	EP 2002-721509	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003166215	A1	20030904	US 2002-135696	20020501
US 6740513	B2	20040525		
US 2004175751	A1	20040909	US 2004-820230	20040408
PRIORITY APPLN. INFO.:			US 2001-813817	A3 20010322
			US 2001-978197	A3 20011017
			WO 2002-US8657	W 20020322
			US 2002-135696	A3 20020501

AB The invention provides protein and cDNA and genomic sequences for a novel **human** protein, which shares sequence homol. to a known protein **kinase**, and is related to the serine/threonine **kinase** subfamily. The gene is **expressed** in teratocarcinoma, ovary, **testis**, nervous tissue, bladder, infant and fetal **brain**, and thyroid gland. Forty two novel single nucleotide polymorphism sites (beyond the ORF or in intron regions) were identified. Thus, the present invention specifically provides isolated peptide and nucleic acid mols., methods of identifying orthologs and paralogs of the protein **kinase** peptides, methods of identifying modulators of the protein **kinase** peptides, and methods of diagnosis and treatment of

diseases associated with the protein kinase.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 31 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:798433 HCAPLUS

DOCUMENT NUMBER: 135:340271

TITLE: Protein and cDNA sequences of a novel ubiquitin
conjugating enzyme sequence homolog 27960 and uses
thereof

INVENTOR(S): Meyers, Rachel A.; Tsai, Fong-Ying

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 117 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081584	A2	20011101	WO 2001-US40607	20010425
WO 2001081584	A3	20020404		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2003224376	A1	20031204	US 2002-184648	20020627
PRIORITY APPLN. INFO.:			US 2000-199500P	P 20000425
			US 2000-187456P	P 20000307
			US 2000-191865P	P 20000324
			US 2000-191964P	P 20000324
			US 2000-192092P	P 20000324
			US 2000-200604P	P 20000428
			US 2000-205408P	P 20000519
			US 2000-211730P	P 20000615
			US 2000-212077P	P 20000615
			US 2000-212079P	P 20000615
			US 2000-235044P	P 20000925
			US 2000-238849P	P 20001006
			US 2001-267494P	P 20010208
			US 2001-801220	A2 20010307
			WO 2001-US7269	A 20010307
			US 2001-815028	A2 20010322
			WO 2001-US9358	A 20010322
			US 2001-816714	B2 20010323
			WO 2001-US9468	A 20010323
			US 2001-817910	A2 20010326
			WO 2001-US9633	A 20010326
			US 2001-842528	B2 20010425
			WO 2001-US40607	A 20010425
			US 2001-844948	A2 20010427
			WO 2001-US13805	A 20010427
			US 2001-861164	B2 20010518
			WO 2001-US16292	A 20010518
			US 2001-882836	A2 20010615
			US 2001-882872	B2 20010615
			US 2001-883060	A2 20010615
			WO 2001-US19138	A 20010615

WO 2001-US19153	A	20010615
WO 2001-US19543	A	20010615
US 2001-962678	A2	20010925
WO 2001-US29963	A	20010925
US 2001-973457	A2	20011009
US 2002-72285	A2	20020208
WO 2002-US3736	A	20020208

AB The invention provides isolated nucleic acids mols., designated 27960 nucleic acid mols., which encode novel ubiquitin-conjugating enzyme family members. The mRNA distribution profiles in various animal tissues and tumors are provided. The invention also provides antisense nucleic acid mols., **recombinant expression** vectors containing 27960 nucleic acid mols., host cells into which the **expression** vectors have been introduced, and nonhuman transgenic animals in which a 27960 gene has been introduced or disrupted. The invention still further provides isolated 27960 proteins, fusion proteins, antigenic peptides and anti-27960 antibodies. Diagnostic methods utilizing compns. of the invention are also provided.

L17 ANSWER 32 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:676960 HCAPLUS

DOCUMENT NUMBER: 135:237660

TITLE: Protein and cDNA sequences of novel **human kinase** interacting protein homologs and uses thereof in diagnosis, therapy and drug screening

INVENTOR(S): Mathur, Brian; Turner, C. Alexander, Jr.

PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066760	A2	20010913	WO 2001-US7499	20010308
WO 2001066760	A3	20020530		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2401971	AA	20010913	CA 2001-2401971	20010308
US 2002082406	A1	20020627	US 2001-802116	20010308
EP 1343901	A2	20030917	EP 2001-918467	20010308
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR			
JP 2004519203	T2	20040702	JP 2001-565914	20010308
PRIORITY APPLN. INFO.:			US 2000-187719P	P 20000308
			WO 2001-US7499	W 20010308

AB This invention provides protein and cDNA sequences for newly identified **human** proteins, designated NHPs, which shares structural similarity with mammalian sugar and sodium-dependent inorg. phosphate **kinase** interacting proteins, and NBMPR-sensitive nucleoside **kinase** interacting proteins. The NHPs are novel proteins that are **expressed** in, inter alia, **human** cell lines and **human** fetal and adult **brain**, **pituitary**, cerebellum, spinal cord, thymus, spleen, lymph node, bone marrow, trachea, fetal and adult kidney, liver, prostate, **testis**, thyroid,

adrenal gland, salivary gland, stomach, small intestine, colon, adipose, rectum, pericardium, **hypothalamus**, cervix, bladder, esophagus, skin, **mammary gland**, placenta, **uterus**, skeletal muscle, pancreas, fetal lung, and ovary cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases associated with inappropriate NHP activity or levels.

L17 ANSWER 33 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:618177 HCAPLUS

DOCUMENT NUMBER: 135:191337

TITLE: Protein and cDNA sequences of novel **human kinase** homologs and uses thereof in diagnosis, therapy and drug screening

INVENTOR(S): Walke, D. Wade; Hu, Yi; Nepomnichy, Boris; Turner, C. Alexander, Jr.; Zambrowicz, Brian

PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001061016	A2	20010823	WO 2001-US5356	20010215
WO 2001061016	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2400785	AA	20010823	CA 2001-2400785	20010215
US 2002038011	A1	20020328	US 2001-783320	20010215
EP 1257652	A2	20021120	EP 2001-912839	20010215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003531577	T2	20031028	JP 2001-559853	20010215
PRIORITY APPLN. INFO.:			US 2000-183582P	P 20000218
			US 2000-184014P	P 20000222
			WO 2001-US5356	W 20010215

AB This invention provides protein and cDNA sequences for newly identified **human** proteins, designated NHPs, which shares structural similarity with animal **kinases**, including cell division control protein **kinases**, serine/threonine protein **kinases** and membrane-associated guanylate **kinases** (MAGUKs). The NHPs are novel proteins that are **expressed** in, inter alia, **human** cell lines and **human** fetal and adult **brain**, **pituitary**, cerebellum, thymus, spleen, lymph node, bone marrow, trachea, fetal and adult liver, prostate, **testis**, thyroid, adrenal gland, pancreas, salivary gland, stomach, small intestine, colon, **uterus**, placenta, **mammary gland**, adipose, esophagus, bladder, cervix, rectum, pericardium, **hypothalamus**, ovary, fetal and adult kidney, and fetal lung cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against

diseases associated with inappropriate NHP activity or levels.

L17 ANSWER 34 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:598145 HCAPLUS
DOCUMENT NUMBER: 135:177273
TITLE: **Cloning**, sequencing and therapeutic use of a
human protein kinase 18477
INVENTOR(S): Kapeller-Libermann, Rosana; Meyers, Rachel A.;
Williamson, Mark
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001059080	A1	20010816	WO 2001-US4027	20010208
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1263939	A1	20021211	EP 2001-910461	20010208
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2000-182059P	P 20000211
			US 2000-659287	A 20000912
			WO 2001-US4027	W 20010208
AB	Novel human protein kinase polypeptides, proteins and nucleic acid mols. are disclosed. Amino acid and encoding cDNA sequences of human protein kinase 18477 are disclosed. An expression pattern of the enzyme in human tissues is established. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-sense antibodies. The invention also provides kinase nucleic acid mols., recombinant expression vectors containing nucleic acid mols. of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing comps. of the invention are also provided.			
REFERENCE COUNT:	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L17 ANSWER 35 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:335429 HCAPLUS
DOCUMENT NUMBER: 132:344131
TITLE: Sequences encoding a novel cbl-SL gene and its encoded tyrosine **kinase**-binding protein, and uses thereof in diagnostic and therapeutic applications
INVENTOR(S): Borriello, Francescopaolo; Band, Hamid
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027865	A1	20000518	WO 1999-US26057	19991105
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRIORITY APPLN. INFO.: US 1998-107470P P 19981106

AB The invention provides protein and cDNA sequences encoding a novel cbl-SL gene/protein and fragments and biol. functional variants thereof. The cbl-SL gene encodes a 50 kDa protein that can associate with a tyrosine **kinase** (phosphorylated or not) or a receptor tyrosine **kinase** (ligand-activated or not) and is believed to play a role in the regulation of a cell's growth, differentiation, and proliferation. Cbl-SL protein activity therefore includes Cbl-SL protein binding at least to the intact epidermal growth factor (EGF) receptor with or without EGF stimulation, or to the Grb-2 (adapter protein) SH2 domain only after EGF stimulation. Preferably, Cbl-SL protein binds phosphorylated tyrosine **kinases** and decreases the level of phosphorylation of the tyrosine **kinase**, and/or down-regulates (or inhibits) **expression** of the tyrosine **kinase**. The cbl-SL gene/protein shares limited homol. with c-cbl, cbl-b, and C. Elegans sli-1. The invention also pertains to therapeutic and diagnostic applications of the foregoing proteins and genes, particularly those relating to cell cycle control disorders and cancer.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 36 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:344111 HCAPLUS
DOCUMENT NUMBER: 132:343301
TITLE: Gene therapy for solid tumors using adenoviral vectors comprising suicide genes and cytokine genes
INVENTOR(S): Woo, Savio L. C.; Chen, Shu-Hsia
PATENT ASSIGNEE(S): Baylor College of Medicine, USA
SOURCE: U.S., 45 pp., Cont.-in-part of U.S. 5,631,236.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6066624	A	20000523	US 1996-600942	19960215
US 5631236	A	19970520	US 1993-112745	19930826
WO 9505835	A1	19950302	WO 1994-US9784	19940825
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1469075	A1	20041020	EP 2004-16403	19940825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
US 6217860	B1	20010417	US 1999-404614	19990924

PRIORITY APPLN. INFO.: US 1993-112745 A2 19930826
WO 1994-US9784 W 19940825
EP 1994-927282 A3 19940825
US 1996-600942 A3 19960215

AB A method is provided for treating localized solid tumors and papillomas in an individual, as well as metastatic **carcinomas**. The method comprises delivering a suicide gene, by way of a **recombinant** adenoviral vector or other DNA transport system, into the tumor, papilloma, or wart of an individual. Subsequently, a prodrug, e.g. ganciclovir, is administered to the individual. Addnl., a method is

provided for treating solid tumors, papillomas, warts and metastatic **carcinomas**, the method comprising introducing both a suicide gene and one or more cytokine genes into the tumor, papilloma, or wart of an individual, and subsequently administering a prodrug to the individual. The methods of the invention may be used to treat several different types of cancers and papillomas, including colon **carcinoma**, prostate cancer, breast cancer, lung cancer, melanoma, hepatoma, **brain** lymphoma, and head and neck cancer.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 37 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:853562 HCAPLUS

DOCUMENT NUMBER: 134:191706

TITLE: Nerve injury-associated **kinase**: a sterile 20-like protein **kinase** up-regulated in dorsal root ganglia in a rat model of neuropathic pain
AUTHOR(S): Rausch, O.; Newton, R. A.; Bingham, S.; Macdonald, R.; Case, C. P.; Sanger, G. J.; Lawson, S. N.; Reith, A. D.

CORPORATE SOURCE: Department of Neuroscience Research, SmithKline Beecham Pharmaceuticals, Harlow, Essex, CM19 5AW, UK

SOURCE: Neuroscience (Oxford) (2000), 101(3), 767-777

CODEN: NRSCDN; ISSN: 0306-4522

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Partial injury of the rat sciatic nerve elicits a variety of characteristic chemical, electrophys. and anatomical changes in primary sensory neurons and constitutes a physiol. relevant model of neuropathic pain. To elucidate mol. mechanisms that underlie the physiol. of neuropathic pain, mRNA differential display was used to identify genes that exhibit increased ipsilateral **expression** in L4/5 dorsal root ganglia, following unilateral partial ligation of the rat sciatic nerve. One set of partial complementary DNA **clones** identified in this screen encoded a protein **kinase**, nerve injury-associated **kinase**. Cloning of the full-length **human** nerve injury-associated **kinase** complementary DNA, together with **recombinant expression** anal., revealed nerve injury-associated **kinase** to be a functional member of a subgroup of sterile 20-like protein **kinases** characterized by the presence of a putative carboxy terminal autoregulatory domain. Induction of nerve injury-associated **kinase expression** in dorsal root ganglia in the rat neuropathic pain model was confirmed by quant. reverse transcription-polymerase chain reaction, and RNA in situ hybridization anal. revealed enhanced levels of nerve injury-associated **kinase** within neurons. Together, the data implicate nerve injury-associated **kinase** as a novel upstream component of an intracellular signaling cascade that is up-regulated in dorsal root ganglia neurons in response to sciatic nerve injury.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 38 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:868076 HCAPLUS

DOCUMENT NUMBER: 134:290999

TITLE: Functional implication of **human** serine/threonine **kinase**, hAIK, in cell cycle progression

AUTHOR(S): Yang, Shun-Chun; Huang, Chian-Hoang; Chen, Nien-Jung; Chou, Cheng-Kung; Lin, Chi-Hung

CORPORATE SOURCE: Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, 112, Taiwan

SOURCE: Journal of Biomedical Science (Basel) (2000), 7(6),

484-493

CODEN: JBCIEA; ISSN: 1021-7770

PUBLISHER: S. Karger AG

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Protein phosphorylation is involved in many biol. activities and plays important roles in cell cycle progression. In the present study, we identified a serine/threonine **kinase**, hAIK, from **human** hepatic cells using degenerated polymerase chain reactions with a pair of primers derived from the highly conserved sequence in the catalytic domain of **kinases**. The full-length hAIK cDNA was then obtained, which contained 403 amino acids and was homologous to Drosophila Aurora2 and yeast lpl1 proteins. Northern blotting anal. revealed that hAIK was highly **expressed** in the **testis** but not in other tissues. **Expressions** of hAIK drastically increased in cancer tissues/cell lines but not in fibroblasts or nontumorigenic cell lines. The **recombinant** hAIK protein phosphorylated itself and histone H1; this phosphorylation activity was totally abolished after a point mutation at the catalytic domain (hAIKm). During the interphase cell, hAIK was found mainly in the cytoplasm; during mitosis hAIK accumulated at the centrosomes. In addition, over-**expression** of hAIK in cancer cell lines (HEK293T and HeLa) appeared to inhibit cell cycle progression. None of these phenomena were observed in hAIKm whose **kinase** activity was rendered inactive. Our results suggest that hAIK protein/activity might modulate cell cycle progression by interacting with the centrosomes and/or proteins associated with these structures.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 39 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:316553 HCAPLUS

DOCUMENT NUMBER: 127:1463

TITLE: **Human** SAK related to the PLK/polo family of cell cycle **kinases** shows high mRNA **expression** in **testis**

AUTHOR(S): Karn, Thomas; Holtrich, Uwe; Wolf, Georg; Hock, Bjoern; Strebhardt, Klaus; Ruebsamen-Waigmann, Helga
CORPORATE SOURCE: Chemotherapeutisches Forschungsinstitut, Frankfurt, 60596, Germany

SOURCE: Oncology Reports (1997), 4(3), 505-510

CODEN: OCRPEW; ISSN: 1021-335X

PUBLISHER: Oncology Reports

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We identified the nucleotide sequence of a cDNA encoding a polypeptide with a **kinase** domain that is related to the catalytic region of Drosophila melanogaster polo, Saccharomyces cerevisiae CDC5 as well as **human** FNK and PLK. The novel gene seems to represent the **human** counterpart of the mouse gene sak. The sequence of SAK predicts a serine/threonine **kinase** of 970 aa. The distribution of SAK mRNA in adult organs is restricted to certain tissues such as **testis** and thymus. Northern analyses of tumor tissues (lung, breast, **brain**) and corresponding normal tissues from the same patient did not reveal SAK **expression**. Comparing the mRNA distribution of the proliferation-associated polo-like **kinase** (PLK) with the **expression** of SAK we observed distinct differences. Thus, we suggest that these **kinases** have unique physiol. roles in different cells or in response to different signals.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 40 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:390815 HCAPLUS

DOCUMENT NUMBER: 127:118828

TITLE: Identification of four novel **human** phosphoinositide 3-**kinases** defines a multi-isoform subfamily
AUTHOR(S): Ho, Liza K. F.; Liu, Dongxu; Rozycka, Magdalena; Brown, Richard A.; Fry, Michael J.
CORPORATE SOURCE: Signal Transduction Team, Section of Cell Biology and Experimental Pathology, Institute of Cancer Research, Haddow Laboratories, Sutton, SM2 5NG, UK
SOURCE: Biochemical and Biophysical Research Communications (1997), 235(1), 130-137
CODEN: BBRC A9; ISSN: 0006-291X
PUBLISHER: Academic
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Phosphoinositide (PI) 3-**kinases** have critical roles in diverse cellular signaling processes and in protein trafficking. This suggests that like other intracellular signaling molcs., e.g., phospholipase C and protein **kinase** C, there might be a large family of PI 3-**kinase** isoforms with the individual members having discrete signaling roles. Reverse transcription-polymerase chain reaction methods, using degenerate oligonucleotide primers against the lipid **kinase** consensus region, revealed eight sequences from **human** cDNA containing a high degree of identity to the family of PI 3-**kinases**. The sequences obtained included the previously described p110 α , p110 β , and p110 γ isoforms and HsVps34. Addnl., we have identified four novel sequences which are related to PI 3-**kinases**. Three of the novel sequences appear to form a distinct sub-family of PI 3-**kinases**. We report the **expression** of these novel PI 3-**kinases** in **human** tissues and in cells derived from normal breast.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 41 OF 45 MEDLINE on STN DUPLICATE 6
ACCESSION NUMBER: 96154673 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8589679
TITLE: Molecular characterization and chromosomal localization of DRT (EPHT3): a developmentally regulated **human** protein-tyrosine **kinase** gene of the EPH family.
AUTHOR: Ikegaki N; Tang X X; Liu X G; Biegel J A; Allen C; Yoshioka A; Sulman E P; Brodeur G M; Pleasure D E
CORPORATE SOURCE: Division of Oncology, Children's Hospital of Philadelphia, Abramson Research Center, PA 19104-4318, USA.
CONTRACT NUMBER: NS08075 (NINDS)
NS25044 (NINDS)
NS30606 (NINDS)

+
SOURCE: Human molecular genetics, (1995 Nov) 4 (11) 2033-45.
Journal code: 9208958. ISSN: 0964-6906.
PUB. COUNTRY: ENGLAND: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-L41939
ENTRY MONTH: 199603
ENTRY DATE: Entered STN: 19960404
Last Updated on STN: 19970203
Entered Medline: 19960327

AB By screening a **human** fetal **brain** cDNA **expression** library using a monoclonal antiphosphotyrosine antibody and by 5' RACE procedures, we have isolated overlapping cDNAs encoding a receptor-type tyrosine **kinase** belonging to the EPH family, DRT (Developmentally Regulated EPH-related Tyrosine **kinase** gene). The DRT gene is **expressed** in three different size transcripts

(i.e. 4, 5 and 11 kb). DRT transcripts are **expressed** in **human brain** and several other tissues, including heart, lung, kidney, placenta, pancreas, liver and skeletal muscle, but the 11 kb DRT transcript is preferentially **expressed** in fetal **brain**. Steady-state levels of DRT mRNA in several tissues, including **brain**, heart, lung and kidney, are greater in the midterm **fetus** than those in the adult. DRT transcripts are detectable at low levels in a **human** teratocarcinoma cell line (NTera-2), but its **expression** is greatly increased after the NTera-2 cells are induced to become postmitotic neurons (NTera-2N) by retinoic acid treatment. These data suggest that DRT plays a part in **human** neurogenesis. A large number of tumor cell lines derived from neuroectoderm **express** DRT transcripts, including 12 neuroblastomas, two medulloblastomas, one primitive neuroectodermal tumor and six small cell lung **carcinomas** (SCLC). Interestingly, several neuroblastoma cell lines with 1p deletion and one SCLC cell line **express** DRT transcripts of aberrant size (i.e. 3, 6 and 8 kb) in addition to those found in normal tissues. We mapped the DRT gene to **human** chromosome 1p35-1p36.1 by PCR screening of **human** -rodent somatic cell hybrid panels and by fluorescence in situ hybridization. As the distal end of chromosome 1p is often deleted in neuroblastomas and altered in some cases in SCLCs, these chromosomal abnormalities may have resulted in the generation of aberrant size transcripts. Thus, the DRT gene may play a part in neuroblastoma and SCLC tumorigenesis.

L17 ANSWER 42 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1995:880629 HCAPLUS

DOCUMENT NUMBER: 124:24704

TITLE: cDNA **cloning**, molecular characterization, and chromosomal localization of NET(EPHT2), a **human** EPH-related receptor protein-tyrosine **kinase** gene preferentially **expressed** in **brain**

AUTHOR(S): Tang, Xao X.; Biegel, Jaclyn A.; Nycum, Lynn M.; Yoshioka, Akira; Brodeur, Garrett M.; Pleasure, David E.; Ikegaki, Naohiko

CORPORATE SOURCE: Divisions of Neurology Research, The Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA

SOURCE: Genomics (1995), 29(2), 426-37
CODEN: GNMCEP; ISSN: 0888-7543

PUBLISHER: Academic

DOCUMENT TYPE: Journal

LANGUAGE: English

AB By screening a **human** fetal **brain** cDNA **expression** library using a monoclonal anti-phosphotyrosine antibody, the authors have isolated a cDNA **clone** encoding a receptor type protein-tyrosine **kinase** belonging to the EPH family, NET (neuronally **expressed** EPH-related tyrosine **kinase**). NET shows 87% homol. in nucleotide sequence and 99% homol. in the deduced amino acid sequence to rat elk, suggesting that NET is the **human** homolog of elk. The NET gene is mapped to **human** chromosome 3q21-q23 by PCR screening of a **human** -rodent somatic cell hybrid panel and by fluorescence in situ hybridization. Examination of NET mRNA **expression** in several **human** tissues has shown that the NET gene is **expressed** preferentially in **brain** as a 5-kb transcript. Steady-state levels of NET mRNA in **human brain** are greater in the midterm **fetus** than in the adult. Lower levels of NET mRNA are found in fetal kidney and adult skeletal muscle. The **expression** pattern of NET mRNA thus differs from that of elk, suggesting that these two gene products may perform distinct roles in **human** and rat. NET transcripts are detected in **human** NTera-2 teratocarcinoma cells after retinoic acid-induced neuronal differentiation. Several

human tumor cell lines derived from neuroectoderm including primitive neuroectodermal tumor, small cell lung **carcinoma**, and neuroblastoma also **express** NET transcripts. Since the NET mRNA **expression** in **human brain** is developmentally regulated and is induced during neuronal differentiation, NET potentially plays important roles in **human** neurogenesis.

L17 ANSWER 43 OF 45 MEDLINE on STN DUPLICATE 7
 ACCESSION NUMBER: 95161080 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 7857658
 TITLE: Isolation and characterization of the **human** DTK receptor tyrosine **kinase**.
 AUTHOR: Crosier K E; Hall L R; Lewis P M; Morris C M; Wood C R; Morris J C; Crosier P S
 CORPORATE SOURCE: Department of Molecular Medicine, School of Medicine, University of Auckland, New Zealand.
 SOURCE: Growth factors (Chur, Switzerland), (1994) 11 (2) 137-44. Journal code: 9000468. ISSN: 0897-7194.
 PUB. COUNTRY: Switzerland
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 OTHER SOURCE: GENBANK-U18934
 ENTRY MONTH: 199503
 ENTRY DATE: Entered STN: 19950404
 Last Updated on STN: 20000303
 Entered Medline: 19950323

AB A cDNA encoding the **human** homologue of the murine DTK receptor tyrosine **kinase** has been isolated from a **human brain** library. The DTK cDNA encodes a mature protein of 850 amino acids with similar structural features to those of the murine receptor. The extracellular domain contains two immunoglobulin-like motifs and two fibronectin type III modules; features which define a new class of receptor tyrosine **kinase**. The **human** DTK gene has been mapped by fluorescent in situ hybridization to chromosome 15q15, and a DTK-related gene identified at chromosome 15q24. In fetal tissues, transcripts for DTK were detected in **brain**, kidney, lung and heart. Prominent **expression** was observed in the embryonal **carcinoma** cell line NT2/D1. **Expression** of the gene is up-regulated in adult tissues with high levels of **expression** in many regions of the adult **brain**. DTK is also abundantly **expressed** in adult kidney, **testis**, and ovary.

L17 ANSWER 44 OF 45 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1993:227170 HCAPLUS
 DOCUMENT NUMBER: 118:227170
 TITLE: Molecular **cloning** and characterization of PKC θ , a novel member of the protein **kinase** C (PKC) gene family **expressed** predominantly in hematopoietic cells
 AUTHOR(S): Baier, Gottfried; Telford, David; Giampa, Leslie; Coggeshall, K. Mark; Baier-Bitterlich, Gabriele; Isakov, Noah; Altman, Amnon
 CORPORATE SOURCE: La Jolla Inst. Allergy Immunol., La Jolla, CA, 92037, USA
 SOURCE: Journal of Biological Chemistry (1993), 268(7), 4997-5004
 CODEN: JBCHA3; ISSN: 0021-9258
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Members of the protein **kinase** C (PKC) family of serine/threonine **kinases** play a key role in regulating the differentiation and growth of diverse cell types and, to date, the **cloning** of seven mammalian PKC genes encoding eight distinct isoforms has been reported.

This report describes the mol. **cloning** and deduced primary structure of a cDNA encoding a novel PKC isoform, termed PKC θ , which was isolated in the course of attempts to identify PKC genes that are **expressed** selectively in hematopoietic cells. Degenerate oligonucleotide primers corresponding to conserved sequence motifs, which distinguish the PKC family from other protein **kinases**, were employed in polymerase chain reactions (PCR) to amplify partial core sequences of putative PKC genes from a **human** peripheral blood lymphocyte-derived cDNA library. DNA sequencing of selected **clones** revealed several PKC-related sequences, including one that, on the basis of sequence comparison with known PKC isoforms, represented a novel PKC isoform. The complete cDNA sequence was determined by anchored PCR **cloning** and sequencing the entire coding sequence, using cDNA derived from a **human** leukemic T cell line (Jurkat). Included within this .apprx.2.7-kilobase pair cDNA is an open reading frame of 2118 nucleotides encoding a putative 82-kDa protein. The deduced primary structure contains consensus sequences characteristic of protein **kinase** catalytic domains and, based on its amino acid sequence and domain structure, is a member of the PKC family. PKC θ displays the highest homol. to PKC δ , lacks the Ca²⁺-binding C2 domain and, thus, belongs to the subfamily of Ca²⁺-independent PKC enzymes which also includes the δ , ϵ , ζ , and η isoforms. RNase protection assays and semiquant. PCR anal. indicated that, although PKC θ transcripts are **expressed** ubiquitously, the highest levels are found in hematopoietic tissues and cell lines, including T cells and thymocytes. In contrast, the **expression** levels in the **brain** and **testes** are considerably lower, and no transcripts were detected in several **human carcinoma** cell lines. A rabbit antiserum raised against a unique (V3 domain) bacterially **expressed** PKC θ fragment immunopptd. specifically an 82-kDa protein from Jurkat cell lysates. Thus, PKC θ represents an addnl. members of the PKC family, and its predominant **expression** in hematopoietic cells suggests that it may play a role in signal transduction and growth regulatory pathways unique to these cells.

L17 ANSWER 45 OF 45 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN

ACCESSION NUMBER: 2002:474993 BIOSIS
DOCUMENT NUMBER: PREV200200474993
TITLE: Molecular **cloning** and characterization of the **human** NIMA-related protein **kinase** 3 gene (NEK3).
AUTHOR(S): Kimura, M. [Reprint author]; Okano, Y.
CORPORATE SOURCE: Department of Molecular Pathobiochemistry, Gifu University School of Medicine, Tsukasamachi-40, Gifu, 500-8705, Japan
yo@cc.gifu-u.ac.jp
SOURCE: Cytogenetics and Cell Genetics, (2001 (2002)) Vol. 95, No. 3-4, pp. 177-182. print.
CODEN: CGCGBR. ISSN: 0301-0171.
DOCUMENT TYPE: Article
LANGUAGE: English
OTHER SOURCE: Genbank-AB072828; EMBL-AB072828; DDBJ-AB072828
ENTRY DATE: Entered STN: 11 Sep 2002
Last Updated on STN: 31 Oct 2002

AB NEKs (NIMA-related **kinases**) are a group of protein **kinases** sharing high amino acid sequence identities with NIMA (never in mitosis gene a) which control mitosis in *Aspergillus nidulans*. We have **cloned** a cDNA for **human** NEK3, a novel **human** gene structurally related to NIMA, by RT-PCR. Its open reading frame encodes a protein of 489 amino acid residues with the calculated molecular mass of 56.0 kDa and a predicted pI of 6.58. Phylogenetic analysis suggests that mouse and **human** NEK3s constitute a subfamily within the NIMA family of protein **kinases**

. The **expression** pattern of NEK3 was studied by RT-PCR and a high level of **expression** was detected in **testis**, ovary, and **brain**, with low-level **expression** being detected in most of the tissues studied. NEK3 mRNA was detected in all the proliferating cell lines studied, and the amount did not change during the cell cycle. The **human** NEK3 gene was assigned to **human** chromosome 13 by somatic cell hybrids and 13q14.2 by radiation hybrid mapping.

=> d his

(FILE 'HOME' ENTERED AT 14:21:51 ON 01 MAR 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 14:24:19 ON 01 MAR 2005

```
L1      1289986 S KINASE?
L2      1289986 S KINASE?
L3      479392 S HUMAN AND L1
L4      6944918 S CLON? OR EXPRESS? OR RECOMBINANT
L5      238969 S L3 AND L4
L6      3408473 S BRAIN OR PITUITARY OR CEREBELUM OR UTERUS
L7      19300 S L5 AND L6
L8      1674498 S MAMMARY (A) GLAND? OR CARCINOMA OR OSTEOSARCOMA
L9      1859 S L7 AND L8
L10     970047 S HYPOTHALAMUS OR TESTIS OR FETUS
L11     242 S L9 AND L10
L12     77760 S SPLICE
L13     6 S L11 AND L12
L14     6 DUP REM L13 (0 DUPLICATES REMOVED)
L15     21453 S HUMAN (3W) L1
L16     63 S L11 AND L15
L17     45 DUP REM L16 (18 DUPLICATES REMOVED)
```

=> e turner c a/au

```
E1      1307      TURNER C/AU
E2      1          TURNER C */AU
E3      145 -->    TURNER C A/AU
E4      3          TURNER C A JR/AU
E5      1          TURNER C A L/AU
E6      5          TURNER C A P/AU
E7      1          TURNER C ALEX/AU
E8      11         TURNER C ALEXANDER/AU
E9      125        TURNER C ALEXANDER JR/AU
E10     87         TURNER C B/AU
E11     23         TURNER C C/AU
E12     126        TURNER C D/AU
```

=> s e8-e9

```
L18     136 ("TURNER C ALEXANDER"/AU OR "TURNER C ALEXANDER JR"/AU)
```

=> e mathur b/au

```
E1      1          MATHUR AVINASH C/AU
E2      1          MATHUR AZAD/AU
E3      69 -->    MATHUR B/AU
E4      46         MATHUR B B/AU
E5      48         MATHUR B B L/AU
E6      27         MATHUR B C/AU
E7      6          MATHUR B D/AU
E8      152        MATHUR B K/AU
E9      29         MATHUR B L/AU
E10     2          MATHUR B M/AU
E11     164        MATHUR B N/AU
E12     138        MATHUR B P/AU
```

=> s e3

L19 69 "MATHUR B"/AU

=> e friddle c j/au

E1 1 FRIDDIE S B/AU
E2 25 FRIDDLE C/AU
E3 54 --> FRIDDLE C J/AU
E4 11 FRIDDLE CARL/AU
E5 57 FRIDDLE CARL J/AU
E6 45 FRIDDLE CARL JOHAN/AU
E7 2 FRIDDLE F E/AU
E8 2 FRIDDLE H/AU
E9 1 FRIDDLE J/AU
E10 2 FRIDDLE J D/AU
E11 1 FRIDDLE JOHN D/AU
E12 1 FRIDDLE JR W D/AU

=> s e6

L20 45 "FRIDDLE CARL JOHAN"/AU

=> d his

(FILE 'HOME' ENTERED AT 14:21:51 ON 01 MAR 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 14:24:19 ON 01 MAR 2005

L1 1289986 S KINASE?
L2 1289986 S KINASE?
L3 479392 S HUMAN AND L1
L4 6944918 S CLON? OR EXPRESS? OR RECOMBINANT
L5 238969 S L3 AND L4
L6 3408473 S BRAIN OR PITUITARY OR CEREBELUM OR UTERUS
L7 19300 S L5 AND L6
L8 1674498 S MAMMARY (A) GLAND? OR CARCINOMA OR OSTEOSARCOMA
L9 1859 S L7 AND L8
L10 970047 S HYPOTHALAMUS OR TESTIS OR FETUS
L11 242 S L9 AND L10
L12 77760 S SPLICE
L13 6 S L11 AND L12
L14 6 DUP REM L13 (0 DUPLICATES REMOVED)
L15 21453 S HUMAN (3W) L1
L16 63 S L11 AND L15
L17 45 DUP REM L16 (18 DUPLICATES REMOVED)
E TURNER C A/AU
L18 136 S E8-E9
E MATHUR B/AU
L19 69 S E3
E FRIDDLE C J/AU
L20 45 S E6

=> s l18 or l19 or l20

L21 233 L18 OR L19 OR L20

=> s l5 and l21

L22 29 L5 AND L21

=> dup rem l22

PROCESSING COMPLETED FOR L22

L23 22 DUP REM L22 (7 DUPLICATES REMOVED)

=> d 1-22 ibib ab

L23 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:29028 HCAPLUS
 DOCUMENT NUMBER: 142:128729
 TITLE: Protein and cDNA sequences of a novel **human**
 protein **kinase** sequence homolog
 INVENTOR(S): Hu, Yi; Wilganowski, Nathaniel L.; **Friddle, Carl**
Johan; Walke, D. Wade
 PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA
 SOURCE: U.S., 14 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6841377	B1	20050111	US 2002-171374	20020613
PRIORITY APPLN. INFO.:			US 2001-297856P	P 20010613

AB The invention provides the protein and cDNA sequences of a novel
human kinase (NHK) sequence homolog. The invention also
 relates to vectors and host cells for **expressing** NHK.
 REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:739850 HCAPLUS
 DOCUMENT NUMBER: 141:238817
 TITLE: Protein and cDNA sequences of a novel **human**
 protein **kinase**
 INVENTOR(S): Walke, D. Wade; Scoville, John; **Friddle, Carl**
Johan
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 17 pp., Division of U. S. Ser.
 No. 196,927.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004175749	A1	20040909	US 2004-803278	20040318
US 6797510	B1	20040928	US 2002-196927	20020520
PRIORITY APPLN. INFO.:			US 2001-293248P	P 20010524
			US 2002-196927	A3 20020520

AB Novel **human** polynucleotide and polypeptide sequences are
 disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic
 applications.

L23 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:790757 HCAPLUS
 DOCUMENT NUMBER: 141:272651
 TITLE: Protein and cDNA sequences of a novel **human**
 protein **kinase** sequence homolog
 INVENTOR(S): Walke, D. Wade; Scoville, John; **Friddle, Carl**
Johan
 PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA
 SOURCE: U.S., 17 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6797510	B1	20040928	US 2002-196927	20020520
US 2004175749	A1	20040909	US 2004-803278	20040318
PRIORITY APPLN. INFO.:			US 2001-293248P	P 20010524
			US 2002-196927	A3 20020520

AB The invention provides protein and cDNA sequences of a novel **human** protein **kinase** sequence homolog. Novel **human** polynucleotide and polypeptide sequences are disclosed that be used in therapeutic, diagnostic, and pharmacogenomic applications.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 22 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
DUPLICATE 1

ACCESSION NUMBER: 2003-16127 BIOTECHDS

TITLE: New nucleic acid molecule encoding a novel **human** protein (NHP), useful for identifying compounds as therapeutic agents for treating a wide variety of symptoms associated with biological disorders or imbalance; involving vector-mediated gene transfer and **expression** in host cell for use in gene therapy and drug screening

AUTHOR: TURNER C A; **MATHUR B**; MATHUR D; FRIDDLE C J

PATENT ASSIGNEE: LEXICON GENETICS INC

PATENT INFO: US 6511840 28 Jan 2003

APPLICATION INFO: US 2001-883134 15 Jun 2001

PRIORITY INFO: US 2001-883134 15 Jun 2001; US 2000-211572 15 Jun 2000

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2003-391258 [37]

AB DERWENT ABSTRACT:

NOVELTY - An isolated nucleic acid molecule comprising a sequence of 2925 base pairs (bp) (I), encoding a sequence of 974 amino acids (aa), all sequences fully defined in the specification, or hybridizing under stringent conditions with washing in 0.1 x SSC/0.1 x SDS at 68degreesC to (I) or its complement, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) a **recombinant expression** vector comprising the isolated nucleic acid molecule; and (2) a host cell comprising the **recombinant expression** vector.

WIDER DISCLOSURE - Also disclosed includes: (1) a **human kinase** protein encoded by the nucleic acid molecule; (2) antagonists or agonists of the protein; (3) transgenic animals that **express** a novel **human** protein (NHP) transgene, or knock-outs; and (4) processes for identifying compounds that modulate the NHP **expression** and/or activity.

ACTIVITY - None given. No biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - The nucleic acid molecule and protein are useful for identifying compounds as therapeutic agents for treating a wide variety of symptoms associated with biological disorders or imbalance. They are also useful for diagnosis, drug screening, clinical trial monitoring, treating physiological disorders or diseases, and in cosmetic or nutraceutical applications. (27 pages)

L23 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:254176 HCAPLUS

DOCUMENT NUMBER: 138:283310

TITLE: Protein and cDNA sequences of a **human** protein **kinase**

INVENTOR(S): Walke, D. Wade; Hilbun, Erin; Donoho, Gregory;
Turner, C. Alexander, Jr.

PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA
 SOURCE: U.S., 11 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6541252	B1	20030401	US 2001-854856	20010514
US 6858419	B1	20050222	US 2001-10720	20011113
PRIORITY APPLN. INFO.:			US 2000-206015P	P 20000519
			US 2001-854856	A2 20010514

AB The invention provides protein and cDNA sequences of a **human** protein that has structural similarity with animal protein **kinases**. The invention further relates to the use of protein **kinase** in therapeutic, diagnostic, and pharmacogenomic applications.

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 22 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
 DUPLICATE 2

ACCESSION NUMBER: 2003-06802 BIOTECHDS

TITLE: New **human kinase** proteins useful for diagnosis, drug screening, clinical trial monitoring, treatment of disorders and diseases, and cosmetic and nutritional applications;

recombinant enzyme protein production and antagonist and agonist for use in gene therapy

AUTHOR: TURNER C A; **MATHUR B**; FRIDDLE C J

PATENT ASSIGNEE: LEXICON GENETICS INC

PATENT INFO: WO 2002081670 17 Oct 2002

APPLICATION INFO: WO 2002-US10786 4 Apr 2002

PRIORITY INFO: US 2001-282036 6 Apr 2001; US 2001-282036 6 Apr 2001

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2003-058538 [05]

AB DERWENT ABSTRACT:

NOVELTY - An isolated nucleic acid comprising encoding a 778, 762 or 703 residue **human kinase** amino acid sequence, given in the specification (sequences I, II and III respectively), is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for an isolated protein having the **kinase** activity of (I), (II) or (III), and which is encoded by a 237, 2289 or 2112 base pair sequence, given in the specification.

WIDER DISCLOSURE - (1) agonists and antagonists of the proteins; (2) antibodies against the proteins; and (3) transgenic knock out animals.

ACTIVITY - None given

MECHANISM OF ACTION - None given

USE - The invention is useful for diagnosis, drug screening, clinical trial monitoring, treatment of disorders and diseases, and cosmetic and nutritional applications (disclosed). (24 pages)

L23 ANSWER 7 OF 22 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
 DUPLICATE 3

ACCESSION NUMBER: 2003-01881 BIOTECHDS

TITLE: Novel polynucleotide encoding **human** proteins sharing sequence similarity with animal **kinases**, useful for drug screening, diagnosis, in gene therapy of disorders and diseases e.g. cancer;

recombinant protein production and sense and antisense sequence use in disease therapy and gene therapy

AUTHOR: TURNER C A; **MATHUR B**

PATENT ASSIGNEE: LEXICON GENETICS INC
PATENT INFO: WO 2002059287 1 Aug 2002
APPLICATION INFO: WO 2002-US1818 22 Jan 2002
PRIORITY INFO: US 2001-263378 23 Jan 2001; US 2001-263378 23 Jan 2001
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2002-599780 [64]

AB DERWENT ABSTRACT:

NOVELTY - An isolated nucleic acid molecule (I) comprising a 2007 or 1827 nucleotide sequence, encoding a novel **human** protein (NHP) comprising a 668 or 608 residue amino acid sequence, given in the specification, is new.

WIDER DISCLOSURE - (1) NHP encoded by (I), that share structural similarity with animal **kinases**; (2) host cell **expressing** systems comprising (I); (3) antibodies to NHP and anti-idiotypic antibodies; (4) fusion proteins comprising NHP; (5) genetically engineered animals that either lack or over **express** (I); (6) antagonists and agonists of NHP; (7) compounds that modulate the **expression** or activity NHP which can be used for diagnosis, drug screening, clinical trial monitoring, treatment of diseases and disorders, and cosmetic or nutraceutical applications; (8) identifying compounds that modulate, **expression** and/or activity of NHP; (9) degenerate nucleic acid variants of (I); (10) vectors that contain (I); (11) nucleotide sequences e.g. antisense and ribozyme molecules, that inhibit **expression** of (I); and (12) proteins that are functionally equivalent to NHPs.

BIOTECHNOLOGY - Preferred Protein: The NHPs are novel proteins **expressed** in **human** cell lines and **human** brain, pituitary, hypothalamus, adipose, cerebellum, adrenal gland, fetal lung and embryo cells.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - Gene therapy. No supporting data is given.

USE - NHP oligonucleotides are useful as hybridization probes for screening libraries and assessing gene **expression** patterns. NHP sequences are useful to identify mutations associated with a particular disease and also as a diagnostic or prognostic assay, and also in the molecular mutagenesis/evolution of proteins that are at least partially encoded by the NHP sequences. Sequences derived from regions adjacent to the intron/exon boundaries of NHP gene can be used to design primers for use in amplification assays to detect mutations within the exons, splice sites, introns that can be used in diagnostics and pharmacogenomics. NHP sequences are used in microarrays or other assay formats, to screen collections of genetic material from patients who have a particular medical condition. NHP nucleotide sequences are useful for drug screening effective in the treatment of symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body, and nucleotide constructs encoding NHP products are used to genetically engineer host cells to **express** NHP products in vivo. These genetically engineered cells function as bioreactors in the body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide construct encoding NHP products are also useful in gene therapy for modulating NHP **expression** and to produce genetically engineered host cells to **express** NHP products in vivo. The encoded NHP polypeptides are useful for generating antibodies, as reagents in diagnostic assays, for identifying other cellular gene products related to NHP and as reagents in assays for screening for compounds that are useful in the treatment of mental, biological or medical disorders and diseases including cancer.

EXAMPLE - None given. (40 pages)

L23 ANSWER 8 OF 22 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
DUPLICATE 4

ACCESSION NUMBER: 2003-00776 BIOTECHDS

TITLE: Novel polynucleotides encoding **human** proteins that

are structurally related to animal **kinases**, useful for drug screening, diagnosis and in gene therapy of biological disorders;
vector-mediated **recombinant** protein gene transfer and **expression** in host cell for use in drug screening and nootropic disease and mental disorder diagnosis and gene therapy

AUTHOR: TURNER C A; **MATHUR B**; FRIDDLE C J
PATENT ASSIGNEE: LEXICON GENETICS INC
PATENT INFO: WO 2002048333 20 Jun 2002
APPLICATION INFO: WO 2001-US49068 12 Dec 2001
PRIORITY INFO: US 2001-289422 8 May 2001; US 2000-255103 12 Dec 2000
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2002-583505 [62]

AB DERWENT ABSTRACT:

NOVELTY - Isolated nucleic acid molecule (I) comprising a nucleotide sequence encoding a novel **human** protein (NHP) of 870, 864, 764, 751, 654, 648, 548, 535, 895, 889, 789, 776, 982, 976, 876, 863, 957, 951, 851 or 838 amino acids given in specification, that share structural similarity with animal **kinases**, including serine-threonine **kinases**, casein **kinases**, calcium/calmodulin-dependent protein **kinases** and mitogen activated **kinases**, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for an isolated nucleic acid molecule comprising a nucleotide sequence that encodes the sequence of 870 amino acids and hybridizes under stringent conditions to the nucleotide sequence of 2613 base pairs given in the specification or its complement.

WIDER DISCLOSURE - Disclosed are: (1) novel **human** membrane proteins (NHPs) encoded by (I), that share structural similarity with mammalian ion channel proteins and particularly voltage-gated potassium channel proteins; (2) host cell **expressing** systems comprising (I); (3) antibodies to NHP and anti-idiotypic antibodies; (4) fusion proteins comprising NHP; (5) genetically engineered animals that either lack or over **express** (I); (6) antagonists and agonists of NHP; (7) compounds that modulate the **expression** or activity NHP; (8) identifying compounds that modulate, **expression** and/or activity of NHP; (9) degenerate nucleic acid variants of (I); (10) vectors that contain (I); and (11) nucleotide sequences (e.g. antisense and ribozyme molecules) that inhibit **expression** of (I).

BIOTECHNOLOGY - Preferred Protein: NHPs are novel proteins **expressed** in **human** cell lines and **human** fetal brain, brain, pituitary, cerebellum, and fetal lung, kidney, and embryo cells.

ACTIVITY - Nootropic.

MECHANISM OF ACTION - Gene therapy. No suitable data is given.

USE - NHP oligonucleotides are useful as hybridization probes for screening libraries and assessing gene **expression** patterns. NHP sequences are useful to identify mutations associated with a particular disease and also as a diagnostic or prognostic assay, and also in the molecular mutagenesis/evolution of proteins that are at least partially encoded by the NHP sequences. Sequences derived from regions adjacent to the intron/exon boundaries of NHP gene can be used to design primers for use in amplification assays to detect mutations within the exons, splice sites, introns that can be used in diagnostics and pharmacogenomics. NHP sequences are utilized in microarrays or other assay formats, to screen collections of genetic material from patients who have a particular medical condition. NHP nucleotide sequences are useful for drug screening effective in the treatment of symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body, and nucleotide constructs encoding NHP products are used to genetically engineer host cells to **express** NHP products in vivo. These genetically engineered cells function as bioreactors in the body delivering a

continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide construct encoding NHP products are also useful in gene therapy for modulating NHP **expression** and to produce genetically engineered host cells to **express** NHP products in vivo. NHP nucleotide sequences may also be used as part of ribozyme and/or triple helix sequences that are useful for NHP gene regulation. The encoded NHP polypeptides are useful for generating antibodies, as reagents in diagnostic assays, for identifying other cellular gene products related to NHP and as reagents in assays for screening for compounds that are useful in the treatment of mental, biological or medical disorders and diseases.

EXAMPLE - No suitable example given. (93 pages)

L23 ANSWER 9 OF 22 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
DUPLICATE 5

ACCESSION NUMBER: 2002-20038 BIOTECHDS

TITLE: Novel **human kinase** polynucleotide useful
in therapeutic, diagnostic and pharmacogenomic applications;
recombinant enzyme protein production via
plasmid **expression** in host cell use in disease
therapy and gene therapy

AUTHOR: FRIDDLE C J; HILBUN E; **MATHUR B**; TURNER C A

PATENT ASSIGNEE: LEXICON GENETICS INC

PATENT INFO: WO 2002042438 30 May 2002

APPLICATION INFO: WO 2000-US43825 20 Nov 2000

PRIORITY INFO: US 2000-252011 20 Nov 2000

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2002-566563 [60]

AB DERWENT ABSTRACT:

NOVELTY - A **human kinase** polynucleotide (I) selected from a polynucleotide comprising a 2079 base pair sequence (S1) that encodes a 692 or 817 amino acid sequence (S2), a polynucleotide that hybridizes to a 2454 base pair sequence (S3) or its complement, and a polynucleotide comprising at least 24 contiguous base pairs from S3, where S1, S2 or S3 is fully defined in the specification, is new.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for an isolated **expression** vector (II) comprising a promoter element operatively positioned to **express** a transcript encoding the 817 amino acid sequence.

WIDER DISCLOSURE - Also disclosed are: (1) a host cell **expression** system **expressing** (I); (2) a protein encoded by (I); (3) a fusion protein comprising the protein encoded by (I); (4) antibodies or anti-idiotypic antibodies to the protein encoded by (I); (5) a genetically engineered animal that either lacks or over **expresses** (I); (6) antagonists or agonists of the protein encoded by (I); (7) a compound that modulates the **expression** or activity of the protein encoded by (I); (8) a pharmaceutical formulation and method for treating biological disorders; and (9) a protein that is functionally equivalent to the protein encoded by (I).

USE - (I) is useful in therapeutic, diagnostic and pharmacogenomic applications, and for identifying compounds that modulate, i.e., act as agonists or antagonists of the gene **expression** or gene product activity. (I) is useful for the identification of protein coding sequences, for mapping a unique gene to a particular chromosome, as additional DNA markers for restriction fragment length polymorphism (RFLP) analysis and in forensic biology, for screening libraries, isolating **clones**, preparing **cloning** and sequencing templates, as hybridization probes, in microarrays or other assay formats, to screen collections of genetic material from patients who have a particular medical condition, to identify mutations associated with a particular disease and also as a diagnostic or prognostic assay. (I) is useful for the detection of mutant **human** proteins, or inappropriately **expressed** proteins for the diagnosis of

disease, for screening for drugs effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of the protein in the body, for generation of antibodies, for identification of other cellular gene products related to the protein, and as reagents in assays for screening for compounds that can be used as pharmaceutical agents in the therapeutic treatment of mental, biological or medical disorders and diseases.

EXAMPLE - None given. (43 pages)

L23 ANSWER 10 OF 22 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
DUPLICATE 6

ACCESSION NUMBER: 2003-00762 BIOTECHDS

TITLE: Novel polynucleotides encoding **human** proteins that share sequence similarity with animal **kinases**, useful for drug screening diagnosis and in gene therapy of biological disorders;
vector-mediated gene transfer, **expression** in host cell and transgenic animal for **recombinant** protein production, drug screening and gene therapy

AUTHOR: TURNER C A; **MATHUR B**

PATENT ASSIGNEE: LEXICON GENETICS INC

PATENT INFO: WO 2002031129 18 Apr 2002

APPLICATION INFO: WO 2001-US32010 11 Oct 2001

PRIORITY INFO: US 2000-239821 12 Oct 2000; US 2000-239821 12 Oct 2000

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2002-583341 [62]

AB DERWENT ABSTRACT:

NOVELTY - An isolated nucleic acid molecule (I) comprising a 2301 (S1) or 2298 (S2) base pair sequence, encoding novel **human** proteins (NHPs) of 766 (S3) or 765 (S4) residue amino acid sequences, all given in the specification, and sharing sequence similarity with animal **kinases**, or a nucleic acid molecule that encodes (S3) and hybridizes under stringent conditions to (S1) or its complement, is new.

WIDER DISCLOSURE - (1) novel **human** membrane proteins (NHPs) encoded by (I), that share sequence similarity with animal **kinases**; (2) host cell **expressing** systems comprising (I); (3) antibodies to NHP and anti-idiotypic antibodies; (4) fusion proteins comprising NHP; (5) genetically engineered animals that either lack or over **express** (I); (6) antagonists and agonists of NHP; (7) compounds that modulate the **expression** or activity NHP; (8) identifying compounds that modulate, **expression** and/or activity of NHP; (9) degenerate nucleic acid variants of (I); (10) vectors that contain (I); and (11) nucleotide sequences (e.g. antisense and ribozyme molecules) that inhibit **expression** of (I).

BIOTECHNOLOGY - Preferred Protein: NHPs share structural similarity with animal **kinases**, calcium/calmodulin-dependent protein **kinases** and mitogen activated **kinases**. They are **expressed** in **human** cell lines and **human** fetal brain, brain, pituitary, spinal cord, testis, adipose and esophagus cells.

ACTIVITY - None given.

MECHANISM OF ACTION - Gene therapy. No biological data is given.

USE - NHP oligonucleotides are useful as hybridization probes for screening libraries and assessing gene **expression** patterns. Sequences derived from regions adjacent to the intron/exon boundaries of NHP gene can be used to design primers for use in amplification assays to detect mutations within the exons, splice sites, introns that can be used in diagnostics and pharmacogenomics. NHP nucleotide sequences are useful for drug screening effective in the treatment of symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body, and nucleotide constructs encoding NHP products are used to genetically engineer host cells to **express** NHP products in vivo. These genetically engineered cells function as bioreactors in the

body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide construct encoding NHP products are also useful in gene therapy for modulating NHP **expression** and to produce genetically engineered host cells to **express** NHP products in vivo. The host cells allow not only for the identification of compounds that bind to the endogenous receptor/ligand of a NHP, but can also identify compounds that trigger NHP-mediated activities or pathways. NHP nucleotide sequences may also be used as part of ribozyme and/or triple helix sequences that are useful for NHP gene regulation. When the unique NHP sequences are knocked-out they provide a method of identifying phenotypic **expression** of the particular gene as well as a method of assigning function to previously unknown genes. The unique NHP sequences are useful for the identification of protein coding sequence, mapping a unique gene to a particular chromosome and to identify mutations associated with a particular disease and also as a diagnostic or prognostic assay. These sequences identify biologically verified exon splice junctions as opposed to splice junctions that may be bioinformatically predicted from genomic sequence alone. The sequences are also useful as additional DNA markers for restriction fragment length polymorphism (RFLP) analysis, in forensic biology, and in defining and monitoring both drug action and toxicity. The encoded NHP polypeptides are useful for generating antibodies, as reagents in diagnostic assays, for identifying other cellular gene products related to NHP and as reagents in assays for screening for compounds that are useful in the treatment of mental, biological or medical disorders and diseases. Addressable arrays comprising NHP sequences are useful to identify and characterize the temporal and tissue specific **expression** of a gene. The NHP sequences can be used in microarrays or other assay formats, to screen collections of genetic material from patients who have a particular medical condition. (41 pages)

L23 ANSWER 11 OF 22 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
 ACCESSION NUMBER: 2003-12822 BIOTECHDS

TITLE: New novel **human** polynucleotides encoding proteins
 sharing sequence similarity with animal **kinases**,
 useful for diagnosing or treating disorders;
human recombinant protein production
 and its encoding gene useful for gene therapy and
 diagnosis

AUTHOR: TURNER C A; **MATHUR B**; FRIDDLE C J
 PATENT ASSIGNEE: TURNER C A; **MATHUR B**; FRIDDLE C J
 PATENT INFO: US 2002161213 31 Oct 2002
 APPLICATION INFO: US 2001-20079 12 Dec 2001
 PRIORITY INFO: US 2001-20079 12 Dec 2001; US 2000-255103 12 Dec 2000
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 OTHER SOURCE: WPI: 2003-288125 [28]

AB DERWENT ABSTRACT:
 NOVELTY - An isolated nucleic acid comprising a nucleotide sequence encoding a sequence having 870, 864, 764, 751, 654, 648, 548, 535, 895, 889, 789, 776, 982, 976, 876, 863, 957, 951, 851 or 838 amino acids, is new.

BIOTECHNOLOGY - Preferred Nucleic Acid: The nucleic acid comprises a nucleotide sequence that: (1) encodes the 870- or 757-amino acid sequence; or (2) hybridizes under stringent conditions to the 2613-bp sequence or its complement.

ACTIVITY - None given.

MECHANISM OF ACTION - Gene therapy.

USE - The novel **human** polynucleotides encoding proteins sharing sequence similarity with animal **kinases** are useful for diagnosing or treating disorders. (78 pages)

L23 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:793784 HCAPLUS

DOCUMENT NUMBER: 137:306640
 TITLE: Identification and cDNA sequence of a novel
human kinase sequence homolog
 INVENTOR(S): Yu, Xuanchuan; Miranda, Maricar; **Friddle, Carl Johan**
 PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081671	A1	20021017	WO 2002-US10787	20020404
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2443319	AA	20021017	CA 2002-2443319	20020404
US 2002164737	A1	20021107	US 2002-116332	20020404
EP 1383880	A1	20040128	EP 2002-731272	20020404
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004528841	T2	20040924	JP 2002-580034	20020404
US 2004229331	A1	20041118	US 2004-843136	20040511
PRIORITY APPLN. INFO.:			US 2001-282031P	P 20010406
			US 2002-116332	A1 20020404
			WO 2002-US10787	W 20020404

AB The present invention relates to the discovery, identification and characterization of a novel **human** cDNA encoding a protein that shares sequence similarity with animal **kinases**, and the corresponding amino acid sequence of this protein. The **human kinase** sequence homolog of the present invention can be used in therapeutic, diagnostic, and pharmacogenomic applications.

L23 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:575249 HCAPLUS
 DOCUMENT NUMBER: 137:136141
 TITLE: **Human protein kinase**, its cDNA and
 protein sequences, and use thereof
 INVENTOR(S): Yu, Xuanchuan; Miranda, Maricar; **Friddle, Carl Johan**
 PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059325	A2	20020801	WO 2001-US50497	20011220
WO 2002059325	A3	20030320		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002123622 A1 20020905 US 2001-28946 20011220

US 6734009 B2 20040511

US 2004209297 A1 20041021 US 2004-791666 20040302

PRIORITY APPLN. INFO.: US 2000-258335P P 20001227

US 2001-28946 A1 20011220

AB The invention provides protein and cDNA sequences for two novel
human protein kinases (2054 and 1958 amino acids resp.),
which are obtained by searching **human** genomic sequence database
(Reference GenBank AC016922) in conjunction with cDNAs prepared and isolated
from

human fetal kidney, testis, and lymph node mRNAs. The novel
protein **kinase** have sequence homol. to **Kinase**
serine/threonine protein **kinase** as well as Citron **kinase**
from a variety of phyla species. The described genes are mapped to
chromosome 12 and a C/G polymorphism is reported for both of them (at
nucleotide 5218/6065 resp.). Methods for the preparation of
recombinant proteins, transgenic animals, and related antibodies
are also described. Novel **human** polynucleotide and polypeptide
sequences are disclosed that can be used in therapeutic, diagnostic, and
pharmacogenomic applications.

L23 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:449887 HCAPLUS

DOCUMENT NUMBER: 137:29079

TITLE: Protein and cDNA sequences of a novel **human**
kinase sequence homolog and therapeutical uses

INVENTOR(S): Walke, D. Wade; Maricar, Miranda; Yu, Xuanchuan;
Friddle, Carl Johan

PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA

SOURCE: PCT Int. Appl., 37 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046428	A2	20020613	WO 2001-US48533	20011207
WO 2002046428	A3	20030417		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

CA 2430711 AA 20020613 CA 2001-2430711 20011207

AU 2002030892 A5 20020618 AU 2002-30892 20011207

US 2002123621 A1 20020905 US 2001-16985 20011207

EP 1349941 A2 20031008 EP 2001-991149 20011207

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004517617 T2 20040617 JP 2002-548145 20011207

PRIORITY APPLN. INFO.: US 2000-251941P P 20001207

AB The present invention discloses protein and cDNA sequences of a novel **human kinase** sequence homolog and its therapeutical uses. Specifically, the invention relates to the discovery, identification, and characterization of nucleotides that encode a novel **human** protein shares structural similarity with animal **kinase**. The invention relates to agonists and antagonists of the **kinase** sequence homolog, and antibodies, as well as DNA sequences that can be used to inhibit or enhance the **expression** of the **kinase** sequence homolog, transgenic animals that **express**, or knockout animals that do not **express** the **kinase** sequence homolog. The invention also relates to processes for identifying compds. that modulate the **kinase** sequence homolog. The invention further discloses that the novel **human kinase** sequence homolog can be used in therapeutic, diagnostic, and pharmaco-genomic applications.

L23 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:172058 HCAPLUS

DOCUMENT NUMBER: 136:227966

TITLE: Protein and cDNA sequences of **human** protein **kinase** sequence homologs and uses thereof in diagnosis, therapy and drug screening

INVENTOR(S): **Friddle, Carl Johan**; Hilbun, Erin; Nepomnichy, Boris; Hu, Yi

PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018555	A2	20020307	WO 2001-US26776	20010828
WO 2002018555	A3	20030227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001085326	A5	20020313	AU 2001-85326	20010828
US 2002147320	A1	20021010	US 2001-940921	20010828
PRIORITY APPLN. INFO.:			US 2000-229280P	P 20000831
			WO 2001-US26776	W 20010828

AB This invention provides protein and cDNA sequences for newly identified **human** proteins, designated NHPs, which shares substantial sequence homol. with animal **kinases**, and particularly NIMA (never in mitosis A) related **kinases**, serine/threonine **kinases**, calcium/calmodulin-dependent **kinases**, and myosin light chain **kinases**. While NHP shares sequence homol. with other protein **kinases**, its primary sequence is unique. **Expression** of NHPs can be detected in, inter alia, **human** cell lines, and **human** fetal and adult brain, pituitary, cerebellum, spinal cord, thymus, spleen, lymph node, bone marrow, trachea, lung, kidney, fetal and adult liver, prostate, testis, thyroid, small intestine, heart, uterus, placenta, mammary gland, adipose, esophagus, cervix, rectum, fetal kidney, and fetal lung (SEQID NOS:2 and 4), or **human** pituitary, kidney, thyroid, skeletal muscle, and heart cells (SEQ ID NOS: 7 and 9). The

described sequences were compiled from sequences available in GENBANK, and cDNAs generated from kidney, testis, trachea, esophagus, pituitary, **human** gene trapped products (SEQ ID NOS: 2 and 4), or bone marrow and skeletal muscle mRNAs. In one embodiment, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases associated with inappropriate NHP activity or levels.

L23 ANSWER 16 OF 22 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN
DUPLICATE 7

ACCESSION NUMBER: 2002-01084 BIOTECHDS

TITLE: Novel polynucleotides encoding **human kinase**
interacting protein useful for drug screening, diagnosis and
in gene therapy of biological disorders;
involving vector-mediated gene transfer for
expression in host cell and antisense
oligonucleotide for use in drug screening,
pharmacogenomics and gene therapy

AUTHOR: Mathur B; Turner Jr C A
PATENT ASSIGNEE: Lexicon-Genetics
LOCATION: The Woodlands, TX, USA.
PATENT INFO: WO 2001066760 13 Sep 2001
APPLICATION INFO: WO 2001-US7499 8 Mar 2001
PRIORITY INFO: US 2000-187719 8 Mar 2000
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2001-557870 [62]

AB An isolated nucleic acid molecule (I) comprising a nucleotide sequence encoding novel **human kinase**-interacting proteins (NHPs) of 187 amino acids and that hybridizes under stringent conditions to a nucleotide sequence of 564 bp or its complement, is claimed. Also claimed is an isolated nucleic acid molecule comprising at least 24 contiguous bases of the sequence. NHP oligonucleotides are useful as hybridization probes for screening libraries and assessing gene **expression** patterns. Sequences derived from regions adjacent to the intron/exon boundaries of NHP gene can be used to design DNA primers for use in amplification assays to detect mutations within the exons, splice sites, introns that can be used in diagnostics and pharmacogenomics. NHP nucleotide sequences are useful for drug screening and nucleotide construct encoding NHP products are useful in gene therapy for modulating NHP **expression** and to produce genetically engineered host cells to **express** NHP products in vivo. (32pp)

L23 ANSWER 17 OF 22 BIOTECHDS COPYRIGHT 2005 THE THOMSON CORP. on STN

ACCESSION NUMBER: 2001-11030 BIOTECHDS

TITLE: Novel isolated **human kinase**
polynucleotide useful for screening for drugs effective in
treatment of symptomatic or phenotypic manifestations of
perturbing normal function of **human kinase**
protein in the body;
recombinant protein production via plasmid
expression in host cell useful in gene therapy

AUTHOR: Mathur B; Turner Jr A C; Abuin A; Friedrich G;
Zambrowicz B; Sands A T
PATENT ASSIGNEE: Lexicon-Genetics
LOCATION: The Woodlands, TX, USA.
PATENT INFO: WO 2001034783 17 May 2001
APPLICATION INFO: WO 2000-US30380 3 Nov 2000
PRIORITY INFO: US 1999-164289 8 Nov 1999
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2001-335921 [35]

AB An isolated **human kinase** polynucleotide (I) selected

from a polynucleotide is claimed. (I) contains at least 24 contiguous bases of a sequence (S) containing 2,682 bp fully defined, a polynucleotide encoding a sequence containing 893 amino acid fully defined, and a polynucleotide that hybridizes under stringent conditions to (S), or its complement. Also disclosed are: a DNA vector; a **recombinant** host cell; degenerate DNA variants of (I); transgenic animals that either lack or over **express** (I); novel **human kinase** protein (NHP); (ant)agonists of (I), and other compounds that modulate that **expression** or activity of (I); a process for identifying (ant)agonists; and antibodies that recognize one or more epitopes of a NHP. (I) is useful for detection of mutant NHP, or inappropriately **expressed** NHPs for the diagnosis of disease. (I) is useful for screening for drugs effective in the treatment of symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body. (I) is useful in the molecular mutagenesis or evolution of proteins. (I) is useful in conjunction with polymerase chain reaction. (I) is useful as a hybridization probe.
(34pp)

L23 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:693529 HCAPLUS

DOCUMENT NUMBER: 135:268247

TITLE: Protein and cDNA sequences of novel **human** phospholipases homologs and uses thereof in diagnosis, therapy and drug screening

INVENTOR(S): Hu, Yi; Nepomnichy, Boris; Donoho, Gregory; Hilbun, Erin; **Turner, C. Alexander, Jr.**; Abuin, Alejandro; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T.

PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068871	A2	20010920	WO 2001-US7994	20010313
WO 2001068871	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2402936	AA	20010920	CA 2001-2402936	20010313
US 2002081595	A1	20020627	US 2001-804969	20010313
EP 1317551	A2	20030611	EP 2001-920329	20010313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004500107	T2	20040108	JP 2001-567355	20010313
PRIORITY APPLN. INFO.:			US 2000-188885P	P 20000313
			US 2000-189693P	P 20000315
			WO 2001-US7994	W 20010313

AB This invention provides protein and cDNA sequences for newly identified **human** proteins, designated NHPs, which shares structural similarity with animal phospholipases, including phospholipases C 8-4. The NHPs are novel proteins that are **expressed** in, inter alia, **human** cell lines and **human** fetal and adult

brain, cerebellum, spinal cord, thymus, spleen, testis, thyroid, adrenal gland, small intestine, colon, adipose, rectum, and placenta cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases associated with inappropriate NHP activity or levels.

L23 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:693527 HCAPLUS
DOCUMENT NUMBER: 135:252804
TITLE: Protein and cDNA sequences of novel **human G** protein-coupled receptor **kinase** homologs and uses thereof in diagnosis, therapy and drug screening
INVENTOR(S): Walke, D. Wade; Wilganowski, Nathaniel L.;
Turner, C. Alexander, Jr.
PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068869	A2	20010920	WO 2001-US7500	20010308
WO 2001068869	A3	20020124		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2402227	AA	20010920	CA 2001-2402227	20010308
US 2002042503	A1	20020411	US 2001-802117	20010308
US 6444456	B2	20020903		
EP 1263967	A2	20021211	EP 2001-916502	20010308
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004500106	T2	20040108	JP 2001-567353	20010308
US 2003004328	A1	20030102	US 2002-217745	20020812
US 6838275	B2	20050104		

PRIORITY APPLN. INFO.:
US 2000-188449P P 20000310
US 2001-802117 A1 20010308
WO 2001-US7500 W 20010308

AB This invention provides protein and cDNA sequences for newly identified **human** proteins, designated NHPs, which shares structural similarity with animal **kinase**, including G protein-coupled receptor **kinases**. The NHPs are novel proteins that are **expressed** in, inter alia, **human** cell lines and **human** fetal and adult brain, pituitary, cerebellum, spinal cord, thymus, kidney, fetal liver, prostate, testis, adrenal gland, small intestine, pericardium, mammary gland, placenta, uterus, and skeletal muscle cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases associated with inappropriate NHP activity or levels.

L23 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:618177 HCAPLUS
 DOCUMENT NUMBER: 135:191337
 TITLE: Protein and cDNA sequences of novel **human kinase** homologs and uses thereof in diagnosis, therapy and drug screening
 INVENTOR(S): Walke, D. Wade; Hu, Yi; Nepomnichy, Boris; **Turner, C. Alexander, Jr.**; Zambrowicz, Brian
 PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001061016	A2	20010823	WO 2001-US5356	20010215
WO 2001061016	A3	20020207		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU; ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2400785	AA	20010823	CA 2001-2400785	20010215
US 2002038011	A1	20020328	US 2001-783320	20010215
EP 1257652	A2	20021120	EP 2001-912839	20010215
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003531577	T2	20031028	JP 2001-559853	20010215
PRIORITY APPLN. INFO.:			US 2000-183582P	P 20000218
			US 2000-184014P	P 20000222
			WO 2001-US5356	W 20010215

AB This invention provides protein and cDNA sequences for newly identified **human** proteins, designated NHPs, which shares structural similarity with animal **kinases**, including cell division control protein **kinases**, serine/threonine protein **kinases** and membrane-associated guanylate **kinases** (MAGUKs). The NHPs are novel proteins that are **expressed** in, inter alia, **human** cell lines and **human** fetal and adult brain, pituitary, cerebellum, thymus, spleen, lymph node, bone marrow, trachea, fetal and adult liver, prostate, testis, thyroid, adrenal gland, pancreas, salivary gland, stomach, small intestine, colon, uterus, placenta, mammary gland, adipose, esophagus, bladder, cervix, rectum, pericardium, hypothalamus, ovary, fetal and adult kidney, and fetal lung cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases associated with inappropriate NHP activity or levels.

L23 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:435241 HCAPLUS
 DOCUMENT NUMBER: 135:41828
 TITLE: Protein and cDNA sequences of a novel **human** protein **kinase** homolog and uses thereof in diagnosis, therapy and drug screening
 INVENTOR(S): Donoho, Gregory; Scoville, John; **Turner, C. Alexander, Jr.**; Friedrich, Glenn; Zambrowicz, Brian; Abuin, Alejandro; Sands, Arthur T.
 PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA

SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042435	A2	20010614	WO 2000-US33240	20001207
WO 2001042435	A3	20011108		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2393332	AA	20010614	CA 2000-2393332	20001207
EP 1240187	A2	20020918	EP 2000-989231	20001207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003064495	A1	20030403	US 2000-733388	20001207
US 6602698	B2	20030805		
JP 2004504005	T2	20040212	JP 2001-544312	20001207
US 2004014112	A1	20040122	US 2003-446175	20030527
US 6806073	B2	20041019		

PRIORITY APPLN. INFO.:
 US 1999-169428P P 19991207
 US 2000-733388 A1 20001207
 WO 2000-US33240 W 20001207

AB This invention provides protein and cDNA sequences for newly identified **human** proteins, designated NHPs, which shares structural similarity with animal **kinases**, and particularly calcium/calmodulin-dependant protein **kinases** and serin/threonine protein **kinases**. The NHP is a novel protein that is **expressed** in, inter alia, **human** cell lines, testis, pituitary, fetal brain, thymus, spleen, cerebellum, trachea, thyroid, adrenal gland, fetal kidney, colon, uterus, pancreas and lung cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases associated with inappropriate NHP activity or levels.

L23 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:247510 HCAPLUS

DOCUMENT NUMBER: 134:261891

TITLE: Protein and cDNA sequences of **human** serine/threonine protein **kinase** and uses thereof in diagnosis, therapy and drug screening

INVENTOR(S): Donoho, Gregory; **Turner, C. Alexander, Jr.**; Nehls, Michael; Friedrich, Glenn; Zambrowicz, Brian; Sands, Arthur T.

PATENT ASSIGNEE(S): Lexicon Genetics Incorporated, USA

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2001023579	A1	20010405	WO 2000-US26621	20000927
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2386213	AA	20010405	CA 2000-2386213	20000927
EP 1220927	A1	20020710	EP 2000-966996	20000927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003510082	T2	20030318	JP 2001-526961	20000927
US 6716616	B1	20040406	US 2000-671050	20000927
EP 1484408	A1	20041208	EP 2004-19791	20000927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2005042626	A1	20050224	US 2004-766691	20040128
PRIORITY APPLN. INFO.:				
			US 1999-156511P	P 19990928
			EP 2000-966996	A3 20000927
			US 2000-671050	A1 20000927
			WO 2000-US26621	W 20000927

AB This invention provides protein and cDNA sequences for newly identified **human** proteins, designated NHPs, which shares substantial sequence homol. with animal **kinases**, and more particular serine/threonine protein **kinases**. While NHP shares sequence homol. with other serine/threonine protein **kinases**, its primary sequence is unique. Its **expression** is detected in various **human** tissues including brain, pituitary, spinal cord, spleen, trachea, kidney, prostate, testis, adrenal gland cells, and gene trapped **human** cells. In one embodiment, the invention relates to diagnostic assays for detecting diseases associated with inappropriate NHP activity or levels. Also disclosed are methods for utilizing NHP in drug screening assays and in therapy directed against diseases associated with inappropriate NHP activity or levels.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:21:51 ON 01 MAR 2005)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, SCISEARCH, HCAPLUS, NTIS, LIFESCI' ENTERED AT 14:24:19 ON 01 MAR 2005

L1	1289986 S KINASE?
L2	1289986 S KINASE?
L3	479392 S HUMAN AND L1
L4	6944918 S CLON? OR EXPRESS? OR RECOMBINANT
L5	238969 S L3 AND L4
L6	3408473 S BRAIN OR PITUITARY OR CEREBELUM OR UTERUS
L7	19300 S L5 AND L6
L8	1674498 S MAMMARY (A) GLAND? OR CARCINOMA OR OSTEOSARCOMA
L9	1859 S L7 AND L8
L10	970047 S HYPOTHALAMUS OR TESTIS OR FETUS
L11	242 S L9 AND L10
L12	77760 S SPLICE
L13	6 S L11 AND L12
L14	6 DUP REM L13 (0 DUPLICATES REMOVED)
L15	21453 S HUMAN (3W) L1
L16	63 S L11 AND L15

L17 45 DUP REM L16 (18 DUPLICATES REMOVED)
 E TURNER C A/AU
L18 136 S E8-E9
 E MATHUR B/AU
L19 69 S E3
 E FRIDDLE C J/AU
L20 45 S E6
L21 233 S L18 OR L19 OR L20
L22 29 S L5 AND L21
L23 22 DUP REM L22 (7 DUPLICATES REMOVED)

	L #	Hits	Search Text
1	L1	56909	kinase\$2
2	L2	46728 3	human
3	L3	18402	l1 same l2
4	L4	70927 1	clon\$3 or express\$3 or recombinant
5	L5	10683	l3 same l4
6	L6	77388 98	hypothalamus or carcinoma or osteosarcoma or mammary (a) gland\$2
7	L7	10684 3	fetus or testis or cerebellum or uterus or pituitary or brain
8	L8	77389 94	l6 or l7
9	L9	5746	l5 same l6
10	L10	1620	l5 same l7
11	L11	6119	l9 or l10
12	L13	1598	pharmacogenomic
13	L14	0	l12 same l13
14	L15	1320	l1 and l13
15	L16	470	l5 and l13
16	L12	279	splice same l11
17	L17	43255	TURNER
18	L18	1915	MATHUR FRIDDLE-CARL- JOHAN
19	L19	45076	l17 or l18
20	L20	20	l12 and l19
21	L21	829	l5 and l19

	Issue Date	Pages	Document ID	Title
1	20050217	81	US 20050037445 A1	Oncology drug innovation
2	20050217	95	US 20050037430 A1	Methods and uses for protein breakdown products
3	20050210	255	US 20050033029 A1	Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
4	20050210	169	US 20050033018 A1	Receptors and membrane-associated proteins
5	20050210	10	US 20050032071 A1	RNA surveillance among curated proteins
6	20050113	55	US 20050009110 A1	Methods of producing antibodies for diagnostics and therapeutics
7	20050113	53	US 20050008638 A1	CNGH0005 polypeptides, antibodies, compositions, methods and uses
8	20050106	46	US 20050002937 A1	Anti-IL-12 antibodies, compositions, methods and uses
9	20041230	29	US 20040265866 A1	Receptor on the surface of activated T-cells: ACT-4
10	20041216	45	US 20040253645 A1	Method for reducing the immunogenicity of antibody variable domains
11	20041209	34	US 20040248286 A1	Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof
12	20041209	36	US 20040248260 A1	IL-13 mutein proteins, antibodies, compositions, methods and uses
13	20041209	45	US 20040248082 A1	RSV proteins, antibodies, compositions, methods and uses

	Issue Date	Pages	Document ID	Title
14	20041202	35	US 20040241754 A1	Modulating neuronal plasticity
15	20041125	227	US 20040235041 A1	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
16	20041125	21	US 20040235026 A1	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
17	20041125	41	US 20040234499 A1	Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
18	20041104	25	US 20040220182 A1	Chromenone derivatives
19	20041104	138	US 20040219521 A1	Novel nucleic acids and polypeptides
20	20041104	168	US 20040219515 A1	BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL HIV REGULATORY GENES AND USES THEREOF
21	20041021	44	US 20040209244 A1	Anti-dengue virus antibodies, compositions, methods and uses
22	20040923	101	US 20040185507 A1	Anti-integrin antibodies, compositions, methods and uses
23	20040923	135	US 20040185485 A1	Gene markers useful for detecting skin damage in response to ultraviolet radiation
24	20040923	35	US 20040185450 A1	MCP-1 mutant proteins, antibodies, compositions, methods and uses
25	20040923	45	US 20040185047 A1	Anti- TNF antibodies, compositions, methods and uses

	Issue Date	Pages	Document ID	Title
26	20040916	35	US 20040181344 A1	Systems and methods for providing diagnostic services
27	20040909	20	US 20040176440 A1	2-Benzoylchromone derivatives
28	20040909	69	US 20040175743 A1	Methods for monitoring drug activities in vivo
29	20040826	48	US 20040167086 A1	REG-like proteins immunoglobulin derived proteins, compositions, methods and uses
30	20040826	22	US 20040166091 A1	Materials and methods for treating disorders of the ear
31	20040812	102	US 20040157297 A1	Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
32	20040729	102	US 20040146924 A1	Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
33	20040722	293	US 20040142335 A1	Method for determining skin stress or skin ageing in vitro
34	20040715	21	US 20040138464 A1	2-Oxadiazolechromone derivatives
35	20040715	28	US 20040136995 A1	Receptor on the surface of activated T-cells: ACT-4
36	20040701	233	US 20040126362 A1	Compositions and methods for WT1 specific immunotherapy
37	20040624	63	US 20040120956 A1	CNGH0004 polypeptides, antibodies, compositions, methods and uses
38	20040610	94	US 20040110221 A1	Methods for diagnosing RCC and other solid tumors

	Issue Date	Pages	Document ID	Title
39	20040603	14	US 20040106181 A1	Novel isoform of human camp-dependent protein kinase, calpha -s , localizes to sperm mid-piece and the use thereof
40	20040527	84	US 20040101874 A1	Targets for therapeutic intervention identified in the mitochondrial proteome
41	20040506	179	US 20040086913 A1	Human genes and gene expression products XVI
42	20040422	32	US 20040077020 A1	Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis
43	20040422	46	US 20040076984 A1	Expert system for classification and prediction of generic diseases, and for association of molecular genetic parameters with clinical parameters
44	20040415	337	US 20040072160 A1	Molecular toxicology modeling
45	20040401	44	US 20040063140 A1	Methods for diagnosis of cancer using erbB-3
46	20040325	82	US 20040058325 A1	Gene expression in biological conditions
47	20040318	209	US 20040053317 A1	Gene segregation and biological sample classification methods
48	20040318	243	US 20040053248 A1	Novel nucleic acids and polypeptides
49	20040318	108	US 20040052777 A1	Kringle polypeptides and methods for using them to inhibit angiogenesis

50	20040311	62	US 20040048305 A1	14171 Protein kinase, a novel human protein kinase and uses thereof
----	----------	----	-------------------------	---

	Issue Date	Pages	Document ID	Title
51	20040311	267	US 20040048249 A1	Novel nucleic acids and secreted polypeptides
52	20040304	42	US 20040043028 A1	Methods and compositions for enhanced protein expression and/or growth of cultured cells using co-transcription of a Bcl2 encoding nucleic acid
53	20040226	259	US 20040038207 A1	Gene expression in bladder tumors
54	20040219	88	US 20040033502 A1	Gene expression profiles in esophageal tissue
55	20040212	518	US 20040030110 A1	Novel proteins and nucleic acids encoding same
56	20040212	570	US 20040029114 A1	Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
57	20040205	37	US 20040023338 A1	IL-4 mutein proteins, antibodies, compositions, methods and uses
58	20040205	37	US 20040023337 A1	IL-13 mutein proteins, antibodies, compositions, methods and uses
59	20040205	63	US 20040023233 A1	Protection against oxidative stress and inflammation by a cytoprotective response element
60	20040205	71	US 20040023231 A1	System for identifying and analyzing expression of are-containing genes

61	20040129	43	US 20040018593 A1	Anti-RELP fusion antibodies, compositions, methods and uses
----	----------	----	-------------------------	--

	Issue Date	Pages	Document ID	Title
62	20040129	252	US 20040018204 A1	Compositions and methods for WT1 specific immunotherapy
63	20040129	43	US 20040018195 A1	Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
64	20040122	53	US 20040014659 A1	Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
65	20040122	74	US 20040014193 A1	Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
66	20040122	108	US 20040014059 A1	Method for the detection of gene transcripts in blood and uses thereof
67	20040122	81	US 20040014047 A1	Antisense modulation of LIM domain kinase 1 expression
68	20040122	146	US 20040014040 A1	Cardiotoxin molecular toxicology modeling
69	20040115	73	US 20040010136 A1	Composition for the detection of signaling pathway gene expression
70	20040115	484	US 20040009479 A1	Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
71	20040115	175	US 20040009167 A1	Anti-pathogen treatments
72	20040108	33	US 20040006207 A1	Ligant (ACT-4-L) to a receptor on the surface of activated CD4+T-cells
73	20040108	52	US 20040005612 A1	Endometrial genes in endometrial disorders

	Issue Date	Pages	Document ID	Title
74	20040108	345	US 20040005563 A1	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
75	20040108	64	US 20040005559 A1	Markers of neuronal differentiation and morphogenesis
76	20040101	106	US 20040002067 A1	Breast cancer progression signatures
77	20031225	222	US 20030235820 A1	Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
78	20031225	36	US 20030235813 A1	In vivo assay and molecular markers for testing the phenotypic stability of cell populations, and selecting cell populations for autologous transplantation
79	20031225	229	US 20030235557 A1	Compositions and methods for WT1 specific immunotherapy
80	20031225	29	US 20030235555 A1	Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
81	20031218	150	US 20030232421 A1	Protein-protein interactions in adipocyte cells (3)
82	20031218	37	US 20030232046 A1	Modified "S" antibodies
83	20031204	23	US 20030224440 A1	Human VNO cDNA libraries

	Issue Date	Pages	Document ID	Title
84	20031204	125	US 20030224413 A1	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
85	20031120	259	US 20030215458 A1	Compositions and methods for WT1 specific immunotherapy
86	20031113	184	US 20030212257 A1	Novel human proteins, polynucleotides encoding them and methods of using the same
87	20031106	128	US 20030207311 A1	Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
88	20031023	209	US 20030198622 A1	Compositions and methods for WT1 specific immunotherapy
89	20031009	42	US 20030190640 A1	Genes expressed in prostate cancer
90	20030918	74	US 20030176651 A1	Multiprotein-complex comprising a nmda receptor and uses thereof
91	20030918	65	US 20030176650 A1	Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
92	20030918	23	US 20030176375 A1	Method of treating anemia
93	20030918	102	US 20030175927 A1	Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
94	20030918	259	US 20030175771 A1	Human Transcriptomes
95	20030911	30	US 20030171546 A1	Chimeric immunoreceptor useful in treating human cancers

	Issue Date	Pages	Document ID	Title
96	20030904	35	US 20030165924 A1	Genes expressed in foam cell differentiation
97	20030904	50	US 20030165485 A1	Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
98	20030821	38	US 20030157105 A1	Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
99	20030807	36	US 20030149247 A1	Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
100	20030807	69	US 20030148305 A1	Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
101	20030807	26	US 20030148296 A1	Differential gene expression in cardiac hypertrophy
102	20030731	31	US 20030143603 A1	Anti-TNF antibodies, compositions, methods and uses
103	20030724	77	US 20030138835 A1	Tumor suppressors
104	20030710	116	US 20030129606 A1	Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
105	20030703	49	US 20030124123 A1	Anti-IL-12 antibodies, compositions, methods and uses
106	20030626	80	US 20030119720 A1	Oligopeptide treatment of anthrax
107	20030619	46	US 20030113744 A1	Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof

	Issue Date	Pages	Document ID	Title
108	20030619	77	US 20030113733 A1	Gene regulator
109	20030605	67	US 20030105284 A1	Small and intermediate conductance, calcium-activated potassium channels and uses thereof
110	20030605	54	US 20030104393 A1	Blood assessment of injury
111	20030605	168	US 20030104358 A1	Diagnosis methods based on microcompetition for a limiting GABP complex
112	20030529	374	US 20030100747 A1	Polymorphisms in the region of the human hemochromatosis gene
113	20030529	72	US 20030100496 A1	Compositions and methods for highly efficient transfection
114	20030522	203	US 20030095971 A1	Compositions and methods for WT1 specific immunotherapy
115	20030508	36	US 20030087270 A1	Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
116	20030508	17	US 20030087226 A1	HUMAN DNA MISMATCH REPAIR PROTEIN
117	20030501	33	US 20030084468 A1	Methods of expressing transgenes
118	20030501	68	US 20030082684 A1	Small and intermediate conductance, calcium-activated potassium channels and uses thereof
119	20030501	68	US 20030082683 A1	Small and intermediate conductance, calcium-activated potassium channels and uses thereof

	Issue Date	Pages	Document ID	Title
120	20030501	23	US 20030082550 A1	Mutations of the cyclooxygenase-2 gene
121	20030417	179	US 20030073888 A1	Screening methods used to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
122	20030417	197	US 20030072767 A1	Compositions and methods for WT1 specific immunotherapy
123	20030327	54	US 20030059918 A1	Regulation of human serine/threonine protein kinase
124	20030320	122	US 20030055220 A1	Protein-protein interactions between Shigella flexneri polypeptides and mammalian polypeptides
125	20030313	95	US 20030049828 A1	MN gene and protein
126	20030313	70	US 20030049725 A1	Anti-TNF antibodies, compositions, methods and uses
127	20030306	67	US 20030044910 A1	Small and intermediate conductance, calcium-activated potassium channels and uses thereof
128	20030306	202	US 20030044783 A1	Human genes and gene expression products
129	20030227	198	US 20030040617 A9	Nucleic acids, proteins and antibodies
130	20030227	122	US 20030040089 A1	Protein-protein interactions in adipocyte cells
131	20030227	67	US 20030040048 A1	Small and intermediate conductance, calcium-activated potassium channels and uses thereof

	Issue Date	Pages	Document ID	Title
132	20030227	73	US 20030040044 A1	Anti-dual integrin antibodies, compositions, methods and uses
133	20030227	72	US 20030040022 A1	Dopamine receptors and genes
134	20030227	208	US 20030039635 A1	Compositions and methods for WT1 specific immunotherapy
135	20030213	112	US 20030030637 A1	Method and system for data analysis
136	20030206	70	US 20030027177 A1	Human DNA mismatch repair proteins
137	20030130	100	US 20030022229 A1	Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
138	20030123	60	US 20030017150 A1	Chronic obstructive pulmonary disease-related immunoglobulin derived proteins, compositions, methods and uses
139	20030116	112	US 20030014420 A1	Method and system for data analysis
140	20030109	30	US 20030009016 A1	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
141	20021226	179	US 20020198362 A1	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
142	20021219	68	US 20020192757 A1	Small and intermediate conductance, calcium-activated potassium channels and uses thereof

	Issue Date	Pages	Document ID	Title
143	20021219	195	US 20020192678 A1	Genes expressed in senescence
144	20021212	113	US 20020188424 A1	Method and system for data analysis
145	20021212	11	US 20020187127 A1	Methods of increasing distribution of nucleic acids
146	20021114	63	US 20020169562 A1	Defining biological states and related genes, proteins and patterns
147	20021114	17	US 20020168670 A1	Identification of disease predictive nucleic acids
148	20021114	38	US 20020168361 A1	Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 alpha subunit
149	20021107	68	US 20020165379 A1	SMALL AND INTERMEDIATE CONDUCTANCE, CALCIUM-ACTIVATED POTASSIUM CHANNELS AND USES THEREOF
150	20021107	55	US 20020164595 A1	Sequence specific DNA binding by p53
151	20021024	30	US 20020156263 A1	Genes expressed in breast cancer
152	20021024	62	US 20020156038 A1	Gene expression profiling of antidepressant action in the brain
153	20021024	34	US 20020155569 A1	Regulation of gene expression through manipulation of mRNA splicing and its uses
154	20021024	36	US 20020155541 A1	Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy

	Issue Date	Pages	Document ID	Title
155	20021024	66	US 20020155531 A1	Small and intermediate conductance, calcium-activated potassium channels and uses thereof
156	20021024	22	US 20020155444 A1	Human VNO cDNA libraries
157	20021003	50	US 20020142444 A1	AL-2 neurotrophic factor
158	20020926	52	US 20020137042 A1	Isolated human phosphatase proteins, nucleic acid molecules encoding human phosphatase proteins, and uses thereof
159	20020912	25	US 20020128215 A1	Novel sequence variants of the human N-acetyltransferase -2 (NAT -2) gene and use thereof
160	20020912	64	US 20020127702 A1	Methods and compositions for regulating cell cycle progression
161	20020905	70	US 20020123096 A1	Dopamine receptors and genes
162	20020829	94	US 20020119544 A1	ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES THEREOF
163	20020815	63	US 20020110808 A1	Toxicant-induced differential gene expression
164	20020808	16	US 20020106662 A1	Prognostic classification of endometrial cancer
165	20020718	56	US 20020094560 A1	ISOLATED HUMAN KINASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN KINASE PROTEINS, AND USES THEREOF

	Issue Date	Pages	Document ID	Title
166	20020711	128	US 20020090624 A1	Gene markers useful for detecting skin damage in response to ultraviolet radiation
167	20020620	37	US 20020077460 A1	Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
168	20020606	31	US 20020068321 A1	Splice choice antagonists as therapeutic agents
169	20020509	194	US 20020055627 A1	Nucleic acids, proteins and antibodies
170	20020502	308	US 20020052308 A1	Nucleic acids, proteins and antibodies
171	20020321	36	US 20020034765 A1	Method for reducing the immunogenicity of antibody variable domains
172	20011206	40	US 20010049358 A1	DSP-12 and DSP-13 dual-specificity phosphatases
173	20011122	36	US 20010044523 A1	Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
174	20011122	30	US 20010044522 A1	Receptor on the surface of activated T-cells: ACT-4
175	20011122	16	US 20010044104 A1	Genes defferentially expressed in secretory versus proliferative endometrium
176	20050201	37	US 6849420 B2	Method for determining modulation of p110.delta. activity
177	20050201	67	US 6849415 B2	TRAF-3 deletion isoforms and uses thereof
178	20050125	43	US 6846911 B2	Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian CD97 .alpha. subunit

	Issue Date	Pages	Document ID	Title
179	20050111	10	US 6841348 B1	Methods for identifying and using maintenance genes
180	20041207	61	US 6828420 B2	Small conductance, calcium-activated potassium channels (SKI)
181	20041207	61	US 6828123 B2	Small DNA encoding conductance, calcium-activated potassium channels (SK3)
182	20041207	62	US 6828122 B2	Nucleic acid encoding small conductance calcium-activated potassium channel (SK1)
183	20041005	24	US 6800617 B1	Methods for restoring wild-type p53 gene function
184	20040928	45	US 6797492 B2	Method for reducing the immunogenicity of antibody variable domains
185	20040928	62	US 6797486 B2	Small and intermediate conductance, calcium-activated potassium channels and uses thereof
186	20040921	109	US 6794137 B2	Gene markers useful for detecting skin damage in response to ultraviolet radiation
187	20040914	20	US 6790936 B1	CAI resistance proteins and uses thereof
188	20040914	61	US 6790615 B2	Methods and compositions for regulating cell cycle progression
189	20040810	162	US 6773883 B2	Prognostic classification of endometrial cancer
190	20040622	98	US 6753175 B2	Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof

191	20040601	25	US 6743780 B1	Plasmid stabilization
-----	----------	----	------------------	-----------------------

	Issue Date	Pages	Document ID	Title
192	20040525	21	US 6740793 B2	Transgenic animal having a disrupted PDE7A gene and uses thereof
193	20040518	22	US 6737412 B2	Antisense oligodeoxynucleotides regulating expression of TNF .alpha.
194	20040504	96	US 6730506 B2	Isolated human kinase proteins
195	20040420	59	US 6723837 B1	Nucleic acid molecule and encoded protein associated with sterol synthesis and metabolism
196	20040224	54	US 6696557 B1	AL-2 neurotrophic factor nucleic acid
197	20040217	29	US 6693226 B1	Transgenic mice expressing human p25
198	20040217	61	US 6692937 B2	DNA encoding small and intermediate conductance calcium-activated potassium channels
199	20040113	26	US 6677312 B1	Methods for restoring wild-type p53 gene function
200	20031230	94	US 6670464 B1	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
201	20031028	41	US 6639060 B1	erbB-3 nucleic acids

	Issue Date	Pages	Document ID	Title
1	20050217	81	US 20050037445 A1	Oncology drug innovation
2	20041104	25	US 20040220182 A1	Chromenone derivatives
3	20041104	138	US 20040219521 A1	Novel nucleic acids and polypeptides
4	20041104	168	US 20040219515 A1	BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL HIV REGULATORY GENES AND USES THEREOF
5	20040923	45	US 20040185047 A1	Anti- TNF antibodies, compositions, methods and uses
6	20040909	20	US 20040176440 A1	2-Benzoylchromone derivatives
7	20040715	21	US 20040138464 A1	2-Oxadiazolechromone derivatives
8	20040318	243	US 20040053248 A1	Novel nucleic acids and polypeptides
9	20040311	267	US 20040048249 A1	Novel nucleic acids and secreted polypeptides
10	20040205	63	US 20040023233 A1	Protection against oxidative stress and inflammation by a cytoprotective response element
11	20030731	31	US 20030143603 A1	Anti-TNF antibodies, compositions, methods and uses
12	20030605	168	US 20030104358 A1	Diagnosis methods based on microcompetition for a limiting GABP complex
13	20030313	95	US 20030049828 A1	MN gene and protein
14	20030313	70	US 20030049725 A1	Anti-TNF antibodies, compositions, methods and uses

	Issue Date	Pages	Document ID	Title
15	20030227	198	US 20030040617 A9	Nucleic acids, proteins and antibodies
16	20030123	60	US 20030017150 A1	Chronic obstructive pulmonary disease-related immunoglobulin derived proteins, compositions, methods and uses
17	20020509	194	US 20020055627 A1	Nucleic acids, proteins and antibodies
18	20020502	308	US 20020052308 A1	Nucleic acids, proteins and antibodies
19	20011002	93	US 6297051 B1	MN gene and protein
20	19990223	60	US 5874308 A	Compositions and methods for modulating cell proliferation using growth factor-polysaccharide binding fusion proteins

	Issue Date	Pages	Document ID	Title
1	20050224	17	US 20050042626 A1	Novel human kinase proteins and polynucleotides encoding the same
2	20050217	213	US 20050037969 A1	Molecular interactions in hematopoietic cells
3	20050217	268	US 20050037966 A1	Keratinocyte growth factor-2
4	20050217	55	US 20050037491 A1	Repair and regeneration of ocular tissue using postpartum-derived cells
5	20050217	309	US 20050037467 A1	83 human secreted proteins
6	20050217	81	US 20050037445 A1	Oncology drug innovation
7	20050217	168	US 20050037419 A1	Compositions and methods relating to lung specific genes and proteins
8	20050217	192	US 20050037022 A1	Albumin fusion proteins
9	20050210	69	US 20050032734 A1	Vectors and methods for immunization or therapeutic protocols
10	20050210	67	US 20050032726 A1	Uses of DNA-PK
11	20050210	142	US 20050032696 A1	Muscle transcription factors
12	20050210	238	US 20050032168 A1	17 human secreted proteins
13	20050210	27	US 20050032065 A1	Methods of prognosis of prostate cancer
14	20050203	266	US 20050026191 A1	Polynucleotides encoding novel guanylate binding proteins (GBP's)

	Issue Date	Pages	Document ID	Title
15	20050203	316	US 20050026182 A1	Human CDNAS and proteins and uses thereof
16	20050203	197	US 20050025797 A1	Medical device with low magnetic susceptibility
17	20050127	101	US 20050020521 A1	In vivo gene silencing by chemically modified and stable siRNA
18	20050127	86	US 20050019927 A1	DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
19	20050127	320	US 20050019866 A1	52 Human secreted proteins
20	20050120	56	US 20050014207 A1	Monoclonal antibody hPAM4
21	20050120	225	US 20050013825 A1	Vaccine containing the catalytic subunit of telomerase for treating cancer
22	20050106	31	US 20050004007 A1	Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
23	20050106	44	US 20050003351 A1	Non-invasive prenatal genetic diagnosis using transcervical cells
24	20041230	24	US 20040268426 A1	P2Y4 receptor transgenic and knockout non-human mammals
25	20041230	100	US 20040266674 A1	Lp mammalian proteins; related reagents
26	20041223	67	US 20040261139 A1	Androgen receptor knock-out transgenic animals
27	20041223	24	US 20040259171 A1	P2Y4 antibody and methods of use

	Issue Date	Pages	Document ID	Title
28	20041216	184	US 20040254419 A1	Therapeutic assembly
29	20041216	70	US 20040253677 A1	mTOR kinase-associated proteins
30	20041216	287	US 20040253672 A1	20 human secreted proteins
31	20041209	247	US 20040248256 A1	Secreted proteins and polynucleotides encoding them
32	20041209	55	US 20040248141 A1	Spliceosome mediated RNA trans-splicing for correction of skin disorders
33	20041209	225	US 20040247613 A1	Treating cancer using a telomerase vaccine
34	20041209	35	US 20040247599 A1	Modulators of the P2Y10 receptor useful in altering T lymphocyte function
35	20041202	98	US 20040242611 A1	NOVEL PHENYLAMINO-PYRIMIDINES AND USES THEREOF
36	20041202	223	US 20040242529 A1	Vector encoding inactivated telomerase for treating cancer
37	20041202	21	US 20040242526 A1	Disruption of the REG pathway
38	20041202	229	US 20040241803 A1	25 human secreted proteins
39	20041202	111	US 20040241759 A1	High throughput screening of libraries
40	20041202	37	US 20040241636 A1	Monitoring gene silencing and annotating gene function in living cells
41	20041125	195	US 20040235113 A1	18 human secreted proteins

	Issue Date	Pages	Document ID	Title
42	20041125	74	US 20040235018 A1	Gene and protein relating to hepatocellular carcinoma and methods of use thereof
43	20041125	97	US 20040234999 A1	Genetic suppression and replacement
44	20041118	13	US 20040229331 A1	Novel human kinase and polynucleotides encoding the same
45	20041111	15	US 20040225005 A1	Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
46	20041111	14	US 20040224407 A1	Expression vector for consistent cellular expression of the tet on repressor in multiple cell types
47	20041111	258	US 20040224387 A1	Keratinocyte growth factor-2
48	20041104	25	US 20040220182 A1	Chromenone derivatives
49	20041104	138	US 20040219521 A1	Novel nucleic acids and polypeptides
50	20041104	168	US 20040219515 A1	BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL HIV REGULATORY GENES AND USES THEREOF
51	20041028	195	US 20040214783 A1	Compositions and methods for treatment of neoplastic disease
52	20041028	35	US 20040214202 A1	Novel human transferase proteins and polynucleotides encoding the same
53	20041028	53	US 20040214190 A1	Mammalian c-type lectins

	Issue Date	Pages	Document ID	Title
54	20041028	53	US 20040214186 A1	Method for identifying constitutively active mutants of mitogen activated protein kinase (mapk) and uses thereof
55	20041021	165	US 20040210289 A1	Novel nanomagnetic particles
56	20041021	34	US 20040210038 A1	Il-1 eta DNA and polypeptides
57	20041021	111	US 20040209831 A1	RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
58	20041021	26	US 20040209297 A1	Novel human kinases and polynucleotides encoding the same
59	20041021	116	US 20040208880 A1	Targeting cellular entry, cell survival, and pathogenicity by dynein light chain 1/PIN in human cells
60	20041021	57	US 20040208870 A1	Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
61	20041021	57	US 20040208869 A1	Uses of anti-integrin alphanubeta3 antibody formulations
62	20041014	33	US 20040203116 A1	IL-1 eta DNA and polypeptides
63	20041014	20	US 20040203059 A1	Novel human proteases and polynucleotides encoding the same
64	20041014	17	US 20040203058 A1	Novel human kinase and polynucleotides encoding the same
65	20041007	39	US 20040197930 A1	Proteomic analysis of biological fluids.

	Issue Date	Pages	Document ID	Title
66	20040930	71	US 20040191860 A1	150 Kda accessory receptor for tgf-beta
67	20040923	69	US 20040186067 A1	Vectors and methods for immunization or therapeutic protocols
68	20040923	45	US 20040185047 A1	Anti- TNF antibodies, compositions, methods and uses
69	20040916	20	US 20040180416 A1	Novel human kinases and polynucleotides encoding the same
70	20040909	20	US 20040176440 A1	2-Benzoylchromone derivatives
71	20040909	24	US 20040175766 A1	Human pyrimidine receptor
72	20040909	17	US 20040175749 A1	Novel human kinases and polynucleotides encoding the same
73	20040902	44	US 20040172678 A1	Transgenic plants for mitigating introgression of genetically engineered genetic traits
74	20040902	81	US 20040171659 A1	Methods for treating diabetes
75	20040902	202	US 20040171123 A1	ALBUMIN FUSION PROTEINS
76	20040902	19	US 20040170624 A1	Medicament for the protection against thrombotic diseases
77	20040902	32	US 20040170614 A1	Somatic cell gene targeting vectors and methods of use thereof
78	20040826	89	US 20040167101 A1	Novel quinolinones and uses thereof
79	20040819	62	US 20040161827 A1	Insect p53 tumor suppressor genes and proteins

	Issue Date	Pages	Document ID	Title
80	20040819	42	US 20040161784 A1	Assays for the detection of microtubule depolymerization inhibitors
81	20040805	14	US 20040154049 A1	Compounds
82	20040805	55	US 20040152671 A1	Novel quinolines and uses thereof
83	20040729	173	US 20040146893 A1	64 human secreted proteins
84	20040729	58	US 20040146879 A1	Novel human genes and gene expression products
85	20040722	27	US 20040142870 A1	N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof
86	20040715	21	US 20040138464 A1	2-Oxadiazolechromone derivatives
87	20040715	65	US 20040137434 A1	Novel nucleic acids and polypeptides
88	20040708	48	US 20040132181 A1	Trans-splicing mediated photodynamic therapy
89	20040610	113	US 20040110939 A1	Complementary DNAs encoding proteins with signal peptides
90	20040610	23	US 20040110837 A1	Regulation of GSK-3 α activity for the treatment or prevention of Alzheimer's disease
91	20040610	58	US 20040109848 A1	Modulation of AP-2 α expression
92	20040610	87	US 20040109844 A1	Methods of treating age-related defects and diseases

	Issue Date	Pages	Document ID	Title
93	20040527	60	US 20040102636 A1	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
94	20040527	297	US 20040101927 A9	Nucleic acids, proteins, and antibodies
95	20040506	150	US 20040087016 A1	Compositions and methods for cell dedifferentiation and tissue regeneration
96	20040506	50	US 20040086907 A1	Combi-molecules having signal transduction inhibitory properties and dna damaging properties
97	20040506	474	US 20040086896 A1	Polynucleotides and polypeptides associated with the NF-kB pathway
98	20040506	97	US 20040086881 A1	Novel human G-protein coupled receptor, BMSOTR, and splice variant thereof
99	20040429	67	US 20040081971 A1	Protein modification and maintenance molecules
100	20040429	97	US 20040081648 A1	Adzymes and uses thereof
101	20040429	93	US 20040081647 A1	Adzymes and uses thereof
102	20040422	379	US 20040077090 A1	Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
103	20040422	253	US 20040076955 A1	Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer

	Issue Date	Pages	Document ID	Title
104	20040415	63	US 20040072288 A1	Methods for altering cell fate to generate T-cells specific for an antigen of interest
105	20040415	25	US 20040071660 A1	Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts
106	20040408	25	US 20040068104 A1	Human galectin-9-like proteins and cDNAs encoding these proteins
107	20040408	20	US 20040067883 A1	Use of matrix metalloprotease inhibitors for the treatment of cancer
108	20040408	44	US 20040067583 A1	Methods for immortalizing cells
109	20040408	70	US 20040067537 A1	Labeled peptides, proteins and antibodies and processes and intermediates useful for their preparation
110	20040401	35	US 20040064849 A1	Use of genes encoding membrane transporter pumps to stimulate the production of secondary metabolites in biological cells
111	20040325	144	US 20040058892 A1	Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase
112	20040325	139	US 20040058355 A1	Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
113	20040325	49	US 20040058344 A1	Trans-splicing mediated imaging of gene expression

	Issue Date	Pages	Document ID	Title
114	20040325	29	US 20040058320 A1	Reagents and methods for identifying and modulating expression of tumor senescence genes
115	20040325	46	US 20040057902 A1	Monoclonal antibody cPAM4
116	20040318	243	US 20040053248 A1	Novel nucleic acids and polypeptides
117	20040318	287	US 20040053245 A1	Novel nucleic acids and polypeptides
118	20040318	42	US 20040052788 A1	Cytokine that induces apoptosis
119	20040311	267	US 20040048249 A1	Novel nucleic acids and secreted polypeptides
120	20040304	372	US 20040044191 A1	123 human secreted proteins
121	20040304	198	US 20040044181 A1	Novel nucleic acids and polypeptides
122	20040304	63	US 20040043010 A1	Delivery of bioactive compounds to an organism
123	20040226	74	US 20040040047 A1	Regulated apoptosis using chemically induced dimerization of apoptosis factors
124	20040226	84	US 20040038860 A1	Reagents and methods for modulating dkk-mediated interactions
125	20040226	61	US 20040038360 A1	Ethanolaminephosphate cytidyltransferase gene and promoter
126	20040226	333	US 20040038276 A1	Secreted proteins and polynucleotides encoding them
127	20040219	234	US 20040034196 A1	98 human secreted proteins

	Issue Date	Pages	Document ID	Title
128	20040219	47	US 20040033222 A1	Anticoagulant and fibrinolytic therapy using p38 MAP kinase inhibitors
129	20040205	73	US 20040025196 A1	POSH nucleic acids, polypeptides and related methods
130	20040205	63	US 20040023233 A1	Protection against oxidative stress and inflammation by a cytoprotective response element
131	20040129	112	US 20040019015 A1	Protection against and treatment of hearing loss
132	20040129	413	US 20040018969 A1	Nucleic acids, proteins, and antibodies
133	20040129	44	US 20040018622 A1	Spliceosome mediated RNA trans-splicing for correction of skin disorders
134	20040122	230	US 20040016025 A1	Rice promoters for regulation of plant expression
135	20040122	14	US 20040014112 A1	Novel human kinase proteins and polynucleotides encoding the same
136	20040122	108	US 20040014083 A1	Detection of heteroduplex polynucleotides using mutant nucleic acid repair enzymes with attenuated catalytic activity
137	20040122	284	US 20040014039 A1	Nucleic acids, proteins, and antibodies
138	20040115	279	US 20040010134 A1	Albumin fusion proteins
139	20040115	286	US 20040010132 A1	53 human secreted proteins

140	20040115	158	US 20040010121 A1	7 Human ovarian and ovarian cancer associated proteins
-----	----------	-----	-------------------------	--

	Issue Date	Pages	Document ID	Title
141	20040115	431	US 20040010119 A1	Novel proteins and nucleic acids encoding same
142	20040115	91	US 20040009510 A1	Allosteric nucleic acid sensor molecules
143	20040115	168	US 20040009491 A1	Nucleic acids, proteins, and antibodies
144	20040115	54	US 20040009490 A1	Polynucleotides, materials incorporating them, and methods for using them
145	20040115	289	US 20040009488 A1	Nucleic acids, proteins, and antibodies
146	20040115	47	US 20040009237 A1	Copper lowering treatment of inflammatory and fibrotic diseases
147	20040108	131	US 20040006218 A1	Chlamydia pneumoniae polynucleotides and uses thereof
148	20040108	241	US 20040005700 A1	Poroplasts
149	20040108	168	US 20040005579 A1	Nucleic acids, proteins, and antibodies
150	20040108	369	US 20040005577 A1	Nucleic acids, proteins, and antibodies
151	20040108	262	US 20040005575 A1	Nucleic acids, proteins, and antibodies
152	20040101	383	US 20040002591 A1	50 human secreted proteins
153	20040101	23	US 20040002534 A1	Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
154	20031225	65	US 20030235883 A1	Novel nucleic acids and polypeptides

	Issue Date	Pages	Document ID	Title
155	20031225	206	US 20030235831 A1	Nucleic acids, proteins, and antibodies
156	20031225	196	US 20030235829 A1	Nucleic acids, proteins, and antibodies
157	20031218	199	US 20030232975 A1	Nucleic acids, proteins, and antibodies
158	20031218	40	US 20030232400 A1	Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
159	20031218	240	US 20030232335 A1	Minicell-based screening for compounds and proteins that modulate the activity of signalling proteins
160	20031211	165	US 20030228301 A1	Novel human proteins, polynucleotides encoding them and methods of using the same
161	20031204	33	US 20030225258 A1	Novel human proteases and polynucleotides encoding the same
162	20031204	78	US 20030225257 A1	Novel human kinases and polynucleotides encoding the same
163	20031204	142	US 20030225025 A1	MDA-7 proteins and methods of use thereof
164	20031204	320	US 20030225009 A1	28 human secreted proteins
165	20031204	94	US 20030224508 A1	Novel vectors and genes exhibiting increased expression
166	20031204	418	US 20030224486 A1	Polynucleotides and polypeptides associated with the NF-kB pathway

	Issue Date	Pages	Document ID	Title
167	20031204	180	US 20030224461 A1	Nucleic acids, proteins, and antibodies
168	20031204	240	US 20030224444 A1	Antibodies to native conformations of membrane proteins
169	20031204	168	US 20030224426 A1	Human G-protein chemokine receptor HSATU68
170	20031204	279	US 20030224425 A1	ACRP30-like polynucleotides, polypeptides, and antibodies
171	20031204	154	US 20030224379 A1	Novel nucleic acids and polypeptides
172	20031204	238	US 20030224369 A1	Reverse screening and target identification with minicells
173	20031127	317	US 20030220489 A1	29 human secreted proteins
174	20031127	242	US 20030219888 A1	Minicell-based bioremediation
175	20031127	176	US 20030219875 A1	Albumin fusion proteins
176	20031127	43	US 20030219785 A1	Targeted drug delivery methods
177	20031127	389	US 20030219758 A1	Nucleic acids, proteins, and antibodies
178	20031127	44	US 20030219412 A1	Somatic gene therapy to suppress secondary cataract formation following eye surgery
179	20031127	242	US 20030219408 A1	Methods of making pharmaceutical compositions with minicells
180	20031120	236	US 20030215893 A1	Nucleic acids, proteins, and antibodies

	Issue Date	Pages	Document ID	Title
181	20031120	12	US 20030215446 A1	Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease
182	20031113	243	US 20030211599 A1	Minicell-based delivery agents
183	20031113	75	US 20030211491 A1	Method and marker for identification of pre-malignancy and malignancy and therapeutic intervention
184	20031113	43	US 20030211490 A1	Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
185	20031113	239	US 20030211086 A1	Minicell-based selective absorption
186	20031106	248	US 20030208058 A1	B7-like polypeptides and polynucleotides
187	20031106	74	US 20030208057 A1	Mammalian genes modulated during fasting and feeding
188	20031106	243	US 20030207833 A1	Pharmaceutical compositions with minicells
189	20031106	17	US 20030207319 A1	Novel human kinases and polynucleotides encoding the same
190	20031106	194	US 20030207285 A1	Nucleic acids, proteins, and antibodies
191	20031106	72	US 20030206887 A1	RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
192	20031030	211	US 20030204069 A1	Segments of the human gene for telomerase reverse transcriptase

	Issue Date	Pages	Document ID	Title
193	20031030	242	US 20030203481 A1	Conjugated minicells
194	20031030	243	US 20030203411 A1	Methods of minicell-based delivery
195	20031030	211	US 20030203361 A1	13 human colon and colon cancer associated proteins
196	20031030	242	US 20030202937 A1	Minicell-based diagnostics
197	20031023	65	US 20030199469 A1	Combination of bryostatin and paclitaxel for treating cancer
198	20031023	113	US 20030199468 A1	DNA sequences comprising gene transcription regulatory qualities and methods for detecting and using such DNA sequences
199	20031023	243	US 20030199089 A1	Membrane to membrane delivery
200	20031023	149	US 20030199088 A1	Minicell-based gene therapy
201	20031023	167	US 20030199043 A1	Albumin fusion proteins
202	20031023	250	US 20030199008 A1	Nucleic Acids, Proteins, and antibodies
203	20031023	243	US 20030199005 A1	Solid supports with minicells
204	20031023	240	US 20030198996 A1	Minicell libraries
205	20031023	242	US 20030198995 A1	Forward screening with minicells
206	20031023	305	US 20030198954 A1	Human cDNAs and proteins and uses thereof

	Issue Date	Pages	Document ID	Title
207	20031023	90	US 20030198627 A1	siRNA knockout assay method and constructs
208	20031016	68	US 20030195168 A1	Therapeutic agents - III
209	20031016	243	US 20030194798 A1	Minicell compositions and methods
210	20031016	185	US 20030194725 A1	Methods for identifying and validating potential drug targets
211	20031016	244	US 20030194714 A1	Minicell-based transformation
212	20031016	155	US 20030194696 A1	Methods of producing a library and methods of selecting polynucleotides of interest
213	20031009	188	US 20030191298 A1	Transcription factor polynucleotides, polypeptides, antibodies, and methods based thereon
214	20031009	46	US 20030191048 A1	Gene expression profile for KSHV infection and methods for treating same
215	20031009	242	US 20030190749 A1	Minicell-producing parent cells
216	20031009	240	US 20030190707 A1	17 human secreted proteins
217	20031009	242	US 20030190683 A1	Minicell-based rational drug design
218	20031009	87	US 20030190637 A1	Mutations in spink5 responsible for netherton's syndrome and atopic diseases
219	20031009	242	US 20030190601 A1	Target display on minicells

	Issue Date	Pages	Document ID	Title
220	20031002	113	US 20030186909 A1	Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
221	20031002	260	US 20030186904 A1	Keratinocyte growth factor-2
222	20030925	122	US 20030181711 A1	Polynucleotide encoding a novel human potassium channel beta-subunit, K+Mbeta1
223	20030925	18	US 20030181705 A1	Novel human kinases and polynucleotides encoding the same
224	20030925	328	US 20030181692 A1	207 human secreted proteins
225	20030925	37	US 20030181413 A1	Raf protein kinase therapeutics
226	20030925	53	US 20030181380 A1	Modulating lymphoid commitment and survival
227	20030925	49	US 20030181377 A1	Inhibition of VEGF receptor signaling reverses tumor resistance to radiotherapy
228	20030925	135	US 20030180744 A1	High affinity oligonucleotide ligands to growth factors
229	20030925	59	US 20030180740 A1	Differential expression screening method
230	20030918	17	US 20030175949 A1	Novel human kinase and polynucleotides encoding the same
231	20030918	256	US 20030175858 A1	186 human secreted proteins
232	20030918	24	US 20030175855 A1	HUMAN SDF-5 PROTEIN AND COMPOSITIONS
233	20030918	235	US 20030175739 A1	Nucleic acids, proteins, and antibodies

	Issue Date	Pages	Document ID	Title
234	20030918	168	US 20030175715 A1	Compositions and methods relating to breast specific genes and proteins
235	20030918	82	US 20030175253 A1	Compositions and methods for diagnosing and treating mental disorders
236	20030911	155	US 20030171267 A1	Albumin fusion proteins
237	20030911	259	US 20030171252 A9	Nucleic acids, proteins, and antibodies
238	20030911	307	US 20030170891 A1	RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
239	20030911	115	US 20030170668 A1	Chromosomal markers and diagnostic tests for manic-depressive illness
240	20030911	310	US 20030170628 A1	Human cDNAs and proteins and uses thereof
241	20030911	54	US 20030170293 A1	Thermotolerant phytase for animal feed
242	20030911	29	US 20030170264 A1	Stabilisation of plasmid inheritance in bacteria
243	20030911	108	US 20030170203 A1	Death domain containing receptors
244	20030904	116	US 20030166911 A1	Trefoil domain-containing polynucleotides, polypeptides, and antibodies
245	20030904	20	US 20030166889 A1	Novel human kinases and polynucleotides encoding the same

	Issue Date	Pages	Document ID	Title
246	20030904	35	US 20030166839 A1	Novel human transferase proteins and polynucleotides encoding the same
247	20030904	308	US 20030166541 A1	83 human secreted proteins
248	20030904	242	US 20030166279 A1	Minicell-based transfection
249	20030904	60	US 20030166277 A1	Targeted vaccine delivery systems
250	20030904	241	US 20030166099 A1	Minicells comprising membrane proteins
251	20030828	35	US 20030162734 A1	Modulation of DENN-MADD expression and interactions for treating neurological disorders
252	20030828	63	US 20030162713 A1	Novel human transporter proteins
253	20030828	57	US 20030162277 A1	Calcium/calmodulin-dependent kinase
254	20030828	308	US 20030162186 A1	Human cDNAs and proteins and uses thereof
255	20030828	118	US 20030162175 A1	NK cell receptor polynucleotides, polypeptides, and antibodies
256	20030821	19	US 20030157539 A1	IRAK-M is a negative regulator of toll-like receptor signaling
257	20030821	179	US 20030157508 A1	Nucleic acids, proteins, and antibodies
258	20030821	307	US 20030157485 A1	Human cDNAs and proteins and uses thereof
259	20030821	151	US 20030157113 A1	Compositions and methods for treatment of neoplastic disease

	Issue Date	Pages	Document ID	Title
260	20030814	148	US 20030152953 A1	Polynucleotide encoding a novel human potassium channel alpha-subunit, K+alphaM2
261	20030814	260	US 20030152921 A1	Full-length human cDNAs encoding potentially secreted proteins
262	20030807	113	US 20030149256 A1	Transferrin polynucleotides, polypeptides, and antibodies
263	20030807	109	US 20030148947 A1	Major intrinsic protein (MIP)-like polynucleotides, polypeptides and antibodies
264	20030807	221	US 20030148490 A1	Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
265	20030807	218	US 20030148443 A1	Epoxide hydrolases, nucleic acids encoding them and methods of making and using them
266	20030807	107	US 20030148264 A1	Phage displayed PDZ domain ligands
267	20030731	269	US 20030144490 A1	Extended cDNAs for secreted proteins
268	20030731	16	US 20030144178 A1	Method for inhibiting C-jun expression using JAK-3 inhibitors
269	20030731	31	US 20030143603 A1	Anti-TNF antibodies, compositions, methods and uses
270	20030724	238	US 20030139327 A9	Nucleic acids, proteins, and antibodies
271	20030724	460	US 20030138432 A1	Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs

	Issue Date	Pages	Document ID	Title
272	20030710	20	US 20030130495 A1	Novel human 7TM protein and polynucleotides encoding the same
273	20030710	115	US 20030130234 A1	Novel indolinones and uses thereof
274	20030710	439	US 20030129685 A1	12 human secreted proteins
275	20030710	17	US 20030129663 A1	Methods and compositions for modulating oxidized ldl transport
276	20030703	180	US 20030125247 A1	Albumin fusion proteins
277	20030703	217	US 20030125246 A9	Nucleic acids, proteins, and antibodies
278	20030703	64	US 20030124590 A1	Carbohydrate response element binding protein and uses thereof
279	20030703	27	US 20030124133 A1	RECEPTOR TYROSINE KINASE WITH A DISCOIDIN-TYPE BINDING DOMAIN
280	20030619	108	US 20030114486 A1	Novel quinolinones and uses thereof
281	20030619	78	US 20030114467 A1	Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
282	20030619	227	US 20030113840 A1	25 human secreted proteins
283	20030619	39	US 20030113796 A1	FIL-1 theta DNAs and polypeptides
284	20030619	322	US 20030113726 A1	Human single nucleotide polymorphisms
285	20030612	174	US 20030109690 A1	Colon and colon cancer associated polynucleotides and polypeptides

	Issue Date	Pages	Document ID	Title
286	20030612	229	US 20030108907 A1	Nucleic acids, proteins, and antibodies
287	20030605	71	US 20030105115 A1	Novel pyridopyrimidines and uses thereof
288	20030605	66	US 20030105065 A1	Novel quinolines and uses thereof
289	20030605	370	US 20030105051 A1	Nucleic acid treatment of diseases or conditions related to levels of HER2
290	20030605	64	US 20030104995 A1	Neuroprotective methods and compositions
291	20030605	69	US 20030104611 A1	Feline immunodeficiency virus gene therapy vectors
292	20030605	45	US 20030104413 A1	Novel Nucleic acids and polypeptides
293	20030605	168	US 20030104358 A1	Diagnosis methods based on microcompetition for a limiting GABP complex
294	20030529	93	US 20030100573 A1	Novel quinazolines and uses thereof
295	20030529	78	US 20030100572 A1	Novel pyridopyrimidones and uses thereof
296	20030522	274	US 20030097666 A1	Novel human genes and gene expression products:II
297	20030522	333	US 20030096951 A1	SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
298	20030522	353	US 20030096398 A1	Novel nucleic acid molecule
299	20030522	197	US 20030096346 A1	Nucleic acids, proteins, and antibodies
300	20030522	99	US 20030096279 A1	Novel nucleic acids and polypeptides

	Issue Date	Pages	Document ID	Title
301	20030522	46	US 20030096262 A1	Uses of Ku70
302	20030522	305	US 20030096247 A1	Human cDNAs and proteins and uses thereof
303	20030515	258	US 20030092615 A1	Nucleic acids, proteins, and antibodies
304	20030515	160	US 20030092611 A9	Nucleic acids, proteins, and antibodies
305	20030515	284	US 20030092102 A1	Nucleic acids, proteins, and antibodies
306	20030515	305	US 20030092011 A1	Human cDNAs and proteins and uses thereof
307	20030501	324	US 20030083481 A1	25 human prostate and prostate cancer associated proteins
308	20030501	59	US 20030083276 A1	Uses of DNA-PK
309	20030501	302	US 20030082758 A1	Nucleic acids, proteins, and antibodies
310	20030501	242	US 20030082681 A1	Nucleic acids, proteins, and antibodies
311	20030501	23	US 20030082674 A1	HUMAN PYRIMIDINE RECEPTOR
312	20030501	59	US 20030082620 A1	Novel human genes and gene expression products: II
313	20030424	513	US 20030077808 A1	Nucleic acids, proteins, and antibodies
314	20030424	202	US 20030077704 A1	Nucleic acids, proteins, and antibodies
315	20030424	176	US 20030077703 A1	Nucleic acids, proteins, and antibodies

	Issue Date	Pages	Document ID	Title
316	20030424	213	US 20030077606 A1	Nucleic acids, proteins, and antibodies
317	20030424	187	US 20030077604 A1	Compositions and methods relating to breast specific genes and proteins
318	20030424	181	US 20030077602 A1	Nucleic acids, proteins, and antibodies
319	20030417	157	US 20030073728 A1	Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
320	20030417	199	US 20030073207 A1	Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
321	20030417	59	US 20030073162 A1	Signal peptide-containing proteins
322	20030417	51	US 20030073083 A1	Methods for predicting chemosensitivity or chemoresistance
323	20030410	173	US 20030069199 A1	Treatment methods based on microcompetition for a limiting GABP complex
324	20030410	65	US 20030069195 A1	Suppression of polymorphic alleles
325	20030410	215	US 20030068627 A1	Nucleic acids, proteins, and antibodies
326	20030410	121	US 20030068624 A1	Compositions and methods relating to lung specific genes and proteins
327	20030410	172	US 20030068616 A1	Drug discovery assays based on microcompetition for a limiting GABP complex
328	20030403	171	US 20030065156 A1	Novel human genes and gene expression products I

	Issue Date	Pages	Document ID	Title
329	20030403	116	US 20030065155 A1	Nucleic acid sensor molecules
330	20030403	113	US 20030064945 A1	Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
331	20030403	17	US 20030064509 A1	Novel chromosomal vectors and uses thereof
332	20030403	14	US 20030064495 A1	Novel human kinase proteins and polynucleotides encoding the same
333	20030403	149	US 20030064381 A1	Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY26, expressed highly in testis and gastrointestinal tissues
334	20030403	146	US 20030064378 A1	Compositions and methods relating to lung specific genes and proteins
335	20030403	198	US 20030064072 A9	Nucleic acids, proteins and antibodies
336	20030327	46	US 20030059917 A1	PAS kinase
337	20030327	262	US 20030059908 A1	Nucleic acids, proteins, and antibodies
338	20030327	235	US 20030059875 A1	Nucleic acids, proteins, and antibodies
339	20030320	105	US 20030054488 A1	Goodpasture antigen binding protein
340	20030320	196	US 20030054421 A1	Nucleic acids, proteins, and antibodies
341	20030320	179	US 20030054420 A1	Nucleic acids, proteins, and antibodies

	Issue Date	Pages	Document ID	Title
342	20030320	171	US 20030054379 A1	Nucleic acids, proteins, and antibodies
343	20030320	178	US 20030054377 A1	Nucleic acids, proteins, and antibodies
344	20030320	248	US 20030054375 A1	Nucleic acids, proteins, and antibodies
345	20030320	190	US 20030054373 A1	Nucleic acids, proteins and antibodies
346	20030320	178	US 20030054368 A1	Nucleic acids, proteins and antibodies
347	20030320	30	US 20030053994 A1	Redirection of cellular immunity by protein tyrosine kinase chimeras
348	20030313	275	US 20030050455 A1	64 human secreted proteins
349	20030313	208	US 20030050231 A1	Nucleic acids, proteins, and antibodies
350	20030313	95	US 20030049828 A1	MN gene and protein
351	20030313	105	US 20030049791 A1	Goodpasture antigen binding protein
352	20030313	70	US 20030049725 A1	Anti-TNF antibodies, compositions, methods and uses
353	20030313	332	US 20030049703 A1	Nucleic acids, proteins, and antibodies
354	20030313	189	US 20030049652 A1	Nucleic acids, proteins, and antibodies
355	20030313	226	US 20030049650 A1	Nucleic acids, proteins, and antibodies
356	20030313	260	US 20030049618 A1	186 human secreted proteins

	Issue Date	Pages	Document ID	Title
357	20030313	60	US 20030049246 A1	Gli protein truncate and uses thereof
358	20030306	160	US 20030044907 A1	Nucleic acids, proteins, and antibodies
359	20030306	165	US 20030044905 A1	Nucleic acids, proteins, and antibodies
360	20030306	334	US 20030044904 A1	Nucleic acids, proteins, and antibodies
361	20030306	19	US 20030044900 A1	Human kinesins and methods of producing and purifying human kinesins
362	20030306	177	US 20030044890 A1	Nucleic acids, proteins, and antibodies
363	20030227	198	US 20030040617 A9	Nucleic acids, proteins and antibodies
364	20030227	173	US 20030039994 A1	Nucleic acids, proteins, and antibodies
365	20030227	164	US 20030039993 A1	Nucleic acids, proteins, and antibodies
366	20030227	28	US 20030039957 A1	Functional protein expression for rapid cell-free phenotyping
367	20030220	297	US 20030036505 A1	Signal transduction pathway component polynucleotides, polypeptides, antibodies and methods based thereon
368	20030213	121	US 20030032776 A1	Polynucleotide encoding a novel human potassium channel beta-subunit, K+Mbeta1
369	20030213	56	US 20030032034 A1	Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides

	Issue Date	Pages	Document ID	Title
370	20030206	401	US 20030027999 A1	143 human secreted proteins
371	20030206	274	US 20030027776 A1	29 human cancer associated proteins
372	20030206	305	US 20030027248 A1	Human cDNAs and proteins and uses thereof
373	20030206	306	US 20030027161 A1	Human cDNAs and proteins and uses thereof
374	20030130	36	US 20030023065 A1	Novel human ATPase proteins and polynucleotides encoding the same
375	20030130	17	US 20030023063 A1	Novel human kinases and polynucleotides encoding the same
376	20030130	112	US 20030022338 A1	Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies
377	20030123	39	US 20030017481 A1	Methods for classifying samples and ascertaining previously unknown classes
378	20030123	60	US 20030017150 A1	Chronic obstructive pulmonary disease-related immunoglobulin derived proteins, compositions, methods and uses
379	20030123	38	US 20030017141 A1	Purposeful movement of human migratory cells away from an agent source
380	20030116	363	US 20030013649 A1	Nucleic acids, proteins, and antibodies
381	20030109	20	US 20030009021 A1	Novel human proteases and polynucleotides encoding the same

	Issue Date	Pages	Document ID	Title
382	20030102	14	US 20030004328 A1	Novel human G-coupled protein receptor kinases and polynucleotides encoding the same
383	20030102	105	US 20030004122 A1	Nucleotide triphosphates and their incorporation into oligonucleotides
384	20030102	41	US 20030003565 A1	Functional lentiviral vector from an MLV-based backbone
385	20021226	52	US 20020197666 A1	HUMAN CHORDIN-RELATED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
386	20021219	145	US 20020192749 A1	Human polynucleotides, polypeptides, and antibodies
387	20021212	33	US 20020187122 A1	IL-1 delta DNA and polypeptides
388	20021205	105	US 20020183518 A1	Modulators of proteins with phosphotyrosine recognition units
389	20021205	142	US 20020183509 A1	METHOD FOR GENERATING A SUBTRACTED CDNA LIBRARY AND USES OF THE GENERATED LIBRARY
390	20021205	38	US 20020183486 A1	Aspartate kinase
391	20021205	147	US 20020182702 A1	ADAM polynucleotides, polypeptides, and antibodies
392	20021205	52	US 20020182656 A1	Methods for regulating vascularization using GEF containing NEK-like kinase (GNK)
393	20021128	78	US 20020177696 A1	Compositions and methods relating to breast specific genes and proteins
394	20021128	167	US 20020177551 A1	Compositions and methods for treatment of neoplastic disease

	Issue Date	Pages	Document ID	Title
395	20021128	55	US 20020177125 A1	Human rhinovirus assays, and compositions therefrom
396	20021128	31	US 20020176851 A1	Redirection of cellular immunity by protein-tyrosine kinase chimeras
397	20021121	16	US 20020173641 A1	Novel human carboxypeptidases and polynucleotides encoding the same
398	20021121	147	US 20020173640 A1	ADAM polynucleotides, polypeptides, and antibodies
399	20021121	332	US 20020173454 A1	Nucleic acids, proteins, and antibodies
400	20021121	209	US 20020172994 A1	28 human secreted proteins
401	20021121	168	US 20020172959 A1	Compositions and methods relating to lung specific genes and proteins
402	20021114	64	US 20020169108 A1	Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
403	20021114	345	US 20020168711 A1	Nucleic acids, proteins, and antibodies
404	20021107	14	US 20020165376 A1	Novel human proteases and polynucleotides encoding the same
405	20021107	194	US 20020165137 A1	Nucleic acids, proteins, and antibodies
406	20021107	13	US 20020164737 A1	Novel human kinase and polynucleotides encoding the same
407	20021107	112	US 20020164693 A1	TM4SF receptor polynucleotides, polypeptides, and antibodies

	Issue Date	Pages	Document ID	Title
408	20021107	142	US 20020164692 A1	Immune system-related polynucleotides, polypeptides, and antibodies
409	20021107	159	US 20020164685 A1	Nucleic acids, proteins, and antibodies
410	20021031	78	US 20020161213 A1	Novel human kinases and polynucleotides encoding the same
411	20021031	188	US 20020161208 A1	Nucleic acids, proteins, and antibodies
412	20021031	154	US 20020160493 A1	Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies
413	20021031	120	US 20020160491 A1	Human Serpin polynucleotides, polypeptides, and antibodies
414	20021031	84	US 20020160388 A1	Compositions and methods relating to lung specific genes and proteins
415	20021024	100	US 20020157132 A1	Plant amino acid biosynthetic enzymes
416	20021017	298	US 20020151681 A1	Nucleic acids, proteins and antibodies
417	20021017	162	US 20020151479 A1	Nucleic acids, proteins, and antibodies
418	20021017	152	US 20020151009 A1	Human polynucleotides, polypeptides, and antibodies
419	20021010	21	US 20020147320 A1	Novel human kinase proteins and polynucleotides encoding the same
420	20021010	33	US 20020147310 A1	IL-1 eta DNA and polypeptides

	Issue Date	Pages	Document ID	Title
421	20021010	321	US 20020147140 A1	Nucleic acids, proteins, and antibodies
422	20021010	79	US 20020146757 A1	Novel nucleic acids and polypeptides
423	20021003	50	US 20020144298 A1	Novel human genes and gene expression products
424	20021003	117	US 20020143152 A1	Polypeptides, their production and use
425	20021003	20	US 20020142287 A1	High throughput assay to detect inhibitors of the map kinase pathway
426	20021003	19	US 20020141992 A1	Medicament for the protection against thrombotic diseases
427	20020926	16	US 20020137913 A1	Novel human kinases and polynucleotides encoding the same
428	20020919	101	US 20020132819 A1	Novel purinse
429	20020919	211	US 20020132767 A1	Nucleic acids, proteins, and antibodies
430	20020919	402	US 20020132753 A1	Nucleic acids, proteins, and antibodies
431	20020919	154	US 20020132255 A1	Compositions and methods relating to breast specific genes and proteins
432	20020912	17	US 20020128458 A1	Novel human kinases and polynucleotides encoding the same
433	20020905	26	US 20020123622 A1	Novel human kinases and polynucleotides encoding the same
434	20020905	13	US 20020123621 A1	Novel human kinase and polynucleotides encoding the same
435	20020829	33	US 20020120113 A1	Novel human proteases and polynucleotides encoding the same

	Issue Date	Pages	Document ID	Title
436	20020829	238	US 20020120103 A1	17 human secreted proteins
437	20020829	66	US 20020119942 A1	Packaging systems for human recombinant adenovirus to be used in gene therapy
438	20020829	45	US 20020119929 A1	Can1 and its role in mammalian infertility
439	20020829	183	US 20020119919 A1	Nucleic acids, proteins, and antibodies
440	20020829	39	US 20020119546 A1	Squalene synthesis enzymes
441	20020829	118	US 20020119519 A1	Trefoil domain-containing polynucleotides, polypeptides, and antibodies
442	20020829	147	US 20020119463 A1	Prostate cancer markers
443	20020815	53	US 20020111474 A1	Chimeric chains for receptor-associated signal transduction pathways
444	20020815	242	US 20020111471 A1	Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
445	20020815	18	US 20020110908 A1	Novel human kinases and polynucleotides encoding the same
446	20020808	42	US 20020107180 A1	Cell surface glycoproteins
447	20020808	133	US 20020106780 A1	Extracellular matrix polynucleotides, polypeptides, and antibodies

448	20020808	117	US 20020106731 A1	Bcl-2-like polynucleotides, polypeptides, and antibodies
-----	----------	-----	-------------------------	---

	Issue Date	Pages	Document ID	Title
449	20020808	74	US 20020106728 A1	NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
450	20020801	58	US 20020103359 A1	Novel human membrane proteins and polynucleotides encoding the same
451	20020801	89	US 20020103161 A1	Novel heterocycles
452	20020801	225	US 20020102638 A1	Nucleic acids, proteins, and antibodies
453	20020801	262	US 20020102604 A1	Full-length human cDNAs encoding potentially secreted proteins
454	20020718	206	US 20020094953 A1	Nucleic acids, proteins, and antibodies
455	20020711	111	US 20020090695 A1	Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies
456	20020711	240	US 20020090674 A1	Nucleic acids, proteins, and antibodies
457	20020711	252	US 20020090673 A1	Nucleic acids, proteins, and antibodies
458	20020711	369	US 20020090672 A1	Nucleic acids, proteins, and antibodies
459	20020711	177	US 20020090615 A1	Nucleic acids, proteins, and antibodies
460	20020704	171	US 20020086823 A1	Nucleic acids, proteins, and antibodies
461	20020704	237	US 20020086822 A1	Nucleic acids, proteins, and antibodies
462	20020704	365	US 20020086821 A1	Nucleic acids, proteins, and antibodies

	Issue Date	Pages	Document ID	Title
463	20020704	176	US 20020086820 A1	Nucleic acids, proteins, and antibodies
464	20020704	258	US 20020086811 A1	Nucleic acids, proteins, and antibodies
465	20020704	296	US 20020086353 A1	Nucleic acids, proteins, and antibodies
466	20020704	335	US 20020086330 A1	Nucleic acids, proteins, and antibodies
467	20020627	10	US 20020082406 A1	Novel human kinase interacting protein and polynucleotides encoding the same
468	20020627	196	US 20020081659 A1	Nucleic acids, proteins and antibodies
469	20020627	107	US 20020081607 A1	Four disulfide core domain-containing (FDCD) polynucleotides, polypeptides, and antibodies
470	20020620	117	US 20020077465 A1	ADAM polynucleotides, polypeptides, and antibodies
471	20020620	209	US 20020077287 A1	28 human secreted proteins
472	20020620	231	US 20020077270 A1	Nucleic acids, proteins, and antibodies
473	20020620	209	US 20020076756 A1	28 human secreted proteins
474	20020620	25	US 20020076396 A1	Intraocular transplantation of encapsulated cells
475	20020613	113	US 20020072596 A1	Transferrin polynucleotides, polypeptides, and antibodies
476	20020606	73	US 20020068354 A1	Feline immunodeficiency virus gene therapy vectors

	Issue Date	Pages	Document ID	Title
477	20020530	284	US 20020065394 A1	Secreted proteins and polynucleotides encoding them
478	20020530	203	US 20020064855 A1	Genes that regulate hematopoietic blood forming stem cells and uses thereof
479	20020530	115	US 20020064844 A1	Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
480	20020530	115	US 20020064826 A1	Cytokine receptor-like polynucleotides, polypeptides, and antibodies
481	20020530	308	US 20020064818 A1	52 human secreted proteins
482	20020523	280	US 20020061521 A1	Nucleic acids, proteins, and antibodies
483	20020509	194	US 20020055627 A1	Nucleic acids, proteins and antibodies
484	20020509	108	US 20020055142 A1	Major intrinsic protein (MIP)-like polynucleotides, polypeptides, and antibodies
485	20020502	97	US 20020052345 A1	Novel prodrugs for phosphorus-containing compounds
486	20020502	308	US 20020052308 A1	Nucleic acids, proteins and antibodies
487	20020502	113	US 20020051984 A1	Kringle domain-containing polynucleotides, polypeptides, and antibodies
488	20020425	69	US 20020048805 A1	FELINE IMMUNODEFICIENCY VIRUS GENE THERAPY VECTORS

489	20020418	13	US 20020045743 A1	Novel human membrane proteins and polynucleotides encoding the same
-----	----------	----	-------------------------	--

	Issue Date	Pages	Document ID	Title
490	20020418	102	US 20020045591 A1	Methods and therapeutic compositions for treating cancer
491	20020418	470	US 20020045230 A1	Nucleic acids, proteins, and antibodies
492	20020418	220	US 20020044941 A1	Nucleic acids, proteins and antibodies
493	20020411	14	US 20020042503 A1	Novel human G-coupled protein receptor kinases and polynucleotides encoding the same
494	20020411	235	US 20020042386 A1	Nucleic acids, proteins, and antibodies
495	20020411	14	US 20020042127 A1	DONOR CELLS EXPRESSING FUSOGENS
496	20020411	181	US 20020042096 A1	Nucleic acids, proteins, and antibodies
497	20020404	66	US 20020040014 A1	Novel aryl fructose-1,6-Bisphosphatase inhibitors
498	20020404	199	US 20020039764 A1	Nucleic, acids, proteins, and antibodies
499	20020404	49	US 20020039581 A1	Antibodies against CTLA4 and uses therefor
500	20020328	54	US 20020038011 A1	Novel human kinases and polynucleotides encoding the same
501	20020328	12	US 20020038009 A1	Novel human kinase protein and polynucleotides encoding the same
502	20020328	107	US 20020037523 A1	IL-6-like polynucleotides, polypeptides, and antibodies
503	20020328	62	US 20020037279 A1	DELIVERY OF BIOACTIVE COMPOUNDS TO AN ORGANISM

	Issue Date	Pages	Document ID	Title
504	20020321	37	US 20020035240 A1	Novel mammalian cell cycle protein
505	20020321	13	US 20020034799 A1	Novel human transporter protein and polynucleotides encoding the same
506	20020321	50	US 20020034758 A1	Novel human genes and gene expressions products: II
507	20020131	119	US 20020012968 A1	Novel drosophila tumor necrosis factor class molecule ("DmTNF") and variants thereof
508	20020131	194	US 20020012966 A1	18 Human secreted proteins
509	20020124	24	US 20020010203 A1	Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
510	20020124	29	US 20020009772 A1	NOVEL HUMAN CALCIUM CHANNELS AND RELATED PROBES, CELL LINES AND MEHTODS
511	20020117	113	US 20020006640 A1	Uteroglobulin-like polynucleotides, polypeptides, and antibodies
512	20011213	16	US 20010051600 A1	Use of interleukin-11 to prevent immune-mediated cytotoxicity
513	20011213	201	US 20010051335 A1	POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM CORN TASSEL
514	20011206	12	US 20010049120 A1	EXPRESSION VECTOR FOR CONSISTENT CELLULAR EXPRESSION OF THE TET ON REPRESSOR IN MULTIPLE CELL TYPES
515	20011122	21	US 20010044113 A1	Invasive detection of colonic biomarkers

516	20011025	21	US 20010034438 A1	Novel human membrane protein and polynucleotides encoding the same
-----	----------	----	-------------------------	---

	Issue Date	Pages	Document ID	Title
517	20011025	9	US 20010034437 A1	Novel human proteases and polynucleotides encoding the same
518	20010823	31	US 20010016194 A1	COMPOUNDS THAT INHIBIT THE BINDING OF RAF-1 OR 14-3-3 PROTEINS TO THE BETA CHAIN OF IL-2 RECEPTOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
519	20010802	64	US 20010011076 A1	COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS
520	20050301	36	US 6861575 B2	Aspartate kinase
521	20050301	13	US 6861241 B2	Human kinase and polynucleotides encoding the same
522	20050301	17	US 6861240 B2	Human kinases and polynucleotides encoding the same
523	20050222	31	US 6858419 B1	Human kinases and polynucleotides encoding the same, and uses thereof
524	20050222	32	US 6858395 B2	Diagnostics assay methods and amelioration of muscular dystrophy symptoms
525	20050215	37	US 6856914 B1	Method, apparatus, media and signals for identifying associated cell signaling proteins
526	20050215	45	US 6855340 B2	Copper lowering treatment of inflammatory and fibrotic diseases
527	20050208	33	US 6852521 B2	Human proteases and polynucleotides encoding the same
528	20050201	68	US 6849612 B2	Oligonucleotide modulation of cell adhesion

	Issue Date	Pages	Document ID	Title
529	20050201	16	US 6849443 B2	Human kinases and polynucleotides encoding the same
530	20050125	160	US 6846650 B2	Compositions and methods relating to lung specific genes and proteins
531	20050111	14	US 6841377 B1	Human kinase and polynucleotides encoding the same
532	20050104	15	US 6838275 B2	Human G-coupled protein receptor kinases and polynucleotides encoding the same
533	20041228	42	US 6835866 B1	Compositions and methods of modulating cholesterol metabolism
534	20041123	67	US 6821957 B2	Vectors and methods for immunization or therapeutic protocols
535	20041109	18	US 6815188 B2	Human kinases and polynucleotides encoding the same
536	20041102	30	US 6812335 B1	Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
537	20041102	22	US 6811775 B2	Reovirus for the treatment of cellular proliferative disorders
538	20041026	48	US 6808887 B2	Uses of Ku70
539	20041019	14	US 6806073 B2	Human kinase proteins and polynucleotides encoding the same
540	20041005	24	US 6800649 B1	Method for inhibiting c-jun expression using JAK-3 inhibitors
541	20040928	17	US 6797510 B1	Human kinases and polynucleotides encoding the same
542	20040921	285	US 6794363 B2	Isolated amyloid inhibitor protein (APIP) and compositions thereof

	Issue Date	Pages	Document ID	Title
543	20040914	24	US 6790626 B2	Human pyrimidine receptor
544	20040831	19	US 6783982 B1	Proteins related to neuronal regeneration and uses thereof
545	20040831	93	US 6783969 B1	Cathepsin V-like polypeptides
546	20040831	31	US 6783955 B2	Polynucleotides encoding human presenilin variant
547	20040824	22	US 6780839 B2	Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD)
548	20040824	16	US 6780640 B2	Human carboxypeptidases and polynucleotides encoding the same
549	20040817	20	US 6777545 B2	Human kinases and polynucleotides encoding the same
550	20040817	20	US 6777221 B2	Human proteases and polynucleotides encoding the same
551	20040810	17	US 6773906 B2	Human kinase and polynucleotides encoding the same
552	20040803	106	US 6770466 B2	Human protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
553	20040713	58	US 6762291 B1	Insect p53 tumor suppressor genes and proteins
554	20040706	54	US 6759223 B2	Calcium/calmodulin-dependent kinase
555	20040622	31	US 6753166 B2	IL-1 eta DNA and polypeptides
556	20040622	112	US 6753164 B2	Nucleic acids encoding human serpin polypeptide HMCIS41

	Issue Date	Pages	Document ID	Title
557	20040622	72	US 6753162 B1	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
558	20040622	48	US 6752981 B1	Prodrugs for liver specific drug delivery
559	20040615	18	US 6750229 B2	Methods for treating skin pigmentation
560	20040608	51	US 6747143 B2	Methods for polymer synthesis
561	20040608	13	US 6746861 B2	Human kinase protein and polynucleotides encoding the same
562	20040601	16	US 6743907 B1	Human proteins and polynucleotides encoding the same
563	20040601	80	US 6743619 B1	Nucleic acids and polypeptides
564	20040511	26	US 6734009 B2	Human kinases and polynucleotides encoding the same
565	20040504	49	US 6730778 B2	Human sel-10 polypeptides and polynucleotides that encode them
566	20040413	129	US 6720408 B2	MDA-7 nucleic acid molecules and pharmaceutical compositions thereof
567	20040413	13	US 6720173 B1	Human kinase protein and polynucleotides encoding the same
568	20040406	18	US 6716616 B1	Human kinase proteins and polynucleotides encoding the same
569	20040330	97	US 6713462 B2	Quinolinones and uses thereof
570	20040330	95	US 6713061 B1	Death domain containing receptors
571	20040316	315	US 6706869 B1	Map kinase phosphatases and polynucleotides encoding them
572	20040316	60	US 6706699 B2	Quinolines and uses thereof

	Issue Date	Pages	Document ID	Title
573	20040302	42	US 6699969 B1	Assays for the detection of microtubule depolymerization inhibitors
574	20040217	244	US 6693077 B1	Keratinocyte growth factor-2
575	20040217	33	US 6692947 B2	Human transferase proteins and polynucleotides encoding the same
576	20040210	37	US 6689560 B1	Raf protein kinase therapeutics
577	20040127	39	US 6683061 B1	Enzyme catalyzed therapeutic activation
578	20040127	30	US 6682740 B1	Peptides derived from complement peptide C3a sequence and antiallergic compositions comprising them
579	20040120	38	US 6680196 B1	Gene that is amplified and overexpressed in cancer and methods of use thereof
580	20040113	105	US 6676935 B2	Tissue specific adenoviral vectors
581	20040106	44	US 6673903 B2	Mammalian cell cycle protein
582	20040106	142	US 6673545 B2	Prostate cancer markers
583	20031230	22	US 6669934 B1	Method of modulating fertility in animals by IL-11
584	20031216	25	US 6663894 B2	Intraocular transplantation of encapsulated cells
585	20031209	37	US 6660256 B1	Porcine mpl ligand
586	20031209	50	US 6660234 B2	Apparatus for polymer synthesis
587	20031118	33	US 6649399 B2	Human proteases and polynucleotides encoding the same

	Issue Date	Pages	Document ID	Title
588	20031111	38	US 6647341 B1	Methods for classifying samples and ascertaining previously unknown classes
589	20031111	52	US 6646243 B2	Nucleic acid reading and analysis system
590	20031104	30	US 6642367 B2	Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom
591	20031104	92	US 6642028 B1	Vectors and genes exhibiting increased expression
592	20031028	41	US 6638731 B2	Human sel-10 polypeptides and polynucleotides that encode them
593	20031014	92	US 6632934 B1	MORC gene compositions and methods of use
594	20031007	25	US 6630455 B1	Methods for inducing mucosal immune responses
595	20031007	49	US 6630308 B2	Methods of synthesizing a plurality of different polymers on a surface of a substrate
596	20030930	25	US 6627733 B2	Receptor tyrosine kinase with a discoidin-type binding domain
597	20030909	77	US 6617438 B1	Oligoribonucleotides with enzymatic activity
598	20030909	207	US 6617110 B1	Cells immortalized with telomerase reverse transcriptase for use in drug screening
599	20030902	37	US 6613318 B1	Methods for identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity
600	20030826	202	US 6610839 B1	Promoter for telomerase reverse transcriptase

	Issue Date	Pages	Document ID	Title
601	20030826	17	US 6610537 B2	Human kinases and polynucleotides encoding the same
602	20030826	93	US 6610536 B2	Nucleic acids and polypeptides
603	20030826	81	US 6610504 B1	Methods of determining SAM-dependent methyltransferase activity using a mutant SAH hydrolase
604	20030826	91	US 6610497 B1	Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
605	20030826	14	US 6610496 B1	Prediction of growth performance and composition in animals, including cattle, from response to growth hormone releasing hormone
606	20030826	101	US 6610482 B1	Support bound probes and methods of analysis using the same
607	20030826	38	US 6610287 B1	Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
608	20030812	80	US 6605443 B1	Method for identifying compounds that affect Smad7 binding
609	20030812	68	US 6605426 B1	Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products

610	20030812	39	US 6605275 B1	Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
-----	----------	----	------------------	--

	Issue Date	Pages	Document ID	Title
611	20030805	14	US 6602698 B2	Human kinase proteins and polynucleotides encoding the same
612	20030729	49	US 6600031 B1	Methods of making nucleic acid or oligonucleotide arrays
613	20030715	31	US 6593512 B1	Transgenic mouse expressing human tau gene
614	20030715	18	US 6593125 B2	Human kinases and polynucleotides encoding the same
615	20030715	108	US 6592865 B2	Methods and compositions for modulating ACE-2 activity
616	20030701	45	US H002074 H	Fertile transgenic corn plants
617	20030701	17	US 6586230 B1	Human kinase and polynucleotides encoding the same
618	20030617	100	US 6579969 B1	Goodpasture antigen binding protein
619	20030617	75	US 6579710 B2	Human kinases and polynucleotides encoding the same
620	20030610	32	US 6576758 B1	Nucleic acid constructs containing hybrid promoters
621	20030610	101	US 6576607 B1	Methods using CNS neurite outgrowth modulators
622	20030610	55	US 6576424 B2	Arrays and methods for detecting nucleic acids
623	20030603	249	US 6573068 B1	Claudin-50 protein
624	20030527	40	US 6569427 B1	Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
625	20030520	52	US 6566495 B1	Very large scale immobilized polymer synthesis

	Issue Date	Pages	Document ID	Title
626	20030506	126	US 6559294 B1	Chlamydia pneumoniae polynucleotides and uses thereof
627	20030429	24	US 6555651 B2	Ligand binding site of rage and uses thereof
628	20030429	53	US 6555340 B1	Nucleic acid encoding bovine extracellular rage binding protein (en-rage)
629	20030429	74	US 6555329 B2	Method for identifying compounds altering higher-order chromatin-dependent chromosome stability
630	20030422	84	US 6551784 B2	Method of comparing nucleic acid sequences
631	20030415	60	US 6548271 B1	Nucleic acids encoding human transporter proteins
632	20030408	24	US 6545264 B1	Systems and methods for high performance scanning
633	20030408	74	US 6544766 B1	Human kinesins and methods of producing and purifying human kinesins
634	20030408	54	US 6544739 B1	Method for marking samples
635	20030401	11	US 6541252 B1	Human kinases and polynucleotides encoding the same
636	20030325	158	US 6537594 B1	Vaccina virus comprising cytokine and/or tumor associated antigen genes
637	20030318	12	US 6534655 B1	Indeno[1,2-C]pyrazole derivatives for inhibiting tyrosine kinase activity
638	20030304	70	US 6528640 B1	Synthetic ribonucleic acids with RNase activity
639	20030218	40	US 6521228 B1	Antibodies directed against trail
640	20030204	54	US 6514719 B1	Methods for identifying compounds that alter kinase activity

	Issue Date	Pages	Document ID	Title
641	20030128	27	US 6511840 B1	Human kinase proteins and polynucleotides encoding the same
642	20030114	92	US 6506558 B1	Very large scale immobilized polymer synthesis
643	20021231	46	US 6500942 B1	Rin2, a novel inhibitor of Ras-mediated signaling
644	20021231	39	US 6500670 B1	Plant pyruvate dehydrogenase kinase gene
645	20021210	50	US 6491871 B1	System for determining receptor-ligand binding affinity
646	20021203	129	US 6489476 B1	Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase
647	20021119	51	US 6482411 B1	Methods of reducing bone loss with CD40 ligand
648	20021105	17	US 6476210 B2	Human kinases and polynucleotides encoding the same
649	20021022	49	US 6468985 B1	Retinoblastoma protein-interacting zinc finger proteins
650	20021022	43	US 6468740 B1	Cyclic and substituted immobilized molecular synthesis
651	20021022	60	US 6468523 B1	Polypeptide compositions toxic to diabrotic insects, and methods of use
652	20021008	35	US 6462186 B1	Human ATPase proteins and polynucleotides encoding the same
653	20021008	42	US 6461645 B1	Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood

	Issue Date	Pages	Document ID	Title
654	20021001	103	US 6458532 B1	Polynucleotides encoding IMP.18p myo-inositol monophosphatase and methods of detecting said polynucleotides
655	20020924	21	US 6455038 B1	Reovirus for the treatment of cellular proliferative disorders
656	20020917	53	US 6451536 B1	Products for detecting nucleic acids
657	20020910	36	US 6448054 B1	Purposeful movement of human migratory cells away from an agent source
658	20020903	34	US 6444870 B1	Methods for assessing the role of calcineurin immunosuppression and neurotoxicity
659	20020903	59	US 6444638 B2	Combinations of PKC inhibitors and therapeutic agents for treating cancers
660	20020903	43	US 6444463 B1	Neurogenic differentiation gene neurod3 and methods for inducing differentiation of cells
661	20020903	15	US 6444456 B1	Human G-coupled protein receptor kinases and polynucleotides encoding the same
662	20020903	41	US 6444446 B1	Calcium binding proteolipid compositions and methods
663	20020827	20	US 6441154 B1	Human proteases and polynucleotides encoding the same
664	20020827	16	US 6441153 B1	Human carboxypeptidases and polynucleotides encoding the same
665	20020827	20	US 6440938 B1	Prevention and/or treatment of allergic conditions

	Issue Date	Pages	Document ID	Title
666	20020827	14	US 6440741 B2	Expression vector for consistent cellular expression of the tet on repressor in multiple cell types
667	20020827	57	US 6440667 B1	Analysis of target molecules using an encoding system
668	20020806	42	US 6429304 B1	Nucleic acids encoding a katanin p60 subunit
669	20020806	120	US 6429291 B1	Hyaluronan receptor protein
670	20020730	20	US 6426351 B1	Chelerythrine-based therapies for cancer
671	20020730	207	US 6426186 B1	Bone remodeling genes
672	20020716	99	US 6420169 B1	Apparatus for forming polynucleotides or polypeptides
673	20020709	98	US 6416952 B1	Photolithographic and other means for manufacturing arrays
674	20020625	41	US 6410687 B1	Polypeptides for the detection of microtubule depolymerization inhibitors
675	20020625	36	US 6410014 B1	Redirection of cellular immunity by protein-tyrosine kinase chimeras
676	20020618	45	US 6407221 B1	Chimeric chains for receptor-associated signal transduction pathways
677	20020618	46	US 6406844 B1	Very large scale immobilized polymer synthesis
678	20020611	49	US 6403957 B1	Nucleic acid reading and analysis system
679	20020611	23	US 6403859 B1	Vitamin B metabolism proteins
680	20020604	72	US 6399782 B1	Benzimidazole inhibitors of fructose 1,6-bisphosphatase
681	20020604	49	US 6399298 B1	Ku70--related methods

	Issue Date	Pages	Document ID	Title
682	20020528	57	US 6395891 B1	Methods and compositions for combating HIV infection
683	20020528	54	US 6395491 B1	Method of information storage and recovery
684	20020521	34	US 6392013 B1	Redirection of cellular immunity by protein tyrosine kinase chimeras
685	20020514	54	US 6388076 B1	Protein tyrosine phosphatase-inhibiting compounds
686	20020514	10	US 6387633 B1	Method for identifying unstable genes
687	20020430	104	US 6379895 B1	Photolithographic and other means for manufacturing arrays
688	20020326	130	US 6361976 B1	Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
689	20020319	38	US 6358923 B1	Cell surface glycoproteins
690	20020312	55	US 6355432 B1	Products for detecting nucleic acids
691	20020305	82	US 6353091 B1	Human N-type calcium channel isoform
692	20020305	16	US 6352833 B1	Methods for discovery of vasoactive compounds for the nitric oxide-cyclic GMP signal pathway
693	20020212	49	US 6346413 B1	Polymer arrays
694	20011225	18	US 6333313 B1	Clinical use of oxytocin alone or in combination to treat bone disorders
695	20011211	46	US 6329143 B1	Very large scale immobilized polymer synthesis
696	20011127	94	US 6323335 B1	Retinoblastoma protein-interacting zinc finger proteins

	Issue Date	Pages	Document ID	Title
697	20011120	44	US 6319679 B1	PAS kinase
698	20011120	38	US 6319494 B1	Chimeric chains for receptor-associated signal transduction pathways
699	20011106	95	US 6312662 B1	Prodrugs phosphorus-containing compounds
700	20011030	49	US 6310189 B1	Nucleotides and analogs having photoremoveable protecting groups
701	20011030	82	US 6309822 B1	Method for comparing copy number of nucleic acid sequences
702	20011023	66	US 6306832 B1	Peptide antiestrogen compositions and methods for treating breast cancer
703	20011023	60	US 6306648 B1	Cyclin-C variants, and diagnostic and therapeutic uses thereof
704	20011002	36	US 6297238 B1	Therapeutic agents
705	20011002	93	US 6297051 B1	MN gene and protein
706	20011002	93	US 6297041 B1	MN gene and protein
707	20010925	52	US 6294672 B1	Indole and azaindole inhibitors of Fructose-1,6-biphosphatase
708	20010918	100	US 6291645 B1	p62 polypeptides, related polypeptides, and uses therefor
709	20010918	43	US 6291642 B1	Mammalian cell cycle protein
710	20010918	50	US 6291183 B1	Very large scale immobilized polymer synthesis
711	20010911	91	US 6287866 B1	.beta.-casein expressing constructs
712	20010904	52	US 6284748 B1	Purine inhibitors of fructose 1,6-bisphosphatase

	Issue Date	Pages	Document ID	Title
713	20010904	35	US 6284247 B1	Human tissue plasminogen activators
714	20010904	73	US 6284240 B1	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
715	20010904	42	US 6284236 B1	Cytokine that induces apoptosis
716	20010828	29	US 6281193 B1	Compounds that inhibit the binding of RAF-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
717	20010821	234	US 6277974 B1	Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
718	20010814	34	US 6274335 B1	Method of treatment using recombinant human tissue plasminogen activator
719	20010731	25	US 6267954 B1	Intraocular transplantation of encapsulated cells
720	20010724	348	US 6265211 B1	Nucleic acid molecules comprising a neocentromere
721	20010717	259	US 6262334 B1	Human genes and expression products: II
722	20010717	381	US 6262333 B1	Human genes and gene expression products
723	20010717	56	US 6261776 B1	Nucleic acid arrays
724	20010710	19	US 6258541 B1	Noninvasive detection of colonic biomarkers using fecal messenger RNA
725	20010626	79	US 6251628 B1	Isolated nucleic acid molecules encoding Smad7
726	20010522	37	US 6235729 B1	Uses of phospholipase C inhibitors

	Issue Date	Pages	Document ID	Title
727	20010501	53	US 6225045 B1	Assays for screening for inhibitors of HIV
728	20010424	31	US 6222025 B1	Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom
729	20010417	117	US 6217882 B1	Use of recombinant swine poxvirus as a live vaccine vector
730	20010403	100	US 6210654 B1	Jak kinases and regulation of cytokine signal transduction
731	20010327	130	US 6207816 B1	High affinity oligonucleotide ligands to growth factors
732	20010313	42	US 6200799 B1	Somatic gene therapy to suppress secondary cataract formation following eye surgery
733	20010227	77	US 6194556 B1	Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
734	20001226	508	US 6166178 A	Telomerase catalytic subunit
735	20001226	43	US 6165753 A	Cyclin E genes and proteins
736	20001121	52	US 6150532 A	Modulators of proteins with phosphotyrosine recognition units
737	20001024	100	US 6136595 A	Jak kinases and regulations of cytokine signal transduction
738	20000919	129	US 6120991 A	Epiligrin, an epithelial ligand for integrins
739	20000912	88	US 6117643 A	Bioluminescent bioreporter integrated circuit
740	20000829	75	US 6110903 A	Benzimidazole inhibitors of fructose 1,6-bisphosphatase
741	20000822	29	US 6106825 A	Entomopoxvirus-vertebrate gene delivery vector and method

	Issue Date	Pages	Document ID	Title
742	20000627	23	US 6080770 A	Modulators of molecules with phosphotyrosine recognition units
743	20000530	92	US 6069231 A	PR domain peptides
744	20000516	22	US 6063800 A	Modulators of molecules with phosphotyrosine recognition units
745	20000502	66	US 6057427 A	Antibody to cytokine response gene 2 (CR2) polypeptide
746	20000425	51	US 6054587 A	Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
747	20000418	130	US 6051376 A	Uses of mda-6
748	20000328	18	US 6043247 A	Modulators of molecules with phosphotyrosine recognition units
749	20000328	38	US 6043056 A	Cell surface glycoproteins
750	20000321	84	US 6040149 A	Assay for identifying agents which act on the ceramide-activated protein kinase, kinase suppressor of ras, and methods of using said agents
751	20000307	75	US 6034212 A	SH3 kinase domain associated protein, a signalling domain therein, nucleic acids encoding the protein and the domain, and diagnostic and therapeutic uses thereof
752	20000222	72	US 6027914 A	Nucleic acids encoding CR6 polypeptide vector and transformed cell thereof, and expression thereof

	Issue Date	Pages	Document ID	Title
753	20000208	59	US 6022740 A	SH3 kinase domain associated protein, a signalling domain therein, nucleic acids encoding the protein and the domain, and diagnostic and therapeutic uses thereof
754	20000201	72	US 6020155 A	Nucleic acids encoding CR1 fusion protein, vector, transfected cell and expression
755	20000125	105	US 6017734 A	Unique nucleotide and amino acid sequence and uses thereof
756	20000111	35	US 6013863 A	Fertile transgenic corn plants
757	20000104	37	US 6010853 A	Siva genes, novel genes involved in CD27-mediated apoptosis
758	19991221	40	US 6004811 A	Redirection of cellular immunity by protein tyrosine kinase chimeras
759	19991109	46	US 5981248 A	Mammalian cell death preventing kinase, DPK
760	19991026	42	US 5973119 A	Cyclin E genes and proteins
761	19991026	23	US 5972978 A	Modulators of molecules with phosphotyrosine recognition units
762	19991012	30	US 5965707 A	Rin2, a novel inhibitor of Ras-mediated signaling
763	19991012	57	US 5965558 A	Modulators of proteins with phosphotyrosine recognition units
764	19991012	41	US 5965439 A	Host defense enhancement
765	19991012	48	US 5965397 A	Secreted proteins and polynucleotides encoding them
766	19991005	103	US 5962224 A	Isolated DNA encoding p62 polypeptides and uses therefor

	Issue Date	Pages	Document ID	Title
767	19990928	24	US 5958957 A	Modulators of molecules with phosphotyrosine recognition units
768	19990914	35	US 5952214 A	Human growth-related CDC10 homolog
769	19990803	39	US 5932445 A	Signal peptide-containing proteins
770	19990615	41	US 5912183 A	Peptide inhibitors of mitogenesis and motogenesis
771	19990615	38	US 5912170 A	Redirection of cellular immunity by protein-tyrosine kinase chimeras
772	19990323	27	US 5885833 A	Nucleic acid constructs for the cell cycle-regulated expression of genes and therapeutic methods utilizing such constructs
773	19990316	69	US 5882894 A	Nucleic acids encoding CR8 polypeptides, vector and transformed cell thereof, and expression thereof
774	19990302	79	US 5877396 A	Mice mutant for functional Fc receptors and method of treating autoimmune diseases
775	19990302	102	US 5877207 A	Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
776	19990223	60	US 5874308 A	Compositions and methods for modulating cell proliferation using growth factor-polysaccharide binding fusion proteins
777	19990216	72	US 5871961 A	Nucleic acids encoding CR2 polypeptides, vector and transformed cell thereof, and expression thereof

	Issue Date	Pages	Document ID	Title
778	19990216	73	US 5871960 A	Nucleic acids encoding CR5 polypeptide, vector and transformed cell thereof, and expression thereof
779	19990209	34	US 5869314 A	Tissue plasminogen activators and derivatives thereof as produced by recombinant means
780	19990209	26	US 5869308 A	Detection method for C-RAF-1 genes
781	19990119	23	US 5861493 A	Process for the synthesis of 2'-O-substituted pyrimidines
782	19981229	86	US 5854004 A	Process for screening substances capable of modulating a receptor-dependent cellular signal transmission path
783	19981222	72	US 5851828 A	Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
784	19981215	35	US 5849556 A	Human growth-related CDC10 homolog
785	19981103	40	US 5830647 A	Hybridization and amplification of nucleic acids encoding mpl ligand
786	19981013	37	US 5821072 A	Combinations of PKC inhibitors and therapeutical agents for treating cancers
787	19980922	81	US 5811304 A	Nucleic acid molecules encoding retinoblastoma protein-interacting zinc finger proteins
788	19980922	41	US 5811288 A	Isoform gene for focal adhesion protein paxillin
789	19980818	45	US 5795723 A	Expression of neurogenic bHLH genes in primitive neuroectodermal tumors

	Issue Date	Pages	Document ID	Title
790	19980609	26	US 5763470 A	Benzopyran compounds and methods for their use
791	19980609	35	US 5763253 A	Methods of preparing tissue plasiminogen activator derivative composition
792	19980602	23	US 5760202 A	Process for the synthesis of 2'-O-substituted pyrimidines
793	19980519	50	US 5753687 A	Modulators of proteins with phosphotyrosine recognition units
794	19980519	34	US 5753486 A	Human tissue plasminogen activator
795	19980317	38	US 5728566 A	Tissue plasminogen activator derivatives
796	19980317	35	US 5728565 A	Methods of preparing tissue plasminogen activator derivatives
797	19980317	77	US 5728536 A	Jak kinases and regulation of Cytokine signal transduction
798	19971230	39	US 5702938 A	Human tissue plasminogen activator
799	19971202	87	US 5693487 A	Nucleic acids encoding max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc and Mad
800	19971125	16	US 5691156 A	Method of inhibiting cell growth with the P.sub.2U receptor
801	19971118	72	US 5688773 A	Method of selectively destroying neoplastic cells
802	19970923	19	US 5670324 A	Use of chimeric CD4-src protein tyrosine kinases in drug screening and detection of an immune response
803	19970819	30	US 5658758 A	Polynucleotides encoding cytostatin I

	Issue Date	Pages	Document ID	Title
804	19970729	20	US 5652225 A	Methods and products for nucleic acid delivery
805	19970729	77	US 5651972 A	Use of recombinant swine poxvirus as a live vaccine vector
806	19970701	74	US 5643761 A	Method for generating a subtracted cDNA library and uses of the generated library.
807	19970429	22	US 5625122 A	Mouse having a disrupted lck gene
808	19970429	117	US 5624818 A	Nucleic acids encoding regulatory proteins that dimerize with Mad or Max
809	19970408	27	US 5618670 A	Detection method for c-raf-1 genes
810	19970304	18	US 5607836 A	Methods of detecting compounds which bind to the P.sub.2U receptor
811	19970128	43	US 5597719 A	Interaction of RAF-1 and 14-3-3 proteins
812	19970121	18	US 5596088 A	DNA Encoding the human P.sub.2U receptor and null cells expressing P.sub.2U receptors
813	19970114	41	US 5594105 A	Peptide inhibitors of mitogenesis and motogenesis
814	19961224	34	US 5587159 A	Human tissue plasminogen activator
815	19960402	23	US 5504192 A	Human insulin receptor endocytic code binding protein
816	19960402	19	US 5504000 A	Chimeric protein tyrosine kinases
817	19950905	76	US 5447862 A	Pectin lyase genes of aspergillus niger
818	19950808	19	US 5439819 A	Chimeric protein tyrosine kinases
819	19950711	8	US 5432076 A	Alteration of the interaction of a T-cell receptor with a protein-tyrosine kinase

	Issue Date	Pages	Document ID	Title
820	19950704	35	US 5429948 A	Human cell line stably expressing 5cDNAs encoding procarcinogen-activating enzymes and related mutagenicity assays
821	19941025	39	US 5359046 A	Chimeric chains for receptor-associated signal transduction pathways
822	19940705	20	US 5326558 A	Megakaryocytopoietic factor
823	19940628	72	US 5324731 A	Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
824	19940412	84	US 5302519 A	Method of producing a Mad polypeptide
825	19931005	9	US 5250431 A	Alteration of the interaction of a T-cell receptor with a proteintyrosine kinase
826	19930309	37	US 5192553 A	Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
827	19930209	37	US 5185259 A	Truncated human tissue plasminogen activator
828	19930119	24	US 5180666 A	Method and cell line for testing mutagenicity of a chemical
829	19910402	39	US 5004681 A	Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood